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Abstract 
The Escherichia coli glucuronylsynthase is an engineered glycosynthase enzyme derived from 
wild-type E. coli β-glucuronidase where a single-point mutation has changed the function of the 
enzyme from a hydrolase to a synthase. The glucuronylsynthase catalyses the formation of a 
glycosidic bond between a glucopyranuronic acid moiety and an alcohol acceptor to yield a 
glucuronide compound. Glucuronides are an important class of compounds in pharmacology 
and toxicology, in medicinal chemistry and in sports anti-doping. Previous work on the 
glucuronylsynthase elucidated conditions for the synthesis of some simple glucuronides and 
provided possibilities for further improvement. 
This thesis covers work undertaken to further develop and understand the glucuronylsynthase 
enzyme as a viable synthetic protocol, especially in the context of steroid glucuronide synthesis 
for anti-doping purposes. This was approached from three different routes, these being the 
synthesis of a range of steroid glucuronides, the synthesis of an 18O-labelled steroid glucuronide 
as an alternative to current labelling protocols, and an investigation into the Michaelis-Menten 
kinetics of the glucuronylsynthase to determine the effect of tert-butanol on the enzyme. An 
additional study into the stability of the glucopyranuronyl donor under the glucuronylsynthase 
conditions was performed to resolve an unanswered question from previous work where 
additional equivalents of sugar appeared to be required for good yields of glucuronide product. 
A set of revised conditions for the synthesis of steroid glucuronides using the 
glucuronylsynthase was developed using tert-butanol as a co-solvent for improved reaction 
rates and solubility of the steroid substrates. A rapid purification method using weak-anion 
exchange (WAX) solid-phase extraction (SPE) was developed for the direct purification of crude 
glucuronylsynthase reactions. A screen of a library of steroid substrates was performed and the 
conversions quantified by 1H NMR integration of the relevant protons to provide a clearer 
understanding of how well the glucuronylsynthase is able to process such steroid substrates. 
Some non-steroidal glucuronides were also prepared, hinting at a broader substrate scope 
beyond steroids and simple alcohols. 
To achieve the second goal a new synthesis of the α-D-glucuronyl fluoride 29 was developed 
excluding ordinary water for maximum incorporation of 18O-labelled water. This sugar was then 
used to synthesise a labelled steroid glucuronide with characterisation performed by 1H NMR 
and mass spectrometry. 
 
 v 
 
The Michaelis-Menten kinetics of the glucuronylsynthase were investigated using 
dehydroepiandrosterone O-(carboxymethyl)oxime 33 as the steroid substrate of choice due to 
its improved aqueous solubility and the variables of tert-butanol concentration and 
temperature were investigated to uncover the effect of tert-butanol on the glucuronylsynthase. 
The hydrolysis of the α-D-glucuronyl fluoride 29 was studied using a fluoride-selective 
electrode for higher sensitivity over previous analytical methods such as a zirconium-based 
fluorescence quenching approach. The initial rates of general base-catalysed hydrolysis in 
various buffers at 37 °C including with and without tert-butanol were measured and the 
corresponding first-order rate constants for hydrolysis were calculated. 
The advancement of the Escherichia coli glucuronylsynthase protocol was thus carried out on 
multiple fronts and this thesis describes such efforts from synthetic and analytical points of 
view. 
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Nomenclature 
This thesis follows the nomenclature as set forth by the IUPAC guidelines, though trivial names 
will be used where possible for brevity. A summary of the carbohydrate and steroid 
nomenclature relevant to this thesis is provided below for convenience to the reader (the 
corresponding IUPAC nomenclature paper is referenced in each case). 
Carbohydrate nomenclature 
The naming and numbering of a carbohydrate is presented below, following the guidelines set 
out by McNaught1, where the acyclic form as a Fischer projection of the parent monosaccharide 
is used as the base (figure i). The configurational descriptor, D or L, is determined by the 
configuration at the “highest-numbered centre of chirality”. In figure i, then, this centre of 
chirality exists at C5. 
 
Figure i: the Fischer project of D-glucose and L-glucose 
Therefore, with the hydroxyl group positioned to the right, this is D-glucose; conversely, with 
the hydroxyl group positioned to the left this is L-glucose (the corresponding enantiomer). 
Upon generation of the cyclic form of the monosaccharide by “hemiacetal ring closure”, the 
newly-produced centre of chirality at C1 is designated as the anomeric carbon, as shown in 
figure ii.  
 
Figure ii: the cyclic Fischer projections of glucose, showing the anomeric carbon in β-D-glucose 
and α-D-glucose 
 xvi 
 
In the β-anomer, the ring oxygen at C5 (red) is formally trans to the C1 oxygen (blue) on the 
anomeric carbon, while in the α-anomer the relationship is formally cis. 
With regards to ring size, the term “pyran” refers to the six-membered cyclic sugars, collectively 
known as the pyranoses. The sugars discussed in this thesis will only cover such sugars and no 
other ring sizes will be examined. 
In terms of naming the C6 carboxylic acid derivative, this changes the terms of glucose, glucoside 
and glucosyl to glucuronic acid, glucuronide and glucuronyl, which will be used throughout this 
thesis. 
Steroid nomenclature 
The naming and numbering of steroids is presented below, following the guidelines set out by 
Moss2. They are defined as compounds “possessing the skeleton of cyclopenta[a]phenanthrene”, 
where methyl groups are positioned at C10 and C13 with the possible existence of alkyl groups 
at C17 (figure iii). Substituents attached to this steroid core are drawn in a standard orientation 
as either into the plane (dashed bond, α-configuration) or out of the plane (bolded bond, β-
configuration) 
 
Figure iii: a) the numbering system for steroids; b) the depiction of the stereochemistry of 
various substituents 
For some steroid cores there are specific names given to these to enable distinction between 
different types of steroids. These names then form the basis for appending the various 
functional groups that may exist therein. Some of these are given in figure iv below: 
 
 xvii 
 
 
Figure iv: some of the common steroid cores (a-c), and d) two examples of named steroids 
using their IUPAC name and their trivial name 
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Chapter 1: Introduction 
1.1 Drug metabolism 
The metabolism of exogenous (xenobiotics) and endogenous compounds by biochemical 
processes plays a central role in uncovering important biological activity and also the clearance 
of such compounds from the body. There are two main phases of metabolism that are known to 
occur in the body: phase I and phase II metabolism. However, these labels should not be taken 
to imply a sequential role for each phase; rather, they comprise a different set of reactions that 
need not necessarily follow on from each other. 
In phase I metabolism xenobiotics are typically subjected to a range of reactions such as 
oxidation and reduction, dehydrogenation and demethylation reactions – in short, they undergo 
minor modifications to their structure by cytochrome P450 enzymes, among others, that can 
either render the compound less active or unmask its latent biological activity3. This phase of 
metabolism usually takes place on the smooth endoplasmic reticulum of liver cells 
(hepatocytes), as many of these enzymes are membrane-bound and the liver is usually the first 
processing centre encountered for drug molecules absorbed via the gastrointestinal tract, 
although it is known to take place in other parts of the body as well.  
A useful example of this is the metabolism of codeine 1, where the molecule is demethylated by 
a cytochrome P450 enzyme designated CYP2D6 to morphine 2, which is well-known for its 
analgesic effects (scheme 1)4–6. Alternatively these modifications may also simply detoxify the 
compound, readying it for elimination from the body in phase II metabolism. 
 
Scheme 1: the phase I metabolism of codeine 1 to morphine 2 by the cytochrome P450 enzyme 
CYP2D6 occurs by an overall demethylation reaction (involving hydroxylation followed by 
hydrolysis) 
Once the xenobiotic is targeted by the body for elimination the drug enters phase II metabolism, 
which typically takes place primarily in the liver and kidneys, although it is known to occur at 
other sites such as the testes, prostate, skin, and even the brain7–12.  
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The xenobiotic or its phase I metabolite(s) is conjugated to a polar molecule such as glucuronic 
acid, sulfate, or glutathione, which are typically charged at physiological pH and which increase 
the water solubility of the conjugate, preparing it for clearance from the body, mainly through 
the urine and bile. This conjugation step also often serves to further detoxify and deactivate the 
xenobiotic as a result of this increased hydrophilicity as it impedes the passive uptake of the 
compound through the cellular membrane13. Naturally this then requires the transport of 
glucuronides out of the cells and various carrier-mediated transport processes are now known 
for the excretion of phase II metabolites in general13–16.   
The most common of these conjugates in humans is the glucuronic acid conjugate, called a 
glucuronide. The class of enzymes involved in glucuronide formation are the UDP-
glucuronosyltransferases (UGTs), which transfer a glucuronyl moiety from an activated 
glucuronic acid, uridine 5’-diphospho-glucuronic acid 3 (UDPGA) to a suitable acceptor 
molecule containing oxygen-, nitrogen-, sulphur- or carboxyl-based functional groups17,18. 
Continuing with the example of codeine metabolism, the phase I metabolite morphine 
undergoes phase II metabolism, catalysed by UGT2B7, to two main metabolites, morphine 3-
glucuronide (M3G, 4) and morphine 6-glucuronide (M6G, 5) (scheme 2)5,19.  
 
Scheme 2: the phase II metabolism of morphine 2 by UGT-mediated conjugation to glucuronic 
acid affords morphine 3-glucuronide 4 and morphine 6-glucuronide 5 
Instead of deactivating morphine, it turns out that the two glucuronides display markedly 
different bioactivities. In the case of M3G 4, the metabolite exhibits an antagonistic effect at the 
μ1 opioid receptor, which is thought to relate to some of the adverse side-effects of morphine 
administration20,21. Conversely, M6G 5 is a potent agonist of the same receptor, leading to the 
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development of alternative methods of morphine administration where the use of M6G reduces 
the dosage of morphine and consequently the occurrence of side-effects22–25. 
1.2 Pharmacology & toxicology 
It used to be thought that phase II metabolism and their glucuronide metabolites thereof were 
primarily a mode of detoxification and excretion, as the glucuronide is usually too polar to cross 
the cell membrane again, though at least one example of glucuronide toxicity was known in the 
late 1960s26. However, the studies above changed this perception such that now the glucuronide 
metabolites of morphine are an oft-quoted example of the role that glucuronides play in 
significantly affecting drug bioactivities, not just as a simple pathway for renal clearance of 
xenobiotics. Over the past few decades further research has revealed other glucuronide 
metabolites that display bioactivities comparable to the parent compound or distinct to and 
arising from the glucuronide27–30. 
The knowledge that glucuronides have an important place in drug metabolism is vital in the 
development of new drug candidates. For example, the evaluation of drug bioactivities (toxicity, 
pharmacokinetics etc.) in a non-clinical setting typically is performed using animals as 
toxicological model systems. This is useful for cases where the metabolite profile is congruent 
between animals and humans but it is not necessarily always the case. It is very much possible 
that a clinically relevant metabolite in humans may not be detected during animal studies, 
though the more common situation is that a metabolite observed in animal studies is found in 
much greater amounts in human studies. Usually this means that further testing of these 
metabolites is required to ensure a comprehensive safety profile for the drug.  
For example, the US Food and Drug Administration recommends that for such metabolites (i.e. 
those found only in humans or in higher amounts) several studies to assess the general toxicity 
(including how the route of administration is involved), genotoxicity, foetal toxicity and 
carcinogenicity should be carried out31. This highlights the need for preparation of phase I and 
phase II metabolites in the context of drug safety profiling. 
One class of glucuronides that has contributed to tighter testing regulations and consequently 
gained notoriety in drug toxicology are acyl glucuronides, obtained from the conjugation of a 
xenobiotic containing a carboxylic acid to glucuronic acid 632. The glucuronide “as is” is not 
particularly noteworthy, but rather it is the range of possible reactions that the glucuronide can 
undergo following conjugation that is postulated to contribute to their unusual and sometimes 
adverse bioactivity (scheme 3)33. 
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Scheme 3: some of the possible pathways of reactivity for acyl glucuronides within the body 
One possible reaction would be the hydrolysis (e.g. by glucuronidase) of the glucuronide to 
release the aglycone (i.e. the drug or corresponding metabolite). This pathway, known as 
enterohepatic recirculation, is general for glucuronides where they can be excreted via the 
biliary system into the intestines. The presence of Escherichia coli β-glucuronidase in the 
intestines then contributes to de-conjugation of the glucuronide liberating the drug molecule 
that can be reabsorbed, increasing the circulation lifetime in the body of a potentially toxic 
compound34. This poses a particular problem in patients with renal impairment and therefore 
poorer renal clearance of the metabolites35,36.  
However, this is more pronounced with acyl glucuronides as they are more susceptible to non-
enzyme mediated hydrolysis compared to other glucuronides, under neutral or slightly basic 
conditions – although they are stable enough to circulate through the body after formation in 
the liver or kidneys33,37. 
A second type of reaction involves acyl migration, where the acyl functionality moves to the C2 
hydroxyl and even subsequent migration to C3 and C438. This can then lead to formation of 
glycation products (such as 7) when the acyl isomer reacts with a suitable amine nucleophile 
(presumably through the ring-opened aldehyde intermediate)39,40. The third type of reaction is 
transacylation where a suitable nucleophile (such as an amine, thiol or even hydroxyl) can 
displace the glucuronyl moiety from the acyl glucuronide to give the drug-protein adduct 8. 
Both of these types of adducts are implicated in side-effects such as adverse immune responses.  
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In fact, for several drugs that display adverse drug reactions (ADRs), such as diclofenac and 
zomepirac, the origins of these symptoms have been attributed to acyl glucuronides41–47. 
However, the actual mechanisms (and the corresponding protein adducts) by which these ADRs 
occur in vivo have not been definitively established, although there is a wealth of direct and 
indirect in vitro evidence44,48–52. Therefore, elucidating the mechanisms of action and the nature 
of the protein adducts in vivo of these acyl glucuronides remains an active area of research. 
1.3 Anti-tumour therapy 
Over the past few decades, glucuronides have not only been seen as end-of-the-line metabolites 
for the clearance of drugs from the body, but also as a possible candidate for the development of 
prodrugs for the treatment of various diseases and tumours. It was first proposed by Fishman 
and Anlyan that tumour environments displayed elevated levels of glucuronidase activity 
compared to healthy tissue and later demonstrated by Bosslet et al. that it is elevated secretion 
of endogenous β-glucuronidase in the necrotic extracellular environment around the tumour by 
monocytes or granulocytes, that was responsible for this observation53,54. Importantly, Bosslet 
et al. also discovered that healthy cells only express glucuronidase internally, in lysozymes. The 
development of a glucuronide conjugate of a suitable anti-tumour agent and a targeted delivery 
system could potentially be a viable approach for cancer therapy, avoiding many of the 
complications associated with standard untargeted chemotherapy therapies.  
Glucuronides are for the most part less active and less toxic forms of the drug, although there 
are exceptions, such as the acyl glucuronides pointed out previously. However, one of the 
disadvantages lies in the fact that glucuronides are also primed for renal clearance as a result of 
the increased water solubility of the molecule. Thus, circumventing this problem is an important 
part of the approach and requires careful compound design. 
One of the earliest examples of glucuronide prodrug delivery, referred to as “antibody-directed 
enzyme prodrug therapy” (ADEPT), was reported by Wang et al. where E. coli β-glucuronidase 
was linked to a monoclonal antibody expressing an antigen binding site that targeted tumour 
cells. It should be pointed out that the endogenously expressed β-glucuronidase is apparently 
insufficiently active to undertake this de-conjugation – clinical chemotherapy trials using 
similar aniline mustard compounds proved to be underwhelming55,56. Therefore, using more 
active glucuronidase enzyme would improve the de-conjugation step and consequent release of 
the drug molecule. 
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This would lead to accumulation of glucuronidase at the tumour surface, forming an 
environment that is highly competent in hydrolysing glucuronides, allowing for release of the 
anti-tumour agent in close proximity to the tumour. The prodrug consisted of a glucuronide 
conjugate of 4-(bis-2-chloroethyl)aminophenol 9, where the parent compound 10 was known 
to be active against human hepatoma cells through alkylation (scheme 4)57.  
 
Scheme 4: Wang et al.’s glucuronide prodrug strategy for the targeted delivery of 4-(bis-2-
chloroethyl)aminophenol 10 to hepatoma cells using ADEPT 
They were able to show that the required concentration of the drug was reduced by 1000-fold 
(likely due to the improved targeting of the drug) and the toxicity of the prodrug was 150-fold 
less than that of the parent drug against rat hepatoma cells in vitro.  
Research towards the use of glucuronides as prodrugs has typically used this targeting strategy 
or variations on a theme to deliver the anti-tumour compound. For example, self-immolative 
linkers have been used to increase the spatial separation of the glucuronyl moiety from the anti-
cancer agent, thereby improving recognition of the glucuronide portion by the glucuronidase 
(scheme 5). Hydrolysis of the glycosidic C-O bond then leads to rapid decomposition of the 
linker and subsequent release of the anti-tumour agent, again in close proximity to the 
tumour58,59.  
 
Scheme 5: the general approach in the use of self-immolative linkers in glucuronide prodrugs 
for the delivery of anti-tumour agents. In blue: the glucuronyl moiety; in red: a typical self-
immolative linker; and in black: R = anti-tumour agent 
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A recent report by Legigan et al. detailed the development of an albumin-binding glucuronide 
prodrug comprising a maleimide moiety (for covalent attachment to albumin) and a self-
immolative linker for rapid release of the anti-tumour agent, in this case doxorubicin 1160 
(scheme 6). Albumin-binding prodrugs have also been used in other areas as a method for the 
target delivery of anti-tumour agents such as carboplatin or camptothecin61,62. Cysteine addition 
at the maleimide allows for covalent attachment to plasmatic albumin, which is then 
transported to the tumour environment through the bloodstream63. Subsequent hydrolysis of 
the glucuronide followed by rapid decomposition of the linker then releases doxorubicin 11.  
For more details on the current state of the  glucuronide prodrug strategy, a review by Tranoy-
Opalinksi et al. is recommended64. Much of the work over the course of the past few decades has 
shown that glucuronide prodrugs present a promising alternative for cancer therapy and their 
synthesis remains an active area of research. 
 
Scheme 6: the doxorubicin (green) glucuronide (blue) prodrug method reported by Legigan et 
al. using a combination of albumin-binding (orange) and self-immolative linker (red) strategies 
to deliver doxorubicin 11 
1.4 Sports drug testing 
The use of performance-enhancing drugs (PEDs) in sports is a well-documented phenomenon 
called doping. The World Anti-Doping Agency (WADA) was formed in 1999 as an internationally 
recognised independent agency to combat doping in sport and in response to the 1998 Tour de 
France doping scandal in which large amounts of PEDs were seized in a police raid. Testing for 
doping and the corresponding scrutiny of athletes has since increased substantially but that has 
not deterred some athletes from doping with the most recent high-profile case being the United 
States Anti-Doping Agency (USADA) report on the systemic doping by the US Postal Service 
cycling team, in particular by Lance Armstrong65.  
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Steroids in particular have great potential for abuse as PEDs in sports due to their capacity to 
boost performance, via increases in muscle mass and strength66,67. However, as for all drugs 
they are usually excreted from the body as glucuronides of the parent compound or more 
commonly the corresponding phase I metabolites68.  
The direct detection of steroid glucuronides is problematic, owing to the sensitivity of the 
metabolite to the high temperature conditions required for gas chromatography-mass 
spectrometry (GC-MS) as well as its poor volatility. To overcome this, the typical detection 
protocol cleaves the glucuronide metabolite (e.g. testosterone 17-glucuronide 12) in the urine 
sample using β-glucuronidase enzyme derived from E. coli, providing the free steroid and 
glucuronic acid. Liquid-liquid extraction and/or solid-phase extraction then isolates the free 
steroid (e.g. testosterone 13) and its metabolites. The free steroid then undergoes enol TMS 
derivatisation using N-methyl-N-(trimethylsilyl) trifluoroacetamide 14 (MSTFA) to afford a silyl 
ether and/or a silyl enol ether 15, improving its volatility for GC-MS analysis (scheme 7)69–71. 
Unfortunately this protocol requires a great deal of sample handling and often there are issues 
with incomplete cleavage of the glucuronide or poor derivatisation conversion to the silyl 
ether72. In addition, the urine sample matrix is known to generate interferences that can reduce 
the sensitivity of the analysis73. 
 
 
Scheme 7: the GC-MS approach to steroid detection, showing sample hydrolysis by 
glucuronidase then enol TMS derivatisation to a steroid derivative 15 that contains a silyl ether 
and a silyl enol ether, ready for analysis 
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An alternative analytical method, liquid chromatography-mass spectrometry (LC-MS) has 
several advantages over GC-MS (scheme 8). For one, it avoids hydrolysis and derivatisation 
steps as it is capable of detecting the metabolite directly, reducing the overall time required for 
analysis74–80. A typical procedure involves extraction of a urine sample using solid phase 
extraction (SPE) to obtain the desired metabolite in high purity, before analysis by liquid 
chromatography. This method is also advantageous in situations where the analyte may be 
present in quantities insufficient for GC-MS analysis or where the analytes are particularly 
sensitive to derivatisation81. 
 
Scheme 8: the LC-MS approach to steroid detection, showing sample clean-up followed by 
direct detection of the steroid metabolite 
An important aspect in identifying the substance of abuse and consequent confirmation of 
doping is that the analyst must compare the data from the metabolite to that of a reference 
material82. For example, a deuterated form of the steroid is often used as the control to compare 
retention times or mass spectrometry fragmentation patterns, but these compounds can be 
either difficult to obtain or not known entirely, especially for novel compounds83. Therefore 
there remains the pressing need for preparation of steroid glucuronide metabolites as reference 
materials. For GC-MS, they can serve to control for all steps of confirmation of the target analyte 
including the hydrolysis step. For LC-MS they are required to confirm a match with a suspected 
steroid metabolite. 
1.5 Strategies for the synthesis of glucuronides 
1.5.1 Chemical synthesis of glucuronides 
It should come as no surprise, given the role of glucuronides in pharmacology, medicinal 
chemistry and sports drug testing, that there has been extensive work on the synthesis of 
glucuronides, although it is only in the past few decades when these aforementioned 
applications became apparent that their synthesis became a prominent area of research.  
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There have been two broad strategies to this end, comprising either chemical or enzymatic 
methods with the disconnection taking place at the glycosidic bond. This then requires the 
combination of a sugar (the “glucuronyl donor”) and the acceptor compound (in the case of an 
alcohol, the “acceptor alcohol”). The following sections will illustrate some of the strategies 
towards this end (for full coverage of these areas, see reviews at the end of this section). 
1.5.1.1 Koenigs-Knorr glucuronylation 
The original chemical strategy for the synthesis of glucuronides was based on the Koenigs-
Knorr reaction published in 1901 for the silver carbonate-promoted synthesis of a range of 
glycosides by the reaction of 2,3,4,6-tetra-O-acetyl-α-D-glucosyl bromide 16 with alcohols 
(scheme 9)84.  
 
Scheme 9: the synthesis of 1-O-β-glucosides by Koenigs & Knorr using silver carbonate 
Similar findings were reported by Fischer and Armstrong, using the protected glucosyl chlorides 
instead85. The glucosyl bromide 16 remains the favoured donor for Koenigs-Knorr-type 
reactions and is commercially available. However, proper handling and storage of the sugar is 
vital to avoid ready decomposition. 
One of the earliest examples of steroid glucuronylation was the preparation of 
dehydroepiandrosterone 3-glucuronide (or “dehydroandrosterone” in the text) by Schapiro in 
193986. The reaction of the corresponding methyl (2,3,4-tri-O-acetyl)-α-D-glucuronyl bromide 
1887,88 with dehydroepiandrosterone 19 (DHEA), with two equivalents of silver carbonate, 
afforded the protected glucuronide 20 in 24% yield. A subsequent hydrolysis with “baryta 
solution” or barium hydroxide, afforded the deprotected glucuronide, first as the barium salt 
then to the free acid 21 by exchange with sulfuric acid (scheme 10). 
As can be seen, the yield for this synthesis is rather low. Indeed, Koenigs-Knorr syntheses are 
typically plagued by low yields or the formation of unwanted by-products, or necessitate the use 
of carefully chosen conditions for sensitive substrates89,90. This comes about due to the fact that 
the sugar is unstable and can readily decompose under the sometimes forcing conditions, which 
also must be strictly anhydrous.  
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Scheme 10: Schapiro’s synthesis of dehydroepiandrosterone 3-glucuronide 21 by Koenigs-
Knorr chemistry using the glucuronyl donor 18 
In addition, most glucuronyl donors are prepared via acyl protection of the alcohols on the 
sugar. This mode of protection (i.e. as an ester) is responsible for the generally high β-selectivity 
observed in Koenigs-Knorr reactions and comes about as a result of neighbouring group 
participation.  
An SN2 reaction at the anomeric position (C1) can form the β-glucuronide directly and is the 
desired pathway (I to II) (scheme 11). However, it is also possible for metal- or Lewis acid-
mediated dehalogenation to form a transient oxonium ion species (I to III) that can be trapped 
by a neighbouring nucleophile on C2, in this instance the carbonyl of the acetyl group, to form 
the oxonium species (III to IV) via neighbouring group participation. Again, SN2 reaction of the 
acceptor alcohol at the anomeric position can lead to formation of the desired β-glucuronide II.  
 
Scheme 11: the pathways leading to formation of the β-glucuronide directly through SN2 
reactions at either the glucuronyl bromide I or the oxonomium species IV. Substituents at the 3-, 
4-, and 5-positions are omitted for clarity (R = alkyl, aryl etc.) 
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However, this process can also lead to the formation of an ortho-ester that can react with the 
acceptor alcohol. Further decomposition of this ortho-ester can afford either the desired 
glucuronide or a transacylation product (scheme 12)91.  
It is clear that there is an additional electrophilic site in this species IV and indeed addition of 
the acceptor alcohol to the cation of IV leads to the formation of ortho-ester V (scheme 12). 
This ortho-ester can open to form an oxonium ion species that is then rapidly captured by 
another equivalent of the acceptor alcohol or another suitable nucleophile e.g. water if the 
reaction is not carefully dried (though the ortho-ester does not always do this completely and 
can persist to complicate purification of the desired glucuronide) to form a mix of α/β 
glucuronides VI. This can then decompose in two ways, the first being elimination of the 
acceptor alcohol to form the glucuronide products IIα/IIβ, and the second being elimination of 
the glucuronyl moiety to afford the C2-deprotected glucuronide VII and the transacylation 
product VIII. 
 
Scheme 12: the ortho-ester pathway leading to formation to either a mixture of α/β 
glucuronides IIα/IIβ or the C2-deprotected glucuronide VII along with the corresponding 
transacylation product VIII 
To avoid this problem higher acyl derivatives, such as the isobutyrates or the pivalates have 
been prepared for use in both Koenigs-Knorr chemistry and also for Schmidt glycosylation (see 
next section), but as might expected their preparation is slow due to the increased steric 
demand and this carries over to the final hydrolysis step92–94.  
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This can also sometimes contribute to elimination of the glucuronyl moiety from acidic phenols, 
or dehydration at the C4-C5 position (seen in the synthesis of Soraprazan glucuronide, for 
example)95,96. However, the formation of by-products is greatly reduced, presumably due to the 
greater steric bulk of the neighbouring groups. This disfavours neighbouring group 
participation, or addition to cation IV, and consequently significantly reduces ortho-ester and 
transacylation by-products. 
From time to time, different metal carbonate reagents are often required to perform a 
transformation that is unsuccessful under standard conditions. For example, to prepare 
glucuronides for phenolic steroids such as estrone 22, it was found that the standard Koenigs-
Knorr conditions (either silver carbonate or various heavy metal oxides) was insufficient and 
cadmium carbonate was developed for this purpose by Conrow & Bernstein (scheme 13)89. 
They were able to obtain a 71% yield of the protected estrone glucuronide 23, which compared 
favourably to silver carbonate (<7%) and the mercury oxide system (25%).  
Scheme 13: the demonstration of cadmium carbonate (CdCO3) as a catalyst for the Koenigs-
Knorr synthesis of protected estrone glucuronide 23 by Conrow & Bernstein 
In summary, the Koenigs-Knorr-based glucuronylation is a venerable and time-tested method 
for glucuronide synthesis. However, there remain inherent disadvantages to this approach, in 
regards to synthetic length (synthesis of the sugar, deprotection) and the formation of by-
products. The necessary use of (heavy) metal carbonates also presents an environmental 
problem due to their inherent toxicities. 
1.5.1.2 Schmidt glycosylation 
In an effort to eliminate some of the disadvantages associated with the Koenigs-Knorr method, 
Schmidt & Michel reported the synthesis of a trichloroacetimidate donor 24, derived from 
glucose. This can be prepared from the corresponding protected 1-hydroxy sugar 25 as shown 
in scheme 14, itself prepared by selective deprotection of 1,2,3,4,6-penta-O-acetyl-β-D-
glucoside 26.  
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Scheme 14: the synthesis of 1-O-trichloroacetimidates such as 24 by the Schmidt protocol 
This trichloroacetimidate approach is commonly referred to as Schmidt glycosylation and 
quickly gained traction within the synthetic community. One of the advantages to this method is 
that the reliance on heavy metal salts is dispensed with; reactions with the 
trichloroacetimidates are typically performed using a Lewis acid catalyst such as boron 
trifluoride (as the diethyl etherate, BF3.OEt2) or trimethylsilyl trifluormethanesulfonate 
(TMSOTf), though use of the latter is rare. This avoids the contamination problem associated 
with Koenigs-Knorr chemistry and indeed this method has been widely applied to the synthesis 
of medicinally-relevant glucuronides, such as those of morphine96–100.  
An additional advantage of this approach over the Koenigs-Knorr reaction was that the order of 
addition can be manipulated and this can give better results, leading to either standard addition 
(glucuronyl donor + acceptor alcohol, then catalyst) or inverse addition (acceptor alcohol + 
catalyst, then glucuronyl donor)101. The latter method was proposed to better preserve 
particularly reactive glycosyl donors where complexation with the Lewis acid catalyst could 
lead to rapid decomposition of the sugar donor. Indeed, the stability of the glucuronyl donor is a 
problem that plagues both the Koenigs-Knorr and Schmidt glycosylation (to a lesser extent). 
As a final note, glucuronides can also be prepared via the oxidation of the corresponding 
glucoside, especially in instances where the glucuronylation step proves to be intractable102. 
Glucuronyl donors are actually poorer sugar donors than most other types as shown by Muller 
et al. and this is attributed to the electron-withdrawing properties of the C6-carboxyl 
functionality that reduces the reactivity of the glucuronyl donor103. For more information on the 
chemical strategy for glucuronylation (and glycosylation in general), some excellent reviews are 
highly recommended94,104–107. 
1.5.2 Enzymatic synthesis of glucuronides 
While it has been shown that chemical synthesis methods are reasonably effective at preparing 
glucuronides, especially via the Schmidt glycosylation method, there are applications for which 
these methods are incompatible; for example, the preparation of glucuronides for compounds 
that are only available in very small quantities or where additional 
functionalisation/deprotection steps and possible by-products can reduce the yield of an 
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already precious glucuronide. It comes as perhaps no surprise that enzymatic methods have 
been developed that function particularly well on these smaller scales and the two main 
approaches using mammalian and bacterial enzymes will be discussed. 
1.5.2.1 Recombinant UGT-mediated synthesis 
The first enzymatic strategy exploits the native glucuronylation activity of endogenous 
mammalian enzymes that are part of the UGT super-family17,29. These enzymes, as mentioned 
previously, perform glucuronylation in the body in phase II metabolism using uridine 5’-
diphosphoglucuronic acid 3 as a co-factor (UDPGA; scheme 15).  
 
Scheme 15: the general scheme for glucuronylation of various glucuronyl acceptors by UGT 
enzymes 
This strategy avoids several problems encountered in the chemical glucuronylation strategy. 
For example, the glucuronide product does not need deprotection as the glucuronyl donor is 
delivered as the free glucuronic acid and so typically require a single-step to prepare the desired 
glucuronide. Additionally these reactions tend to be stereospecific as would be expected from 
an enzyme-catalysed reaction. 
Naturally, these enzymes have been used to synthesise glucuronides of pharmaceutically-
relevant drugs and steroids among other substrates108–116. These enzymes are usually used as 
either a liver microsome preparation or expressed as a membrane-bound protein preparation, 
with the use of the UDPGA sugar 3 and various other co-factors present in the reaction mixture, 
such as MgCl2 and D-saccharic acid 1,4-lactone (as a β-glucuronidase inhibitor). 
While avoiding some of the problems associated with chemical methods, there remain several 
obstacles that prevent this method from becoming a general approach for glucuronide 
synthesis. The first are the enzymes themselves: the UGT enzymes function only as membrane-
bound proteins, which can pose a significant challenge for their expression and handling117–122. 
The liver preparations from which the enzymes are obtained also require animal sacrifice (for 
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microsomes obtained from rat, dogs etc.), which pose ethical problems of their own. 
Additionally the yields of the glucuronides tend to be fairly low, both in mass yields and in 
percentage yields, tending towards milligram quantities and <20% yields, although scaled-up 
syntheses have been attempted110,111. The UDPGA sugar 3 is also fairly unstable and expensive 
(e.g. $1580 per gram in the Sigma-Aldrich catalogue as of November 2015), requiring careful 
handling to ensure its usefulness in the reaction123. 
Additionally, the UGT enzyme superfamily comprises many different isoforms and expression of 
one particular isoform may not selectively afford the desired glucuronide as they can have 
overlapping substrate preferences, which can then necessitate expression of multiple isoforms 
or the use of a different liver preparation, which all contribute to additional time costs124. 
1.5.2.2 The Escherichia coli E504G β-glucuronylsynthase 
The second enzymatic strategy involves the use of a bacterially-derived engineered enzyme as 
the catalyst for glucuronylation, known as the β-glucuronylsynthase, and was pioneered by the 
McLeod group125. This enzyme is derived from the β-glucuronidase found in E. coli, although the 
β-glucuronidase enzyme is found in humans, other mammals and other microorganisms, the 
key difference being that the other glucuronidases are involved in oligosaccharide processing 
while the E. coli β-glucuronidase primarily acts to de-conjugate glucuronides to obtain 
glucuronic acid 6, which it uses as a carbon source126–130.  
The use of E. coli, and a β-glucuronidase deficient strain, as the expression system is pertinent as 
its genome is fully sequenced and biochemical techniques such as genome manipulation, cell 
growth and protein expression for this system are well developed and understood, thus 
avoiding many of the complications associated with the mammalian enzyme-based strategy. 
It is important to discuss the mechanism through which the wild-type enzyme carries out 
hydrolysis of glucuronides as this is critical to how the synthase works. The glucuronidase is 
well characterised and the mechanism is considered analogous for both prokaryotes and 
eukaryotes. The active site of E. coli glucuronidase is known to contain two key glutamate 
residues at positions 413 (E413) and 504 (E504), which function as a general acid/base and a 
nucleophile/nucleofuge respectively with the overall mechanism is considered to be a hybrid 
SN1/SN2 double displacement mechanism (scheme 16)131–133. The crystal structure of the E. coli 
β-glucuronidase was recently resolved as an inhibitor-bound tetramer with these active site 
residues clearly evident52. 
The first step in this mechanism involves SN2 reaction by the E504 residue at the anomeric 
carbon, facilitated by the E413 residue functioning as a general acid, which breaks the glycosidic 
bond, displacing the agylcone and forming an enzyme-linked intermediate (scheme 16). This 
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step is also considered to possess some SN1 character as the ring oxygen is capable of donating 
electrons to stabilise an electron-deficient anomeric carbon in the “exploded” transition state. 
 
Scheme 16: the mechanism of glucuronide hydrolysis by the E. coli β-glucuronidase 
The second step involves the entry of water into the active site. The E413 residue now functions 
as a general base and the E504 residue functions as a nucleofuge, facilitating the SN2 reaction at 
the anomeric carbon by water – again, with some SN1 character due to electron donation by the 
ring oxygen – and releasing the newly-formed glucuronic acid 6 from the enzyme with overall 
retention of configuration. This glucuronic acid is used by the organism as a source of carbon, 
and so the β-glucuronidase enzyme has evolved to be have promiscuous hydrolytic activity for a 
broad range of glucuronide substrates134. 
It may be expected that if an alcohol instead of water were to participate in the second 
nucleophilic substitution, it would be possible to form a transglycosylated product. This is 
known to occur and can be exploited to synthesise oligosaccharides but the transglycosylated 
product remains a substrate for hydrolysis, especially under aqueous conditions, typically 
resulting in poor yields unless careful substrate selection or perturbation of the enzymatic 
equilibrium is performed (e.g. with organic co-solvents)135–139. 
To overcome the limitations inherent in the transglycosylation approach, MacKenzie et al. 
developed the first glycosynthase mutant in which a β-glucosidase found in Agrobacterium sp. 
was subjected to a single-point mutation to remove hydrolytic activity140. The glutamate at 
position 358 was mutated to an alanine residue (E358A) to remove the nucleophile, thereby 
preventing degradation of the glucoside product 27. However, the rest of the active site remains 
intact and synthesis can be performed in the presence of a synthetically-derived α-D-glucosyl 
fluoride 28, where entry of the sugar into the active site leads to an SN2 reaction, facilitated by 
the other glutamic acid residue acting as a general base, of the acceptor alcohol at the anomeric 
carbon (scheme 17). This then leads to accumulation of the glucoside product 27. 
Chapter 1: Introduction 
18 
 
Scheme 17: the Agrobacterium sp. E358A mutant, with a proposed mechanism illustrating the 
synthesis of glycosides such as 27 using α-D-glucosyl fluoride 28 
The α-D-glucosyl fluoride donor 28 serves to mimic the enzyme-linked intermediate and in the 
presence of an acceptor alcohol (in this example a glucoside derivative) led to the formation of a 
new glycosidic bond. The synthesis of oligosaccharides (e.g. dimers, trimers) was achieved in 
good yields (66-92% for the glucose series) without any observed hydrolysis of the products. In 
addition, due to the stereospecific nature of enzymes, the corresponding glycosides can be 
prepared as single anomers, avoiding some of the pitfalls encountered in chemical syntheses. So 
far, this approach has been successfully demonstrated for the preparation of other 
oligosaccharides and glycosides141–146. 
At this point the use of glucosyl fluoride as the sugar donor should be noted as an especially 
important aspect of this approach. As mentioned previously, the sugars used in the chemical 
synthesis of glucuronides tend to be unstable, especially to moisture. The advantage of glycosyl 
fluorides is the greater strength of the C-F bond that increases the resistance of the sugar to 
hydrolysis. For example, the bond dissociation energies for CH3X (where X = F, Cl, Br, and I) are 
115, 84, 72 and 58 kcal/mol147. However, it should be pointed out that the hydrolysis of the 
glucosyl fluoride 28 leads to the formation of hydrogen fluoride and this is an even stronger H–
F bond, which contributes to the driving force for this reaction. The bond enthalpies for the 
overall process for the hydrolysis of methyl fluoride to methanol by water (in brackets are the 
enthalpies in kcal/mol): 
CH3F (115) + H2O (118.82) ⟶ CH3OH (92.1) + HF (136.25) 
give a reduction of 5.47 kcal/mol but the most dramatic change is the much higher bond 
enthalpy of HF demonstrating the increased bond strength147. 
Ultimately, glycosyl fluorides are stable enough to be used unprotected in aqueous conditions 
without significant decomposition and the fluorine atom is small enough such that it does not 
present any additional unfavourable steric demands, making it particularly useful in 
glycosynthase applications148. 
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Based on the glycosynthase approach developed by MacKenzie et al. it became apparent that a 
similar approach could be applied to the E. coli β-glucuronidase to afford a glucuronylsynthase 
that would be conceptually distinct to the use of mammalian enzymes for glucuronide synthesis. 
A single-point mutation at position 504 from glutamic acid to glycine removes the nucleophilic 
residue while leaving the glutamic acid at 413 intact. This then affords a glucuronylsynthase 
that is able to perform synthesis as mentioned previously, using α-D-glucuronyl fluoride 29 
(FGlu) as the sugar donor. The proposed mechanism for the synthase is analogous to the one for 
the glycosynthase of MacKenzie et al. (scheme 18).  
Scheme 18: the E. coli E504G mutant, with a proposed mechanism illustrating the synthesis of 
glucuronides 
In an initial screen based on a spectrophotometric assay developed by Wong et al., the aglycone 
specificity of the β-glucuronidase was probed using 2-deoxy-2-fluoro β-D-glucuronyl fluoride 
30. This compound contains two fluorine atoms that have differing roles. The first fluorine at 
the anomeric carbon remains a good leaving group, facilitating the formation of the enzyme-
linked intermediate, but the second fluorine atom acts to destabilise any carbocation character  
at the anomeric centre (due to electron withdrawal) and therefore the second step to release 
the sugar is substantially slowed, allowing for the trapping of an enzyme-linked intermediate. 
The competency of various alcohol acceptors in re-activating the hydrolytic activity of the 
enzyme was then assayed alongside p-nitrophenol glucuronide 31, which would also be 
hydrolysed should the enzyme be re-activated. This would then demonstrate the aglycone 
specificity of the inhibited β-glucuronidase enzyme for the various alcohol acceptors and this 
could be extrapolated to the glucuronylsynthase enzyme (scheme 19)149.  
Interestingly, no carbohydrate-based acceptors were able to sufficiently reactivate the enzyme 
compared to control experiments. Instead, it turned out that non-carbohydrate acceptors such 
as primary alcohols, cyclic secondary alcohols, substituted benzyl alcohols or naphthalene 
methanol derivatives were much better at reactivating the enzyme, showing that the enzyme 
appeared to prefer non-carbohydrate acceptors (figure 1).  
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This makes some sense as enteric E. coli i.e. those in the gut flora must compete with other 
microflora for a limited supply of carbohydrate-based nutrients150. However, most of the 
carbohydrates are known to be contained in mucosal polysaccharides and E. coli does not 
produce enzymes that are capable of degrading these polysaccharides, relying on other 
microorganisms to do this for them151,152. Therefore E. coli must be able to process whatever 
monosaccharide degradation products it comes into contact with e.g. glucuronides, thereby 
providing some explanation for the observed broad substrate scope as mentioned previously. 
 
Scheme 19: the spectrophotometric assay of the aglycone specificity of E. coli β-glucuronidase 
based on the protocol developed by Wong et al., showing the release of p-nitrophenol 32 as a 
result of the reactivation of the β-glucuronidase by some alcohol R–OH 
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Figure 1: some of the alcohol acceptors that were able to restore the hydrolytic activity of the 
inactivated β-glucuronidase enzyme 
1.6 Synthesis using the E504G glucuronylsynthase 
Three synthase mutants were obtained in the early stages of the synthase, these being alanine (-
Me; E504A), serine (-CH2OH; E504S) and glycine (-H; E504G) and tested for synthase activity 
using some of these alcohol acceptors. and of these, the serine mutant afforded no observed 
glucuronide product, while the alanine mutant was outperformed by the glycine mutant125.  
While the initial screen showed an interesting range of alcohol acceptors were suitable for the 
glucuronylsynthase protocol these substrates are also quite hydrophobic and in some cases 
required the use of additives such as dimethyl sulfoxide (DMSO) and n-dodecyl β-maltoside 
(DDM) to solubilise them, though at some cost to enzyme stability over time. Sodium phosphate 
buffer (NaPi) at 50 mM, pH 7.5 was used to maintain the pH of the reaction while the reactions 
were conducted at 37 °C to improve reaction rates over those observed at 21 °C. An 
investigation into the effect of pH of the reaction showed that the glucuronylsynthase has a 
broad operating pH range, much like the wild-type β-glucuronidase, with an optimum range at 
about pH 7-8153,154. In addition the glucuronylsynthase reaction typically required several days 
(3-4 d) to achieve optimum yields for the reaction, though no detectable enzyme degradation 
was observed by Wilkinson. 
This method was used to synthesise glucuronides of some simple alcohols in moderate to good 
yields (such as those in figure 1). In addition, the method was shown to be quite scalable, with 
some glucuronides prepared on hundreds of milligram scale125. However, for applications in the 
synthesis of steroid glucuronides, the method was not as impressive, with conversions typically 
obtained from 6-26% (table 1)155.  
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Scheme 20: the synthesis of DHEA 3-glucuronide 21 from DHEA 19 using the oxime 
solubilising strategy to improve the yield of glucuronide 
Table 1: previous syntheses of some steroid glucuronides using the glucuronylsynthase 
Glucuronylsynthase reaction Yield 
 
14 mg, 21%; 
75% of epi-
androsterone 
35 recovered 
 
8 mg, 12%; 
71% of 
testosterone 
13 recovered 
 
4 mg, 6%; 
93% of 
nandrolone 38 
recovered 
Chapter 1: Introduction 
23 
 
 
11 mg, 17%; 
20% of 
dehydroepi-
androsterone 
19 recovered 
 
While the yields were only modest for this range of steroids, what was interesting was that an 
oxime derivative of DHEA 19, dehydroepiandrosterone O-(carboxymethyl)oxime 33 (CMO-
DHEA), proved to be much more amenable to the glucuronylsynthase protocol compared to just 
DHEA 19, with a yield of 76% for the former compared to 17% for the latter. Later experiments 
revealed that additional equivalents of glucuronyl fluoride 29, and higher temperatures, could 
further drive the reaction to completion with a yield of 98% achieved with five equivalents of 
the sugar (the 76% yield was achieved with a single equivalent of sugar at room temperature). 
However, this remained a lengthy route to the synthesis of steroid glucuronides with 
deprotection required at the end (scheme 20).  
This suggested that an improved synthesis of steroid glucuronides would involve improving 
their solubility in aqueous conditions by the addition of solubilising tags, although an 
alternative, shorter approach would certainly be more desirable. 
It was discovered by Wilkinson that increasing the number of equivalents of α-D-glucuronide 
fluoride 29 could improve the yield of CMO-DHEA 3-glucuronide 34 from 48% (1 eq.) to 98% (5 
eq.) as assayed by HPLC. During this study the synthase reaction appeared to stop after a period 
of 14 h unless further equivalents of α-D-glucuronyl fluoride 29 were added. 
It was originally thought that the sugar quality was subpar despite characterisation data 
pointing to excellent purity. It was known that the sugar is heat-sensitive at 40 °C, a problem 
that is encountered when removing solvent on the rotary evaporator (an experience typically 
not repeated) during the isolation of the sugar. 
This raised questions about the stability of the sugar under the reaction conditions, which are 
conducted at 37 °C. An attempt by Wilkinson to examine this non-enzymatic hydrolysis of the 
sugar was carried out using 500 MHz 1H NMR and warming the D2O solution of sugar at 37 °C. 
Following the reaction over a period of 21 h, the formation of α/β glucuronic acid 6 could be 
observed with the hydrolysis rate constant kH determined to be 1.3 x 10–6 s–1 (scheme 21). This 
corresponds to a half-life of about 148 h or ~6.2 d, significantly longer than the duration of the 
glucuronylsynthase reaction. 
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Scheme 21: the 1H NMR study of the non-enzymatic hydrolysis of α-D-glucuronyl fluoride 29 
Unfortunately this had a few flaws in methodology, namely that the solvent does not replicate 
the sodium phosphate buffer that is used in the glucuronylsynthase reaction and does not take 
into account the effects of reaction additives155. This is important as sodium phosphate is known 
to increase the rate of hydrolysis of the α-D-glucosyl fluoride156. If this could be further 
investigated in a setting that more closely replicates the glucuronylsynthase conditions this 
would provide more information on the stability of the sugar in the synthase protocol.  
Instead, the additional equivalents of α-D-glucuronyl fluoride 29 were relieving what appeared 
to be product inhibition155. This makes sense as the glucuronide would be a suitable substrate 
for the wild-type β-glucuronidase and therefore would be expected to bind well to the synthase. 
A set of experiments was performed where CMO-DHEA 3-glucuronide 34 was added to the 
glucuronylsynthase reaction for 2-phenylethanol 39 in varying concentrations and the initial 
rate of formation of the corresponding glucuronide 40 was monitored (figure 2). 
  
Figure 2: the plot of initial rate of formation of 2-phenylethanol glucuronide 40 against the 
concentration of CMO-DHEA 3-glucuronide 34. Conditions: FGlu 29 (5 (green circle), 10 (red 
triangle) and 20 (blue diamond) μM), E504G (0.03 mg/mL), NaPi (100 mM, pH 7.5), 21 °C. 
Further analysis of this data appeared to show that CMO-DHEA 3-glucuronide 34 displayed 
predominantly competitive product inhibition of the 2-phenylethanol glucuronylsynthase 
reaction. Indeed, the kic (competitive inhibition parameter) for CMO-DHEA 3-glucuronide 34 
was shown to be 73 μM, indicating that the glucuronide binds much more tightly than the 
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parent steroid (discussed below). However, the apparent KM for α-D-glucuronyl fluoride 29 was 
about 0.15 μM and therefore the sugar binds even more tightly, providing a possible explanation 
for the observation that more equivalents of the sugar reduces product inhibition. 
1.7 Kinetics of the E504G glucuronylsynthase 
During the course of investigating the kinetics of the E504G glucuronylsynthase reaction CMO-
DHEA 32 was used as a model substrate to perform these studies due its superior aqueous 
solubility compared to the other steroids. 
However, the first attempt to generate a Michaelis-Menten plot of the data revealed that the 
steroid displayed substrate inhibition kinetics (figure 3) rather than normal Michaelis-Menten 
kinetics. Experimentally, a reaction performed with a saturating concentration of glucuronyl 
fluoride 29 and CMO-DHEA 33 at a concentration of 4 mM afforded less glucuronide product 
than the same reaction performed with the parent steroid at 2 mM, confirming the observation 
of substrate inhibition153. This led to a revision of the synthase protocol where steroid 
glucuronylsynthase reactions were performed at 0.69 mM (the approximate maximum of the 
substrate inhibition curve in figure 3) to improve the yields of the corresponding glucuronides. 
A possible solution (though not recognised at the time) to this problem came about from an 
investigation into the use of reaction additives as a way of improving the solubility of the 
typically hydrophobic substrates that have been used throughout Wilkinson’s studies. As 
mentioned previously DMSO and DDM have been used to improve the solubility of such 
substrates and their use arose from this study. 
 
Figure 3: the kinetics curve for CMO-DHEA 33 displaying substrate inhibition instead of 
Michaelis-Menten behaviour. Conditions: FGlu 29 (1 mM), E504G (0.06 mg/mL), NaPi (100 mM, 
pH 7.5), 21 °C. 
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However, such additives ultimately led to reduced overall yields. For example, the synthesis of 
CMO-DHEA 3-glucuronide 34 in the absence of additives afforded the glucuronide product in a 
76% yield, but in the presence of DMSO (4.3% v/v) the yield fell to 41%. Therefore an 
investigation into other additives on the glucuronylsynthase, both based on initial rate studies 
and overall yields was pursued by Wilkinson, in the search for a potentially better additive. In 
the initial rate study, all additives studied displayed a reduced initial rate compared to the 
control (no additive) in the glucuronylsynthase reaction for 2-phenylethanol 39 (figure 4).  
 
Figure 4: the effect of various reaction additives on the initial rates of the glucuronylsynthase 
reaction for 2-phenylethanol 39. Conditions: 2-phenylethanol 39 (94 mM), FGlu 29 (1 mM), 
E504G (0.05 mg/mL), NaPi (100 mM, pH 7.5), 21 °C. 
In the reaction yields study an interesting result was found where tert-butanol at a 
concentration of 5% v/v displayed a markedly greater initial rate of reaction followed by an 
improved yield over the other additives (figure 5). Looking to examine the solubility enhancing 
effect of tert-butanol a second study was performed where the concentration of CMO-DHEA 33 
was increased to 5 mM. 
In this second study the enhancing effect (in terms of reaction rate and yield) of tert-butanol 
was even more pronounced as is evident in figure 6. Intriguingly it showed that an increase in 
tert-butanol concentration displayed no marked improvement in the final yield of glucuronide. 
A further study with 10 mM CMO-DHEA 33 could only be accomplished with 10% v/v tert-
butanol, but it again showed a still greater increase in reaction rate. These results appeared to 
show that in the presence of tert-butanol the pronounced substrate inhibition observed in the 
absence of additives (as seen in figure 3) appears to be much diminished or indeed absent 
entirely. 
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Figure 5: the reaction profile for glucuronylsynthase reaction for CMO-DHEA 33 at 2 mM with 
various additives. Conditions: FGlu 29 (3 equiv.), E504G (0.4 mg/mL), NaPi (100 mM, pH 7.5), 
37 °C. 
 
Figure 6: the reaction profile for the glucuronylsynthase reaction for CMO-DHEA 33 at 5 mM 
with various additives. Conditions: FGlu 29 (3 equiv.), E504G (0.4 mg/mL), NaPi (100 mM, pH 
7.5), 37 °C. 
A follow-up experiment on the initial rates for the glucuronylsynthase reaction of the CMO-
DHEA 33 in the presence of several additives showed that while the other additives such as 
DDM, glycerol and DMSO displayed little improvement over the control, tert-butanol displayed a 
very pronounced improvement in initial rates and indeed with 10% v/v tert-butanol the initial 
rate appeared to steadily increase with substrate concentration (figure 7).  
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Figure 7: the effect of various reaction additives on the initial rates of the E504G 
glucuronylsynthase reaction for CMO-DHEA 33. Conditions: FGlu 29 (3 eq.), E504G (0.4 
mg/mL), NaPi (100 mM, pH 7.5), 37 °C. 
However, it should be noted that the reaction profile studies were all performed at 37 °C as well 
and indeed this apparent reduction in or disappearance of substrate inhibition as a possible 
result of tert-butanol was not investigated further as the aim of these studies was focused on the 
solubility-enhancing effect of tert-butanol with the ultimate goal of significantly improving the 
concentration of the hydrophobic steroid substrates in the glucuronylsynthase reaction. 
This meant that the actual contribution to this observed increase in initial rate and reaction 
yield for the glucuronylsynthase reaction for CMO-DHEA 33 could not be pinned down to either 
tert-butanol or temperature. To state this point in another way, substrate inhibition for CMO-
DHEA 33 was observed at 21 °C in the absence of tert-butanol but was not observed at 37 °C in 
the presence of tert-butanol, but no experiments to isolate either variable were performed. 
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1.8 Project goals 
This project had several goals that were pursued and are detailed in the following chapters.  
In chapter 2, the synthesis of steroid glucuronides using an improved protocol was the primary 
focus, in particular for analytical scale syntheses. This would provide a useful method for the 
preparation of steroid glucuronides for anti-doping purposes where milligram quantities of 
pure glucuronide are sufficient for use as reference standards in LC-MS analysis. Based on the 
interesting kinetics findings by Wilkinson, the glucuronylsynthase protocol was revised to 
include tert-butanol as a 10% v/v concentration on the basis that it would help activate the 
enzyme. This has the added bonus of improving the concentration of the steroid substrates in 
the mostly aqueous conditions and would address the key challenge of using hydrophobic 
substrates such as steroids under the aqueous conditions necessary for the glucuronylsynthase 
protocol.  
Firstly, a rapid purification method was required to enable the analysis of reactions on the 
milligram scale as standard chromatography techniques would prove to be too laborious. The 
approach taken was to use solid-phase extraction, or SPE, to perform this rapid purification. A 
previous exploratory method of purifying glucuronides using solid-phase extraction was 
attempted by Wilkinson but was not as successful as anticipated155. 
Secondly, a screen of steroid substrates was performed to determine the steroids that will be 
amenable to the glucuronylsynthase protocol. Following on from this a quantitative analysis of 
the glucuronylsynthase protocol for steroid glucuronides was performed to provide more 
information on the expected different reactivities of the steroid substrates. Scale-up syntheses 
of a number of steroid glucuronides was also performed to afford characterisation data for 
some poorly characterised glucuronides. Finally, synthesis of some non-steroidal glucuronides 
was performed to hint at the broader substrate scope of the glucuronylsynthase protocol. 
In chapter 3, the protocol was explored in the context of labelled glucuronides, where an 
alternative method for labelling glucuronides was demonstrated as a proof-of-concept. This 
involved the use of 18-oxygen (18O) as the labelling atom instead of the more standard 2-
deuterium (2H) for a simpler method to access a broad range of labelled steroid glucuronides. 
To do this an alternative method for the preparation of the α-D-glucuronyl fluoride 29 was 
developed, as a direct consequence of the mechanism of the required oxidation reaction. This 
was then used to prepare a labelled bis-glucuronide derivative of epiandrosterone 35. 
In chapter 4 the kinetics of the glucuronylsynthase was examined with regards to tert-butanol 
and temperature in an effort to pin down the origin of the improvement in initial rates, with an 
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emphasis on Michaelis-Menten kinetics modelling. Two variables were examined, that of tert-
butanol concentration (0% and 10%) and temperature (21 °C and 37 °C). It was expected that at 
21 °C without tert-butanol the resulting curve will display substrate inhibition. A change in tert-
butanol concentration or temperature would then be expected to yield interesting information 
on the effect that both variables exert on the kinetics of the enzyme and further analysis would 
be expected to provide clues to the effect of tert-butanol on the glucuronylsynthase reaction. 
In addition, the stability of the glucuronyl fluoride under the glucuronylsynthase conditions was 
investigated to determine if the sugar is decomposing at a significantly rapid rate to affect the 
overall yield of glucuronide. Experiments were performed in various buffers and at 37 °C to 
replicate the glucuronylsynthase reaction conditions. The effect of tert-butanol was also 
investigated at 10% v/v.  
Ultimately, the extension of the glucuronylsynthase protocol through the use of tert-butanol and 
the development of a simple and rapid solid-phase extraction-based purification protocol is 
expected to transform this synthetic protocol from one that is challenging to perform, with 
examples only for simple alcohols, to one that is readily accessible to most skill levels with 
synthetic examples available for more complex substrates. The reduction in operational 
complexity, along with an improvement in yields of the glucuronide targets, is expected to be 
the first step towards the broader adoption of the glucuronylsynthase protocol as an alternative 
enzymatic method for the synthesis of glucuronides, not just on analytical scales as 
demonstrated in this thesis, but potentially on synthetically-useful scales where the mammalian 
approach is no longer feasible. 
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Chapter 2: Synthesis of steroid glucuronides 
2.1 Introduction & previous work 
As mentioned in section 1.6, the E504G glucuronylsynthase protocol was used to prepare 
glucuronides of steroids such as those seen previously in table 1. However the poor 
conversions for these steroids would have to be overcome to develop the glucuronylsynthase 
protocol as an alternative approach for glucuronide synthesis. In particular, for analytical 
applications (e.g. for the preparation of steroid glucuronides for anti-doping purposes) greater 
conversions would be necessary considering that only small amounts of starting material are 
often used or available. 
As has been emphasised in section 1.6, the steroid substrates are quite hydrophobic 
compounds and this presents a challenge in dissolving them under the aqueous conditions. One 
modification to the glucuronylsynthase protocol was the discovery that tert-butanol appeared 
to improve the reaction rates and overall yields of the synthase reaction using CMO-DHEA 33 at 
5% or 10% v/v at 37 °C. Most importantly it was the only reaction additive studied by 
Wilkinson that did not display any deleterious effects on the initial rates of the synthase 
reaction. Out of the choice of 5% or 10% v/v, it appeared that at 10% the synthase reaction was 
much faster compared to that observed for 5% v/v tert-butanol. The higher concentration of 
tert-butanol would serve to improve the concentration of steroids in solution as well. 
Additionally, upon inspecting the kinetics of CMO-DHEA 33 in Wilkinson’s study at 21 °C it was 
found that a maximum rate was achieved around 0.69 mM and concentrations either side of this 
led to diminished initial rates (in the case of higher concentrations, the rates were greatly 
reduced) due to apparent substrate inhibition. It was anticipated that these modifications would 
then form the basis for a revised glucuronylsynthase protocol that could improve upon the poor 
conversions of the initial steroid glucuronide experiments. 
2.2 Synthesis of steroid glucuronides 
2.2.1 Development of the solid-phase extraction protocol 
The previous method of purification for glucuronides from the glucuronylsynthase reaction 
employed normal- or reverse-phase chromatography with a mobile phase of either 7:2:1 ethyl 
acetate:methanol:water or 25% aqueous acetonitrile with 0.1% formic acid. As might be 
expected on analytical scales these chromatographic methods were time-consuming and 
resulted in the loss of material or contamination with silica gel to give inaccurate yields. 
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Therefore a different purification method was sought to simplify the approach on analytical 
scales and solid-phase extraction was selected as the most viable method to this end. 
2.2.1.1 Principles of solid-phase extraction 
It is useful at this point to discuss the principles of solid-phase extraction. Solid-phase extraction 
(hereafter abbreviated as SPE) is an analytical technique commonly used in anti-doping 
laboratories for quick and efficient extraction of compounds of interest from a matrix such as 
urine. It is commonly used alongside the other well-known analytical techniques (especially in 
anti-doping laboratories) such as gas chromatography-mass spectrometry (GC-MS) and liquid 
chromatography-mass spectrometry (LC-MS)75. 
What differentiates SPE from standard chromatography methods is that the separation of 
compounds from a mixture by SPE is dependent upon the differing chemical properties of the 
compound and their resulting absorption onto a solid support (sorbent), whereas by flash 
column chromatography the separation depends upon the retention of the compounds on silica. 
Typically, SPE is performed in cartridge form as opposed to the use of a glass column and can be 
used as an array of cartridges when high-throughput purification is required. 
The sorbent for a cartridge has various functional groups attached, with some having high 
affinity for anions, others for cations, and still others for lipophilic/hydrophilic interactions, 
depending on the type of cartridge used. Through the use of carefully chosen mobile phases 
during elution it is theoretically possible to separate all or most of the components selectively 
with very little if any contamination. 
As an example of how SPE works, figure 8 illustrates the extraction of DHEA 3-glucuronide 21 
directly from a reaction mixture by the use of an Oasis WAX (weak anion exchange) cartridge, 
referred to as a mixed mode polymeric, weak anion exchange system. The reaction mixture 
contains the parent steroid 19, α-D-glucuronyl fluoride 29 (with possible hydrolysis product 6), 
the glucuronide product 21, and the glucuronylsynthase enzyme. 
There are three key components present on the sorbent of the cartridge. The first component is 
the polymeric hydrocarbon functionality (green), which provides the lipophilic interaction with 
the similarly lipophilic backbone of the steroid. The second component is the hydrophilic, 
neutral functionality (red), such as the γ-lactam, which provides the polar interactions with the 
hydroxyl groups on the sugar.  
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Figure 8: the chemistry of an Oasis WAX SPE cartridge, illustrating the purification method for a 
crude glucuronylsynthase reaction of DHEA 19, with the corresponding functionalities on the 
sorbent, colour-coded for clarity 
The third and perhaps the most important component is the ionic functionality (blue) of 
piperazine, or more specifically the piperazinium cation, which is generated by the initial pre-
conditioning of methanol followed by water to protonate piperazine, which is sufficiently basic 
at about pH 6-7. This provides the necessary ionic interaction with the carboxylate moiety of the 
sugar, also charged at pH 6-7, allowing it to trap the sugar and the glucuronide. 
The first mobile phase (in this example; other mobile phases may be used depending on 
requirements) is 2% v/v aqueous formic acid, which serves to elute the sugar(s) and any salts 
selectively by protonating the carboxylate group. This may also protonate the same group on 
the glucuronide 21, but since this leads to an effectively neutral organic compound the 
glucuronide (and the parent steroid 19) does not partition favourably into the mobile phase, 
while the sugar is readily eluted.  
Once the aqueous formic acid elution is completed, the cartridge is then washed thoroughly 
with water, which returns the pH of the mobile phase to about 6-7, thereby re-ionising the 
carboxylate on the glucuronide 21. 
 
Chapter 2: Synthesis of steroid glucuronides 
34 
 
Elution with methanol is then performed. The parent steroid 19 is readily soluble in methanol, 
as is the glucuronide 21. However, as the glucuronide 21 exhibits a charged interaction with the 
stationary phase it does not partition into the mobile phase, while the parent steroid 19 is 
readily eluted. 
All that remains to be done is to elute the glucuronide 21 from the sorbent. This is achieved by 
using 5% v/v ammonium hydroxide in methanol as the mobile phase. Here, ammonium 
hydroxide deprotonates the piperazinium cations, removing the charged interaction and 
allowing the glucuronide to partition into methanol and elute from the SPE cartridge in the form 
of an ammonium salt. 
There are many different cartridge types that may be used depending on the components 
present in the mixture of interest, and manufacturers may publish some recommended 
methodologies for their cartridges.  
2.2.2.2 SPE cartridge evaluation 
For evaluation of solid phase extraction as a rapid purification technique for the 
glucuronylsynthase reaction, two cartridges for SPE that were on hand in our laboratory were 
trialled, namely the Oasis WAX cartridge (as previously described) and the Bond Elut Certify II 
cartridge (manufactured by Varian), both of which were mixed-mode reverse-phase anion 
exchange cartridges. A number of protocols were also examined for use with these cartridges. 
These were the Oasis WAX and the Australian Racing Forensic laboratories (AFRL) protocols for 
the WAX cartridge, and the Oasis MAX, ARFL, and manufacturer’s protocols for the Bond Elut 
Certify II cartridge (figure 9). 
A concentration of 0.69 mM stock solution in buffer and 10% (v/v) tert-butanol was prepared 
for both DHEA 19 and DHEA 3-glucuronide 21 in a 1:1 mixture used to simulate an enzyme 
reaction where ~50% conversion had occurred. 
 The first cartridge, the Oasis WAX cartridge, uses mixed-mode reverse-phase sorbent 
containing polar and weak anion exchange functionalities (as seen previously in figure 8).  
Using the WAX protocol, we initially observed that DHEA 3-glucuronide 21 was being eluted in 
the flow-through (solvent from loading the enzyme reaction on the cartridge). In fact, we could 
only load about 1% of the resin mass – for example, the WAX cartridge has a stated resin mass 
of 60 mg – and so we were only able to separate ~0.5 mg at a time.  
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However, once the loaded mass was reduced (for all future SPE analyses as well) we no longer 
observed any loss of glucuronide during loading. A water wash was also inserted in between the 
2% (v/v) aqueous formic acid and methanol fractions when glucuronide was observed to elute 
in the methanol fraction, with the concern that some of the glucuronide was still protonated and 
could therefore co-elute with the parent steroid 19. A subsequent purification using this 
protocol and cartridge afforded clean isolation of the glucuronide with no observed parent 
steroid contaminant. 
 
Figure 9: The four protocols examined for solid phase extraction of glucuronides 
The ARFL protocol did not appear to match the degree of selective elution that was afforded by 
the WAX protocol, with elution of the glucuronide observed in both flow-through and methanol 
fractions (which also contained the parent steroid) as well as the final MeOH : EtOAc : formic 
acid fraction, and was not investigated further. 
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The Bond Elut Certify II cartridges were then evaluated to see if they could also perform as well 
as the Oasis WAX cartridge in cleanly isolating the glucuronide product. The Bond Elut Certify II 
cartridge is also a mixed-mode cartridge with hydrophobic (C8) and strong anion exchange 
(SAX) functionalities present on the sorbent. 
Using the Oasis MAX protocol it was observed that the parent steroid selectively eluted in the 
methanol fraction but the glucuronide eluted in all but the flow-through fractions, and so this 
protocol was not investigated further. 
The ARFL protocol did not provide satisfactory results either, with the glucuronide observed to 
elute in the water fraction as well as the methanol fraction, which resulted in the contamination 
of the glucuronide with parent steroid. Therefore, this protocol was not investigated further. 
Finally, the use of the manufacturer’s protocol for the Certify II cartridge was examined. It was 
observed that the glucuronide eluted in the same fraction as the parent steroid and therefore it 
again could not be applied. 
In summary, the Bond Elut Certify II cartridge was unable to isolate the glucuronide product 
cleanly, in contrast to the successful isolation of glucuronide product by the Oasis WAX 
cartridge. 
A final test of the utility of the Oasis WAX cartridge was its effectiveness in purifying DHEA 3-
glucuronide 21 (from a synthesis with DHEA 19) from a glucuronylsynthase reaction, with the 
reaction mixture loaded directly onto the cartridge. Using the modified Oasis WAX protocol 
(with the extra water wash) it was again observed that clean separation of glucuronide from 
parent steroid DHEA 19 was achieved, confirming its viability as the purification protocol for 
the glucuronylsynthase reaction. Consequently the Oasis WAX cartridge with modified protocol 
was used for purifying the glucuronylsynthase reaction. 
2.2.2 Screening the steroid library 
While a few steroid substrates were tested previously by Wilkinson, the broader scope of the 
synthase protocol remained unexamined. Therefore a screen of a suitably diverse steroid 
library was performed. For example, different stereochemistries of the alcohols, different 
structural features etc. would be desirable to demonstrate the broad applicability of this 
protocol. 
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The steroids chosen for the primary screen are shown in figure 10 and 11 with the expected 
sites of glucuronylation highlighted in blue. There are a range of stereochemistries about the 
alcohol acceptor site (compare epiandrosterone 35, androsterone 43, etiocholanolone 46 or 
testosterone 13 and epitestosterone 41) and different structural features (compare 
epiandrosterone 35 with methandriol 44, mesterolone 45, nandrolone 37 and estrone 22). 
 
Figure 10: the initial steroid library for the glucuronylsynthase protocol screen. Highlighted in 
blue are the expected sites of glucuronylation and numbering at the sites are provided for ease 
of reference (e.g. “the C3 position is an expected site of glucuronylation for epiandrosterone”) 
 
Figure 11: the estrogen and cholestane steroids chosen for the initial screen 
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In addition there are a couple of tertiary alcohols present that could potentially also react 
productively (methandriol 44 and methyltestosterone 48). However, these sites are very 
sterically hindered and it was expected that if glucuronylation were to occur at all (an 
interesting prospect by itself) then the conversion to the glucuronide would be low. Some 
representative steroids from the cholesterol family were also chosen (compare lithocholic acid 
49 with cholestene-3β,25-diol 52, for example). 
A qualitative assessment was performed for the steroid library to determine how well the 
enzyme could process each steroid. The 1H NMR spectra and mass spectra of the purified 
compounds were examined and the relative intensities of the key peaks were assessed, such as 
those for the anomeric proton, the steroid backbone etc.  
The results of this screen and the predicted products are presented in table 2 with the end 
assessment of each reaction given as tick marks, with three ticks indicating excellent reactivity 
(e.g. a high quality 1H NMR spectrum), two ticks indicating moderate reactivity (e.g. an average 
1H NMR spectrum where some key peak are either indistinguishable or undetectable) and one 
tick indicating poor reactivity (e.g. poor signal-to-noise ratio in the 1H NMR spectrum or only 
detectable by mass spectrometry). 
Table 2: the results of the qualitative screen of the steroid library 
Entry Glucuronylsynthase reactiona Assessment 
1 
 
   
2 
 
 
3 
 
 
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4 
 
   
5 
 
   
6 
 
   
7 
 
   
8 
 
 
9 
 
  
10 
 
  
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11 
 
 
12 
 
   
13 
 
   
14 
 
 b 
15 
 
   
16 
 
 
17 
 
NRc 
Chapter 2: Synthesis of steroid glucuronides 
41 
 
aReaction conditions: steroid (~1 mg, 1.0 equiv., 0.69 mM), α-D-glucuronyl fluoride (5.0 equiv.), 
tert-butanol (10% v/v), NaPi (50 mM, pH 7.5), E504G glucuronylsynthase (final concentration = 
0.2 mg/mL), 37 °C, 3 d. bContained some parent steroid in the final product. cNo reaction. 
Pleasingly, several important steroid glucuronides such as those of testosterone 13, 
epitestosterone 41, nandrolone 37 and methandriol 44 afforded sufficient quantities of the 
corresponding glucuronides for 1H NMR spectra with excellent signal-to-noise ratio. In addition, 
glucuronides of etiocholanolone 46 and androsterone 43 were part of a successful WADA 
research project on longitudinal monitoring of steroid abuse and their successful syntheses here 
directly demonstrates the potential utility of this approach for anti-doping efforts157.  
Androsterone 43 exhibited the lowest activity when compared to etiocholanolone 46 and 
epiandrosterone 35, which could most likely be attributed to the axial orientation of the C3 
hydroxyl in androsterone 43 as opposed to the equatorial orientation of the same hydroxyl 
group for etiocholanolone 46 and epiandrosterone 35. However, etiocholanolone 46 is also 
somewhat more hindered than epiandrosterone 35 as the cis-fused A & B rings contribute to 
steric bulk around the alcohol (figure 12).  
 
Figure 12: the three-dimensional representations of epiandrosterone 35, etiocholanolone 46 
and androsterone 43 showing the arrangement of the C3 hydroxyl groups 
The successful syntheses of glucuronides of estrone 22 and estradiol 51 were also achieved, 
with mono- and bis-glucuronylation observed for estradiol 51, suggesting that phenol-based 
glucuronides are readily accessed by the glucuronylsynthase, even when another reactive 
alcohol is present.  
For estradiol 51, by 1H NMR it appeared that approximately two-thirds of the mixture contained 
a C17 glucuronide, and that approximately one-third of the mixture was bis-glucuronide, 
assuming that the C17 hydroxyl is more reactive due to the delocalisation of the lone pairs on 
the phenolic oxygen into the aromatic ring. However, this remained conjecture until further 
quantitative analyses could be performed. 
The poorer reactivity of the cholesterol derivatives may be explained by their higher relative 
hydrophobicity conferred by the long hydrophobic alkyl chain attached to the C17 carbon. This 
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translated into difficult reaction preparations as dissolving them in aqueous media even with 
10% v/v tert-butanol proved to be impossible and all resisted complete dissolution with the 
final reactions performed with a saturated solution of the steroids. It appears that further 
hydroxylation on the backbone of the steroid does not improve yield (a glucuronide of 
cholestane-3β,5α,6β-triol 53 was not observed even by mass spectrometry), but the presence of 
a polar group on the pendant alkyl chain, as found in lithocholic acid 49 (shorter chain with a 
carboxylic acid) and cholestene-3β,25-diol 52 (a hydroxyl group at C25) seems to greatly 
improve solubility, although again saturated solutions resulted. 
The sample of lithocholic acid glucuronide 64 was unfortunately contaminated with some 
parent steroid though this was not unexpected as the presence of a carboxylate would aid 
retention of the parent steroid on the cartridge sorbent during the methanol wash. However, 
this would prevent isolation and consequent characterisation of the pure glucuronide. At the 
time of screening alternative methods of purification were not available within the group but 
with recent developments in C18 SPE methodology it is envisaged that future experiments with 
steroids such as lithocholic acid 49 using C18 SPE purification would be able to separate the 
more polar glucuronide from the parent steroid. 
Methyltestosterone 48 was expected to be a difficult prospect due to the greater steric 
hindrance as a tertiary alcohol compared to the other secondary alcohols in the screen. While 
trace amounts were detected in mass spectrometry for methyltestosterone glucuronide 61, no 
bis-glucuronide was observed for methandriol 44 and cholestene-3β,25-diol 52, with 
glucuronylation observed to take place solely at the C3 hydroxyl group. This suggested that in 
the presence of alternative reactive centres the glucuronyl moiety will react preferentially at the 
less sterically hindered sites, as expected. 
Curiously, boldenone 47 also afforded only trace amounts of glucuronide, despite its similarities 
to the other successful C17 hydroxylated steroids. Whether the different shape of the A ring of 
the steroid is the cause for such a significant reduction in yield of glucuronide remained 
unknown. 
From the initial screen a general trend began to emerge from the data. It appeared that the C3 β-
hydroxylated steroids have the highest reactivity, followed by their C17 β-hydroxylated 
counterparts. The α-hydroxylated steroids make up the next tier of reactivity, with the least 
reactive steroids those that are either poorly soluble under the conditions (e.g. coprostanol 50) 
or particularly sterically hindered, such as methyltestosterone 48. To put this another way the 
reactivity trend appears to be C3 β-OH > C17 β-OH > C3 α-OH ≈ C17 α-OH. 
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Figure 13: the low-resolution negative-mode electron-spray ionisation (LR-ESI) mass spectrum 
for methyltestosterone 17-glucuronide 61 showing the small peak observed for the glucuronide 
It was also pleasing to see that a broad range of steroid substrates could be processed by the 
glucuronylsynthase albeit with varying degrees of success. This broad substrate scope reflects 
the comment in section 1.5.2.2 that E. coli must compete with other gut microflora for a limited 
supply of nutrients and therefore the β-glucuronidase enzyme with which it uses to harvest the 
glucuronic acid as a carbohydrate source from glucuronides must then be fairly non-specific for 
the aglycone portion of the molecule. 
2.2.3 Conversion experiments 
Having qualitatively assessed the steroid library under the glucuronylsynthase protocol it was 
time to perform a quantitative analysis of these substrates to provide a firmer understanding of 
just how well each steroid performs. This involved eluting both the parent steroid and the 
glucuronide product so that a quantitative analysis of the relevant protons in the mixture by 1H 
NMR (either 400 or 600 MHz, with 800 MHz used in rare instances) could be performed by 
determining the ratio of parent steroid and glucuronide product, which would give a % 
conversion for the reaction. For example, if the same proton in both compounds integrated to 1 
proton each, then this would indicate a 50% conversion to the glucuronide product. 
This required a modification of the SPE protocol described in figure 8, where DHEA 3-
glucuronide 21 was separated from the parent steroid DHEA 19. To elute both compounds 
together the methanol wash had to be omitted as otherwise the parent steroid would be eluted 
preferentially. Therefore, after the water wash direct elution of both compounds was achieved 
by elution with 5% v/v methanolic ammonium hydroxide. 
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This approach was adopted as precise analysis of yields would not be reliable on milligram 
scales. The steroids and their conversions examined in this manner are shown in table 3. The 
successful steroids from the qualitative screen, as well as some additional compounds of 
interest, were subjected to this quantitative study. 
Table 3: the conversion experiment results for the glucuronylsynthase reactions with a range of 
steroid substrates 
Entry Glucuronylsynthase reactiona Conversionb 
1 
 
90% 
2 
 
<5%c 
3 
 
25% 
4 
 
87% 
5 
 
32% 
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6 
 
50% 
7 
 
28% 
8 
 
64% 
9 
 
8% 
10 
 
13% 
11 
 
12% 
12 
 
<5%c 
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13 
 
33% 
14 
 
88%d 
15 
 
36% 
16 
 
20% 
17 
 
21% 
18 
 
22% 
aReaction conditions: steroid (~1 mg, 1.0 equiv., 0.69 mM), α-D-glucuronyl fluoride (5.0 equiv.), 
tert-butanol (10% v/v), NaPi (50 mM, pH 7.5), E504G glucuronylsynthase (final concentration = 
0.2 mg/mL), 37 °C, 2 d. bAs determined by 1H NMR integration of the relevant protons (as 
indicated on the steroid structures). cNot observed by 1H NMR. dEluted as a 1.0:1.6:1.1 mixture 
of 3-mono-, 17-mono- and 3,17-bis-glucuronides as determined by 600 MHz 1H NMR 
integration. 
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One subtle difference between the initial screen and the conversion analysis is that the reaction 
duration was reduced from 3 days to 2 days. This is because the enzyme had been observed to 
display some hydrolytic activity (albeit slow) when incubated at room temperature with para-
nitrophenol glucuronide (colour change apparent after ~3-5 h) – this was a routine test to check 
for hydrolytic activity and enzyme preparations that displayed rapid hydrolysis i.e. rapid yellow 
colouration of the solution were discarded. This rate of hydrolysis was never quantified but the 
mere observation of such activity led to the reduction in reaction time in an effort to minimise 
the hydrolytic loss of glucuronide while maintaining high synthetic yield of the glucuronide. 
An explanantion for this may be found in the expression of the glucuronylsynthase. Electro-
competent, β-glucuronidase deficient strains of E. coli cells are transformed using a plasmid 
vector containing the glucuronylsynthase and kanamycin-resistance genes.  
These transformed cells are then grown on Luria Broth agar selection plates containing 
kanamycin and X-Gluc 74. Kanamycin serves to weed out cells that have not been transformed 
(as without the kanamycin resistance gene they would be susceptible), while X-Gluc 74 serves 
as a colorimetric indicator of glucuronidase activity, as cleavage of the glucuronide liberate 
compound 75a, which dimerises to form a vivid blue/indigo compound 75b (scheme 22).  
 
Scheme 22: i) the hydrolysis of X-Gluc 74 by E. coli glucuronidase liberates compound 75a that 
ii) dimerises to the vivid blue/indigo compound 75b, used to indicate the presence of 
glucuronidase enzyme 
Colonies that are both colourless and of good size are then chosen for overexpression at 37 °C of 
the glucuronylsynthase enzyme. However, it was sometimes that case that bacterial colonies 
that grew well on the plate without displaying any blue colouration still ended up displaying 
some hydrolytic activity in the final enzyme preparation. 
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Although the selection and expression of the enzyme is expected to be strongly biased towards 
expression of only the glucuronylsynthase, it was observed by Shu-Ann Chan in the Ollis group 
that the presence of hydrolytic activity in the final enzyme prep could still arise due to the 
phenomenon of translational misincorporation, where errors in protein translation could lead 
to low levels of incorporation of a glutamate in the active site, leading to the presence of 
undesired wild-type protein in the final preparation, which would then display hydrolytic 
activity alongside synthetic activity158,159.  
Even though the frequency of such an event is on the order of 10–5 to 10–6, this posed a problem 
as the kcat for the glucuronidase, for CMO-DHEA 33, is much higher than the kcat for the 
glucuronylsynthase: 76 s–1 vs. 1.4 x 10–3 s–1 respectively, with the glucuronidase on the order of 
105 times faster than the glucuronylsynthase153. Therefore, even a 1:10–5 occurrence of 
misincorporation would have a demonstrable impact on glucuronylsynthase conversions. 
Additionally, some difficulties were encountered during various preparations of the enzyme, 
where expression of the enzyme was not successful at all despite the observation of good colony 
growth on the agar selection plate. The origin of this problem was investigated for some time as 
it presented a significant roadblock to the completion of this project. Later preparations of the 
enzyme, by a method developed by Shu-Ann in the Ollis group using an alternate plasmid vector 
and electro-competent cells were observed to have negligible hydrolytic activity and much more 
consistent and higher expression of enzyme, where milder expression conditions (at 30 °C 
overnight) were proposed to contribute to this higher yield and absence of translational 
misincorporation. 
Glucuronylation at the respective positions on the steroids led to a substantial downfield shift of 
the oxymethine proton, typically ranging from 0.24-0.31 ppm. The anomeric proton always 
displayed a coupling constant of 7.8-8.0 Hz, which is consistent with a β-glycosidic linkage that 
contains an axial-axial relationship between the anomeric and the adjoining proton (figure 14). 
To give a related example, in 2,3,4,6-tetra-O-acetyl-α-D-glucosyl fluoride 76, which has an axial-
equatorial relationship between these two protons, the coupling constant is 2.8 Hz, whereas in 
the 1,2,3,4,6-penta-O-acetyl-β-D-glucoside 26 the coupling constant for the axial-axial 
relationship of the same protons is 8.4 Hz. 
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Figure 14: the trans-diaxial relationship and axial-equatorial relationship between the 
anomeric proton and the adjacent proton, highlighted in red, with a related sugar example 
highlighting the observed coupling constants for the anomeric proton 
For steroids where there is no oxymethine proton to observe, such as estrone and estradiol (at 
C3), the shifts are slightly larger at about 0.32-0.34 ppm for H1, H2 and H4. Additionally the 
anomeric proton on the glucuronyl moiety at C3 for these two steroids is obscured by the water 
peak (δ 4.79 ppm) in the deuterated methanol solvent due to the increased de-shielding of that 
proton as a result of the aromatic ring. 
For some steroids such as DHEA 19 the conversion could not be determined from inspecting the 
shift in the H3 protons, but surprisingly there is a discernible shift in the H6 proton, though 
analysis at 600 MHz is necessary as the resolution on the 400 MHz spectrometer was 
insufficient to achieve baseline separation of the relevant peaks (figure 15). This method of 
analysis was used to quantify the conversion for these types of steroids. 
 
Figure 15: the 600 MHz 1H NMR for the conversion experiment for DHEA 3-glucuronide 21 
showing the peaks for H6 (5.41 ppm), H20 (4.40 ppm), H3 (3.66 ppm) and the sugar protons 
The general reactivity trends observed from the initial screen were borne out in the conversion 
analysis. For example the C3 β-hydroxylated steroids such as epiandrosterone 35 and DHEA 19 
afforded the corresponding glucuronides in excellent conversion (90% & 87% respectively).  
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This stands as an impressive improvement over the previous synthesis of epiandrosterone 3-
glucuronide 36 and DHEA 3-glucuonide 21 (21% and 17% respectively) and vindicates the 
addition of tert-butanol to the reaction condition. 
Interestingly the other examples of methandriol 44 & pregnenolone 68 had greatly reduced 
conversions, which could be attributed to the different structural elements at the C17 position. 
In fact, methandriol 44 proved to be challenging to dissolve, which would have contributed to 
this reduced conversion. Pregnenolone 68 did not have this issue but the acetyl functionality 
might present some unfavourable interactions with the enzyme active site that affects the 
conversion, as it otherwise contains the same core as DHEA 19.  
The 17 β-hydroxylated steroids such as testosterone 13 and nandrolone 37 comprise the next 
tier of reactivity as seen previously. This is rationalised to be a consequence of the adjoining 
methyl group that would sterically hinder nucleophilic approach of the alcohol on the 
glucuronyl fluoride 29. Also, testosterone 13 is one of two steroids (the other being DHEA 19) 
that are routinely used to assess the activity of glucuronylsynthase preparations. Indeed, 
conversions for testosterone 13 and DHEA 19 are observed to have only minimal deviations 
about the conversions given in table 3 (n = 3, ±5%) when conducted under the same reaction 
conditions. 
In the initial screen boldenone 47 performed surprisingly poorly. A recrystallisation of the 
available material (from 100% acetone) was carried out to see if increased purity could improve 
the conversion. However, after observing a similarly low conversion (8%) for the glucuronide 
the poor reactivity is likely to be attributable to the unusual shape of the A ring. 
The second attempt at methyltestosterone 17-glucuronide 61 was poor again as might be 
expected and again only a small peak in the mass spectrum was observed. This confirms that 
tertiary alcohols fare very poorly under the glucuronylsynthase conditions but this is true also 
for chemical glucuronylation methods where the glucuronide 61 could only be prepared in 
3.5% yield (15 mg from 270 mg of the parent steroid). 
For some 17-hydroxylated steroids such as androstanolone 42 and mesterolone 45 the 
conversions were quite poor compared to testosterone 13, a finding that was suggested in the 
initial screen. These two are another set of steroids (as well as the cholestene,3β-25-diol 52) 
that were poorly soluble under the reaction conditions and again these reactions could only be 
performed using a saturated solution leading to lower conversions.  
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Some new steroids were included in the conversion analysis to replace some of the steroids 
from the initial screen including the designer steroids trenazone 70 and furazadrol 72. Designer 
steroids are chemically modified derivatives of legally approved steroids for therapeutic use – 
the catch is that these modified steroids are not approved for this purpose. Therefore their 
biological activities (e.g. side-effects, metabolic products) have not been well-studied83,160–162. In 
particular, reference data for these steroids and their metabolites may not be available, enabling 
athletes to avoid being caught in doping tests, posing a serious challenge for anti-doping efforts 
and the fairness of sporting endeavours. 
The isoxazole steroid furazadrol 72 is one such designer steroid that is known to possess some 
anabolic activity but has never been approved for such use and is marketed online as a “dietary 
supplement” to avoid regulatory requirements. 
It was found by Parr et al. that the dietary supplement Orastan-A, which claimed to contain 
oxadiazole 77, did not actually contain the stated compound but instead contained the isoxazole 
THP ether 78 (as one of two isoxazole steroids found), which suggested that intentional or 
unintentional mislabelling appears to be a tactic to avoid or circumvent legal requirements163. 
Therefore, there remains a need for the synthesis of such steroids and their corresponding 
metabolites such as the glucuronides for reference materials and to develop screening methods 
that can be then implemented in routine anti-doping analyses. 
 
Figure 16: the isoxazole THP ether 78 claimed as furazadrol 77 on the supplement Orastan-A 
as determined by Parr et al. 
The poorer conversions compared to testosterone 13 are likely related to the unusual core 
structures of the steroids that may have some unfavourable interactions with the enzyme active 
site. Additionally trenazone 70 was soluble under the conditions but furazadrol 72 afforded a 
fine suspension in solution. However, their successful preparation demonstrates the utility of 
the glucuronylsynthase protocol for preparing glucuronides of steroids of this type. 
To further demonstrate the utility of the approach for synthesising relevant anti-doping steroid 
glucuronides, a deuterated steroid glucuronide 80 was prepared from the parent steroid, d5-
etiocholanolone 79 (scheme 23). Etiocholanolone 46 was approved for study in WADA 
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research for monitoring longitudinal (long-term analysis) abuse of testosterone, for which 
etiocholanolone (among other known testosterone metabolites, both phase I and phase II) was 
used to develop a suitable analytical method. Preparing the deuterated form of the glucuronide 
would thus provide a source of labelled material for quantification of doping, by the use of an 
internal standard.  
This reaction was performed on 1 mg of parent steroid and sufficient steroid glucuronide was 
obtained for a high quality 1H NMR164. One point to note is that no conversion was obtainable for 
this reaction as might be expected from observing the parent steroid structure – there is no 
oxymethine proton or any nearby relevant protons that would assist in this analysis. However, 
the conversion with non-labelled etiocholanolone 46 was 25% and it would not be expected 
that a deuterated steroid would afford a significantly different conversion. 
 
Scheme 23: the synthesis of d5-etiocholanolone 3-glucuronide 80 using the glucuronylsynthase 
protocol 
2.2.4 Large-scale syntheses  
At this point, there had been a significant amount of characterisation data obtained for the 
various glucuronides studied so far. During the course of the initial screen, 1H NMR data and 
mass spectral data had been acquired for most of the compounds, but the data was not analysed 
in great detail due to the low scale of the experiments. This is simply due to the challenge of 
obtaining the large quantities of enzyme that would be required for large scale reactions, which 
restricted experiments to milligram scales – for example, the initial screen was conducted on 1 
mg of steroid substrate.  
Throughout the course of the conversion study, higher quality 1H NMR data was acquired where 
possible (alongside the corresponding mass spectral data at both low and high resolution), 
which allowed for further characterisation of the glucuronides. However, there remained some 
glucuronides that could not be characterised by NMR in a satisfactory manner, such as 
androsterone 3-glucuronide 54 and methyltestosterone 17-glucuronide 61, simply as a result of 
their especially poor reactivity under the glucuronylsynthase reaction conditions. Retention 
factors were also acquired where possible. 
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For some of the substrates examined it was found that the NMR data in the literature was either 
incomplete or missing entirely. For example, glucuronides of epiandrosterone 35 and 
pregnenolone 68 had no NMR data with both having been prepared in the 1960s when NMR 
was less widely adopted than today165,166. For methandriol 44, trenazone 70 and furazadrol 72, 
the corresponding glucuronides were not known and so these five steroids were prepared on 5 
or 10 mg scale depending on the steroid – for less soluble steroids more starting material was 
required to obtain useful quantities of glucuronide.  
Scaled-up syntheses of these compounds were performed at the relevant scales and all yielded 
excellent quantities of glucuronide. However, the larger scale required a slight adjustment to the 
purification protocol.  
As seen in section 2.2.2.2 the SPE cartridges can be overloaded with material, leading to 
leakage of the glucuronide and flow-through of impurities. For a 500 mg sorbent cartridge the 
maximum amount is typically taken to be 5 mg of parent steroid (1% of the sorbent weight). For 
the 10 mg reactions, then, the purification has to take place as a split sample, either with two 
SPE cartridges in parallel or sequentially. Previous applications of the glucuronylsynthase 
protocol on larger scales for steroid glucuronide synthesis have involved normal-phase flash 
silica chromatography or reverse-phase chromatography, which would ultimately be tedious, 
especially where careful separation is required. If future applications of this protocol require 
preparation higher quantities of glucuronide, there are commercially available high-throughput 
multi-line setups that may be used to speed up analysis and the final purification. 
For these five steroid glucuronides, both 1H and 13C NMR data were acquired. In some cases 
additional 2D NMR experiments such as 13C HSQC and 13C HMBC were required to assign some 
of the carbon peaks. This then allowed for the reporting of both sets of NMR data for these 
previously unknown or uncharacterised compounds164. 
It was interesting to observe that the conversions determined by 1H NMR analysis also typically 
mirrored the isolated yields of the same glucuronide. For example, the conversions and isolated 
yields of epiandrosterone 3-glucuronide 36 (90% and 84% respectively), etiocholanolone 3-
glucuronide 55 (25% and 20% respectively), and DHEA 3-glucuronide 21 (87% and 94% 
respectively) 
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2.3 Synthesis of non-steroidal glucuronides 
With a large array of steroid substrates having been examined and their viability under the 
glucuronylsynthase conditions characterised, a brief foray into the synthesis of some non-
steroidal glucuronides was undertaken. This would serve to expand the library of substrates 
that the glucuronylsynthase can access and further this protocol as an alternative enzymatic 
approach for glucuronide synthesis. 
The first substrates targeted in this approach were the opioid compounds codeine 1 and 
morphine 2, and the related alkaloid galanthamine 81 (figure 17).  
As mentioned in section 1.2, the glucuronides of these compounds, in particular of morphine, 
presented interesting synthetic targets for their therapeutic utility. Currently, the synthesis of 
glucuronides of the first two compounds is performed by chemical methods involving 
glucuronylation then deprotection to afford the corresponding free glucuronide97,167–169. 
Interestingly, a glucuronide of galanthamine 81 has not yet been reported as a synthetic 
product, though it has been studied as a metabolic product170.  
 
Figure 17: the alkaloids targeted as part of the broader substrate scope examination 
If the glucuronylsynthase were able to access these metabolites then their synthesis could be 
accomplished in a single step, further simplifying their preparation. A previous attempt by 
Wilkinson failed to afford any glucuronide, but armed with the new protocol a second attempt 
might yield more promising results155. 
In the event, codeine 1, morphine 2, and galanthamine 81 were subjected to the 
glucuronylsynthase protocol. Due to concerns about the purification via the SPE conversion 
method, the crude reaction mixture was analysed by TLC. Unfortunately no product was 
detected and further inspection by mass spectrometry of this mixture, as well as of the relevant 
fractions after SPE confirmed this outcome.  
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There could be a number of reasons for this, one of which could be due the optimal substrate 
concentration for the reaction. As the current glucuronylsynthase protocol is optimised for 
steroidal glucuronides, the reaction parameters (e.g. substrate concentration) may be different 
from what would be required for optimal synthesis of alkaloid-based glucuronides. 
Additionally, the size of the substrate could prove to be an impediment, for if the substrate 
simply cannot fit in the active site then the explanation would be obvious. For example, it would 
be logical to presume that if the wild-type E. coli β-glucuronidase could not hydrolyse morphine 
3,6-bis-glucuronide (or any of the mono-glucuronides) then neither could the E. coli 
glucuronylsynthase prepare those glucuronides. 
In a report Brown et al. showed that a number of glucuronidases could be used to hydrolyse 
morphine 3,6-bis-glucuronide 82 selectively at the phenolic position to afford morphine 6-
glucuronide 5171. However, they used glucuronidases from other sources (e.g. abalone, limpets 
or bovine liver) to perform this reaction. Initial efforts to prepare a morphine glucuronide 
attempted to exploit the known transglycosylation activities of hydrolases (as described in 
section 1.5.2) using E. coli β-glucuronidase, p-nitrophenyl glucuronide 31 and morphine 2 
were unsuccessful (scheme 24).  
 
Scheme 24: Brown et al.’s route to morphine 6-glucuronide 5 using a glucuronidase approach 
However, other reports have shown that E. coli β-glucuronidase can hydrolyse the 
corresponding morphine glucuronide metabolites, although the protocol calls for an overnight 
hydrolysis172. This then suggests that the reactivity of the β-glucuronidase and consequently the 
glucuronylsynthase towards alkaloid substrates is simply poorer than observed for steroidal 
compounds. Indeed, as no glucuronide was ever observed in mass spectrometry analyses, this 
suggested that if the reaction is slow then at the very least it requires more than the two days 
allocated for the reaction. Additionally, the glucuronidase activity towards a particular substrate 
may not necessarily translate to a similar level of glucuronylsynthase activity. 
The antibiotic chloramphenicol 83 was another substrate that was tested under the 
glucuronylsynthase protocol (scheme 25).  
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Scheme 25: the two possible chloramphenicol glucuronides 84 and 85 that might be prepared 
as part of the broader substrate scope experiments 
Chloramphenicol 83 is a broad spectrum antibiotic that has been used in the past to treat 
various bacterial diseases. However, in human medicine its use is limited to minor ailments 
such as conjunctivitis (as a topical application) due to documented cases of the rare but fatal 
aplastic anemia, where blood cell production by bone marrow is disrupted173. Additionally, 
there is no characterised dose-response effect meaning that the mere presence of 
chloramphenicol is sufficient cause for alarm.  
For such reasons the use of chloramphenicol 83 was banned in the US (1991) and the EU (1994) 
and monitoring of food products, such as those of poultry and seafood, and developments in 
monitoring methods, now takes place to ensure compliance174–176. The preparation of 
glucuronides of antibiotics such as chloramphenicol 83 would expand the scope of the synthase 
protocol to these types of compounds, providing a medicinally-relevant application of the 
glucuronylsynthase.  
With two possible sites for glucuronylation it remained uncertain as to which position would be 
favoured, though based on purely steric reasons it was expected that glucuronylation at the 
primary alcohol would be favoured over the secondary alcohol.  
The synthesis of the glucuronide proceeded smoothly with chloramphenicol 83 dissolving well 
under the solvent conditions, which boded well for the formation of glucuronide, though it 
remained a question of just how high the conversion would be as a previous attempt by 
Wilkinson failed to afford any glucuronide.  
However, after SPE conversion analysis of the reaction, chloramphenicol displayed an 11% 
conversion to a glucuronide. The position of glucuronylation required further examination by 
NMR experiments, specifically by HMBC correlations, to show that the anomeric carbon and 
protons (C12, H12) on the sugar displayed correlations consistent with the primary glycoside 
(H3, C3 respectively) and not with the secondary glycoside (H1, C1 respectively; figure 18) on 
chloramphenicol.  
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Figure 18: the HMBC correlations in 84 for C3-H12 and C12-H3 indicating C3 glucuronylation 
Additionally, the H1 protons do not display a shift, while compared to the H3 protons 
experience a 0.25 ppm downfield shift consistent with glucuronylation. This confirms the 
hypothesis that the primary alcohol would be the favoured site of glucuronylation as is likely 
based on steric reasons. As a side note chloramphenicol 3-glucuronide 84 is also the major 
metabolite of chloramphenicol 83 metabolism in the human body177–179.  
The low conversion for chloramphenicol 3-glucuronide 84 in general could be rationalised by 
the steric hindrance presented by the dichloroacetamide moiety. This appears to be the first 
well-characterised synthesis of chloramphenicol 3-glucuronide 84, as it is usually encountered 
in the literature as an in vitro metabolic product rather than a synthetic product. There is one 
other example of a synthesis of chloramphenicol 3-glucuronide 84 by using immobilised UGT 
enzymes though no yield or characterisation data is given180.  
Additionally, 4-methylumbelliferone 86 (also known as 7-hydroxy-4-methylcoumarin or 
hymecromone) was investigated as a possible substrate. This compound belongs to a class of 
compounds known as umbelliferones, which are 7-hydroxylated coumarins. 4-
Methylumbelliferone 86 is used in hepatobiliary/bile therapy and recent research has 
demonstrated that it may also have vasoprotective effects and may play a role in inhibition of 
tumours as a result of the inhibition of the synthesis of hyaluronan181–185. The glucuronide has 
been used as a fluorescent compound for enzyme characterisation (e.g. kinetics) or 
identification186,187.  
In the event, 4-methylumbelliferone 86 was subjected to the glucuronylsynthase reaction and 
pleasingly no solubility issues were encountered. SPE conversion analysis indicated 53% 
conversion to the target glucuronide 87, which compares favourably to literature syntheses of 
the glucuronide, which range from 37% (4 steps) to 31% (2 steps) (scheme 26)188,189.  
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Scheme 26: the synthesis of 4-methylumbelliferone 7-glucuronide 87 from 4-
methylumbelliferone 86 as part of the broader substrate scope experiments 
The middling conversion of this reaction for this planar molecule (as opposed to, say DHEA 19) 
is likely the result of the phenolic nature of the alcohol acceptor, which naturally is less 
nucleophilic due to delocalisation of electron density from the oxygen atom into the aromatic 
ring. However, the higher conversion for this substrate compared to literature demonstrates the 
potential usefulness of the glucuronylsynthase protocol as an alternative to standard chemical 
glucuronylation procedures. 
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2.4 Conclusions and future work 
In summary, a solid-phase extraction method was developed for the purification of the 
glucuronylsynthase reaction using a mixed mode polymeric, weak anion exchange system that 
was able to effectively retain steroid glucuronides for selective elution in consequently high 
purity. This purification procedure was then used to clean up glucuronylsynthase reactions 
directly without the need for prior handling of the enzyme reaction. 
Seventeen steroids were examined the initial qualitative screen to probe the reactivity of each 
one under the revised glucuronylsynthase protocol. Quantitative analysis was then performed 
by conversion experiments using 1H NMR analysis of the key proton shifts, with some steroids 
requiring higher field instruments to elucidate the corresponding conversions.  
A general trend in reactivity was uncovered during the course of this study where the 3β-
hydroxylated steroids were the most amenable to the synthase protocol, followed by the 17β-
hydroxylated counterparts. The α-hydroxylated steroids were the least reactive of all with 
examples such as androsterone 43 being particularly inaccessible. This reactivity trend is 
expected to correlate with the steric hindrance about the hydroxyl groups, especially for the 17-
hydroxylated steroids where the adjoining methyl group impedes access to the hydroxyl group. 
However, poor reactivity was also encountered with the 3β-hydroxylated steroids (for example 
methandriol 44) among others and this was attributed to the poor solubility of these steroids, 
reducing their concentration in solution and therefore the final yield of glucuronide. 
While solubility of the steroid substrate plays an important role in the final yield of the 
glucuronide, it is not necessarily the whole story and that possible unfavourable interactions 
with the enzyme active site may also present a further set of impediments that reduce the final 
yield. However, the specific nature of these interactions remains unknown. A crystal structure of 
the glucuronylsynthase enzyme with substrate or product bound would be expected to provide 
more useful information on this aspect. 
Future work on the use of the glucuronylsynthase protocol as an alternative method for 
preparation of glucuronides in general will likely require expanding the substrate scope even 
further, either through optimisation for other substrates (e.g. a possible solution for alkaloid 
substrates) or directed evolution of the enzymes, work that is ongoing in the McLeod and Ollis 
research groups. Perhaps even higher alcohols could be trialled as co-solvents to dissolve some 
of the more insoluble steroids, such as androstanolone 42 or the cholestanes. 
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Other substrates that could prove interesting include the N-linked glucuronides such as the one 
observed for stanozolol 88 by Schanzer et al., where both the O- and N-glucuronides of 
stanozolol were observed in a chemical synthesis the purposes of developing detection methods 
for anti-doping applications (figure 19)190.  
As discussed in section 1.2, acyl glucuronides present medicinally intriguing compounds and 
are pharmacologically relevant compounds that have abnormal activities. Development of a 
method for their successful synthesis would expand the scope of the enzyme further for 
medicinally-relevant substrates.  
However, acyl glucuronides are known to be unstable in alkaline conditions so reactions at pH 
5-6 would be required. This will likely not present a significant problem as Wilkinson observed 
in previous studies that the initial rate of the enzyme is not adversely affected in a pH range of 
5.5-9.5153. For example, a possible target could be the preparation of ibuprofen acyl glucuronide 
89, which is a known metabolite of ibuprofen and surprisingly does not exhibit any of the 
detrimental effects that have been attributed to other acyl glucuronides (figure 19)191,192. 
 
Figure 19: other possible glucuronide targets include the N-linked glucuronides such as 
stanozolol 4-N-glucuronide 88 and ibuprofen acyl glucuronide 89 
Having successfully developed a solid-phase extraction-based purification protocol, this 
simplified the task of purifying glucuronylsynthase reactions that previously required tedious 
column chromatography procedures, allowing for rapid isolation of steroid glucuronides on an 
analytical scale. In addition, the successful application of tert-butanol as an organic co-solvent 
for this reaction greatly improved the solubility of various steroid substrates that previously 
proved challenging to dissolve in solution. This in turn led to a significant improvement in the 
yields of the corresponding steroid glucuronides, which was a consequence of the higher 
concentration of substrate in solution. Furthermore the application of the new protocol towards 
non-steroidal compounds such as chloramphenicol 83 and 4-methylumbelliferone 86 hinted at 
a broader substrate scope encompassing more than just steroidal and simple alcohol 
compounds. 
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This now sets the stage for the ready adoption of the glucuronylsynthase protocol as an 
alternative enzymatic method for the synthesis of glucuronides on an analytical scale. While the 
materials for the reaction – glucuronylsynthase enzyme and glucuronyl fluoride 29 – may 
sometimes prove to be challenging to acquire, the steps of conducting the reaction and purifying 
the glucuronide product has been operationally simplified. Indeed, it might be expected that 
someone with only a basic level of training in organic chemistry could very well perform this 
reaction successfully and potentially with the same yields as described in this study. 
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Chapter 3: The synthesis of 18O-labelled glucuronides 
3.1 Introduction to labelled glucuronides 
Isotopically-labelled steroids are used in sports anti-doping for quantifying the recovery of 
steroid analytes during the analytical process and have been important in providing a 
quantitative approach to the anti-doping effort. They fulfil the roles of internal standards and 
are expected to behave analogously to the corresponding unlabelled steroid throughout. In GC-
MS analysis of steroidal glucuronide metabolites the cleavage of the glucuronide must be 
performed followed by subsequent derivatisation to the corresponding TMS or otherwise 
modified derivative. Therefore the labelled steroid must be sufficiently resistant to the same 
degradation pathways as the unlabelled steroid that could lead to loss of the labelling moiety 
and it is for this reason that labelled steroids and their glucuronide metabolites come in 
deuterated form193. 
Typical methods for the synthesis of deuterium-labelled steroids involve the reaction of the 
steroid in question with base and deuterated solvent or where other reactions are involved (e.g. 
reduction) the relevant deuterated reagent is required (scheme 27)194–196. For example, in the 
synthesis of tris-labelled androstanolone 42, protection of the C3 ketone in androstanolone 42 
as an ethylene ketal, follow oxidation of the C17 alcohol affords a readily enolisable ketone 90. 
Treatment with sodium deuteroxide in monodeuterated methanol leads to bis-deuteration at 
C16, which is then followed by reduction back to the secondary alcohol with sodium 
borodeuteride. Acid-mediated cleavage of the ketal affords the tris-labelled steroid 91197. This is 
then typically followed by a two-step chemical glucuronylation and deprotection step as seen in 
section 1.5.1.1. 
 
Scheme 27: the synthesis of tris-labelled androstanolone 91 and its glucuronide 92 using 
deuterated reagents 
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Depending on the intended labelled targets, the preparation of the labelled steroid and its 
glucuronide conjugate can be a laborious task, especially when considering scenarios where 
multiple derivatives need to be prepared. 
Additionally there are some deuterium-labelled substrates that can be unstable. For example, 
the hydrogens at C16 on 17-keto steroids are next to an enolisable ketone that can lead to loss 
of the label. Also labelled estrogen-based steroids are known to be labile under certain pH 
conditions at the ortho-position, which can reduce the isotopic purity of the compound196,198. 
Conversely LC-MS analysis may not require hydrolysis of the glucuronide as it is able to detect 
the metabolite directly. As such labelled steroid glucuronides can be used in much the same way 
as in GC-MS i.e. as an internal standard. 
An alternative labelling approach presented below offers a few interesting advantages (scheme 
28). As noted above, the synthesis of the requisite deuterium-labelled glucuronide requires the 
preparation of each steroid individually. By presenting the labelling moiety on the sugar donor 
as opposed to on the alcohol acceptor, this reduces the task down to a single synthesis of the 
labelled sugar. A conceptually similar approach has been reported by Brun et al. on 13C labelling 
of cello-oligosaccharides for NMR spectroscopic purposes199. 
 
Scheme 28: a proposed alternative approach to preparing labelled steroid glucuronides using 
an 18O-labelled glucuronyl fluoride to provide the labelling moiety 
It is useful at this point to discuss the standard route towards the synthesis of the unlabelled α-
D-glucuronyl fluoride 29 (scheme 29). The synthesis commences with per-acetylation of D-
glucose 93 to afford the per-acetylated sugar 26 as a mixture of α/β-anomers at C1, whereupon 
the β-anomer can be selectively obtained by recrystallisation from methanol.  
The per-acetate is then fluorinated with Olah’s reagent to afford the α-fluorinated sugar 94. 
Subsequent deprotection via methanolysis yields the unprotected α-D-glucosyl fluoride 28, 
which is subjected to flash silica column chromatography to remove traces of glucosyl fluoride 
28.  
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The α-D-glucosyl fluoride 28 is then oxidised by catalytic TEMPO under basic conditions (for 
reasons that will be apparent later) using a modified method of Heeres et al. to afford the α-D-
glucuronyl fluoride 29200.  
Purification by anion-exchange chromatography (AEX) of the crude reaction mixture affords the 
α-D-glucuronyl fluoride 29 as the ammonium salt (as determined by X-ray crystallography) that 
is synthetically acceptable155. However, an additional rapid recrystallisation from 70% aqueous 
ethanol can be performed where higher purity of the α-D-glucuronyl fluoride 29 is required e.g. 
for kinetics studies. 
 
Scheme 29: the standard route for the synthesis of unlabelled α-D-glucuronyl fluoride 29 
3.2 Method development 
3.2.1 The oxidation of alcohols by TEMPO 
The use of 2,2,6,6-tetramethyl-1-piperidinyloxy, free radical 95 (TEMPO) as a reagent for the 
oxidation of alcohols to their carbonyl derivatives has been known for some time now and their 
easy preparation has led to the development of highly efficient and mild catalytic and 
stoichiometric methods for oxidation201,202. The mechanism of this oxidation has been studied 
quite extensively in both basic and acidic media as the rates of oxidation of primary and 
secondary alcohols differs depending on the pH. 
Stable organic nitroxyl-based radicals were known since the beginning of the 20th century and 
mainly involved conjugated nitroxyl radicals, with the unconjugated nitroxyl radicals, such as 
TEMPO 95, being developed later203. Their application in the oxidation of alcohols was first 
reported by Golubev et al. who also established that the active oxidant species is derived from a 
disproportionation (promoted by a co-oxidant e.g. NaOCl, NaOBr in basic conditions etc. or acid 
under acidic conditions) of the TEMPO radical 95 to generate an oxoammonium species 96 and 
a hydroxylamine species 97 (figure 20)204.  
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Figure 20: the acid-promoted disproportionation of TEMPO 95 to afford the oxoammonium 96 
and the hydroxylamine 97 
The actual mechanism by which the oxoammonium performs the oxidation has been the subject 
of some debate. Rate-wise, it was determined by Golubev et al. that oxidation of secondary 
alcohols is faster than that for primary alcohols at low pH (<4) but that the rate increases and 
the selectivity is reversed in basic conditions (figure 21)205.  
 
Figure 21: a summary of Golubev et al.’s findings regarding reaction rates and selectivity of the 
TEMPO-mediated oxidation of alcohols 
Studies by Semmelhack et al. suggested that in basic conditions addition of the primary or 
secondary alcohol to the nitrogen centre, followed by the intramolecular abstraction of a proton 
and consequent elimination of the carbonyl species, was the predominant mechanism206. 
However, they were unable to definitively rule out a second mechanism where the alcohol 
attacks at the oxygen centre of the oxoammonium species, with the consequent proton 
abstraction performed by the lone pair on nitrogen (figure 22, bottom mechanism).  
The origin of selectivity in the reaction was a key unanswered question. Studies on this were 
undertaken by various groups but it was not until de Nooy et al. published a mechanistic study 
that the issue became clearer207.  
They proposed that, based on steric demands at the alcohol centre, the cyclic, concerted 
mechanism of Semmelhack et al. was favoured under basic conditions (figure 22, top 
mechanism). This would explain the observation that primary alcohols are oxidised faster than 
secondary alcohols under these conditions due the greater steric bulk of the secondary alcohols 
impeding the necessary intramolecular proton abstraction. Conversely under acidic conditions 
this steric demand disappears as in the Bobbitt model where proton abstraction is proposed to 
occur via an intermolecular process208.  
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Figure 22: the Semmelhack et al. mechanistic proposal for the oxidation of alcohols in basic 
conditions. Highlighted in blue is the addition of the alcohol at the nitrogen centre and in red 
the addition of the alcohol at the oxygen centre. Semmelhack et al. favoured the top mechanism 
but did not have enough evidence to disprove the bottom mechanism 
These conclusions were reinforced by computational analysis by Bailey et al. where the 
equilibrium constants for the formation of the alkoxide-nitroxide complexes decreased 
significantly with increasing steric bulk of the alcohol in basic conditions209. Interestingly, they 
also proposed a formal hydride transfer to occur under acidic conditions, where the change in 
free energy for the conversion of isopropanol 98 to protonated acetone 99 is much lower than 
that for the conversion of methanol to protonated formaldehyde (scheme 30). 
 
Scheme 30: a possible mechanism for the formal hydride transfer as proposed by Bailey et al. 
showing the hydride transfer from isopropanol 98 to the oxoammonium species 96, affording 
the hydroxylamine 97 and protonated acetone 99 
The knowledge that the oxoammonium cation is the active oxidant species has driven the 
preparation and development of oxoammonium salts that can be used directly in the TEMPO 
reaction. Mercandante et al. developed a facile method for the preparation of 4-acetamido-
2,2,6,6-tetramethyl N-oxopiperidinium tetrafluoroborate 100 (hereafter referred to as 
“Bobbitt’s salt”) as a stable oxoammonium salt for this purpose (figure 23)202.  
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Figure 23: TEMPO 95 and the stable oxoammonium 100 as a tetrafluoroborate salt  
These oxidants are used stoichiometrically (either 1 or 2 equivalents depending on the desired 
final carbonyl species) in the reaction as there is no co-oxidant present. This would prove to be 
something of interest as detailed in the next section. 
3.2.2 The synthesis of α-D-(18O2)-glucuronyl fluoride 101 
The strategy for preparing a labelled version of glucuronyl fluoride 29 aimed to exploit a 
subtlety of the TEMPO oxidation not mentioned previously. In aqueous conditions the TEMPO 
oxidation is able to prepare carboxylic acids from the corresponding primary alcohols through a 
mechanism shown in figure 24.  
  
Figure 24: the mechanism for the oxidation of primary alcohols to carboxylic acids involves an 
aldehyde hydrate that can be further oxidised to the carboxylic acid 
The first oxidation of the primary alcohol 102 to the aldehyde 103 (where R or R’ = H) proceeds 
as seen previously and this aldehyde is able to form an aldehyde hydrate 104 in aqueous 
conditions. It is this hydrate intermediate that can then undergo a second oxidation to yield the 
carboxylic acid 105. Therefore, it is possible to exploit the aldehyde hydrate 104 by way of 
changing the solvent from normal water to 18O-labelled water. Exchange of an equivalent of 
unlabelled water from the sugar with a molecule of labelled water H218O is then expected to 
afford the labelled sugar. 
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As described previously the synthesis of the α-D-glucuronyl fluoride 29 was performed under 
basic conditions with the reaction pH maintained at ~9.5±0.5 via periodic addition of sodium 
hydroxide and the use of a pH meter. Sodium hypochlorite was used as the co-oxidant for 
TEMPO 95 in stoichiometric quantities (2 equivalents) to achieve oxidation to the carboxylic 
acid (scheme 31). For the reasons described above this then leads to selective oxidation of 
primary alcohols over secondary alcohols with no oxidation of the secondary alcohols observed. 
 
Scheme 31: the standard conditions for oxidation of α-D-glucosyl fluoride 28 to α-D-glucuronyl 
fluoride 29 by TEMPO 95 
Purification is performed via anion-exchange chromatography (AEX), which has been a source 
of problems for isolation and purity in the past. Chloride impurities were present in samples of 
the isolated glucuronyl fluoride and proved to be resistant to further removal.  
It was discovered that careful regeneration of the anion exchange resin was required to ensure 
that the anionic counter-ions were thoroughly exchanged. Regeneration of the column occurs 
step-wise with 1 M hydrochloric acid (HCl; to pH ~1), 1 M sodium hydroxide (NaOH; to pH ~14) 
and then 1 M of the anion of choice, in this case ammonium bicarbonate (NH4HCO3), which was 
expected to be highly volatile for facile removal after isolating the sugar, with thorough washing 
with milliQ water in between to bring the pH of the mobile phase to ~7 each time.  
Increasing the contact time that each wash has with the resin (i.e. HCl, NaOH and NH4HCO3) to a 
minimum of 1 hour appeared to sufficiently remove the previous anionic counter-ion and 
subsequent preparations of the α-D-glucuronyl fluoride 29 were free of such impurities as 
determined by elemental analysis. 
While these conditions worked well for the synthesis of the glucuronyl fluoride 29 on 
preparative scale, they would be unfeasible for the synthesis of labelled glucuronyl fluoride on 
analytical scale.  
The first hurdle would be the control of pH – the use of a pH meter would be impractical on 
volumes less than 10 – 15 mL as the bulb must be covered by solution for accurate readings. 
This was solved by the use of a buffered solution – specifically, a sodium bicarbonate/carbonate 
buffer. The parameters of the buffer (pH, concentration) required some optimisation with the 
final pH set to 9.0±0.1 at a concentration of 0.5 M to account for any acid produced during the 
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reaction. Indeed, the buffer could be repeatedly prepared without requiring any further 
adjustment of the pH (as determined by a pH meter) through the careful weighing of buffer 
components. 
The second requirement was for an oxidation method that did not rely on the use of sodium 
hypochlorite, as the reagent comes as an aqueous solution, obviously unviable for a reaction 
where exclusion of normal water is critical. It was at this point that Bobbitt’s salt 100 was 
considered.  
An initial experiment with the carbonate buffer performed on 10 mg scale with α-D-glucosyl 
fluoride 28 (on ice ~ 4 °C, overnight) afforded the glucuronyl fluoride in quantitative 
conversion by 1H NMR analysis, which was a highly encouraging result. Unfortunately this could 
not be reproduced in further attempts, with thin-layer chromatography showing only poor 
conversion to the α-D-glucuronyl fluoride 29. 
A literature search was undertaken to find other mild oxidation methods for the desired 
reaction. A method developed by Epp & Widlanski where TEMPO 95 was used with 
stoichiometric iodobenzene diacetate 106 (2.2 equivalents; hereafter referred to as BAIB) to 
convert the primary alcohols on synthetic nucleotides to their corresponding carboxylic acids in 
good yields (scheme 32)210. Upon inspection of the conditions, it appeared that BAIB 106 was 
added in such quantities so that the reaction is heterogeneous, where only partial solution of 
BAIB would be achieved. 
 
Scheme 32: the oxidation of protected nucleosides by Epp and Widlanski using a TEMPO/BAIB 
oxidation system in acetonitrile and water 
Interestingly, there was a reference to Anelli’s work where there is a discussion of the possible 
temperature dependence of the reaction201. The oxoammonium species was suggested to be 
temperature sensitive and that low temperatures (e.g. 0 °C) would be beneficial in extending the 
lifetime of the active oxidant species compared to when the reactions were performed at room 
temperature. Therefore, future reactions were all performed on ice. 
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Another report by Breton et al. detailed the use of 2,6-lutidine in combination with an 
oxoammonium salt, where the base removes excess protons generated during the oxidation 
reaction to avoid an undesirable side reaction where comproportionation regenerates two 
equivalents of TEMPO via the consumption of one equivalent of the oxoammonium salt and the 
N-hydroxylamine (scheme 33)211. In a system without a co-oxidant this would be a dead-end 
for the reaction. Therefore more equivalents of the oxoammonium salt were required to 
compensate for this, in addition to using 2,6-lutidine to remove acid from the reaction, and all 
future reactions with Bobbitt’s salt were conducted using five equivalents of the oxidant. 
 
Scheme 33: the proposed comproportionation by Breton et al. for the side-reaction between 
the oxoammonium species 96 and the hydroxylamine 97 to regenerate the nitroxyl radical 95 
Additionally, a new model substrate, methyl α-glucoside 107, was chosen to more closely mimic 
the target substrate glucosyl fluoride. This would also relieve pressure on stocks of glucosyl 
fluoride 28 while method development was still in progress. 
With two methods in hand methyl α-glucoside 107 was subjected to the oxidation conditions 
for about 5 hours before TLC analysis was performed with the results indicating that the 
reaction with Bobbitt’s salt had progressed to apparent completion while the TEMPO/BAIB 
reaction was still at about <25 % conversion. Previously, TLC analysis was the only analysis 
performed on these reactions (due to poor conversion) but this result was sufficiently intriguing 
to work up by neutralisation and extraction with chloroform for 1H NMR analysis (scheme 34), 
which pleasingly indicated complete conversion to the desired methyl α-D-glucuronide 108. 
 
Scheme 34: the synthesis of methyl α-D-glucuronide 108 via two different oxidation conditions 
The TEMPO reaction was allowed to continue to the 24 h mark, at which point TLC analysis 
indicated complete conversion as well. Additionally 1H NMR analysis was performed on the 
crude reaction mixture after neutralisation and reconstitution in D2O, which also indicated 
quantitative conversion.  
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Both methods worked quite well with methyl α-D-glucoside 107 and were used in the oxidation 
of α-D-glucosyl fluoride 28 (scheme 35). After 24 h, TLC analysis of the reactions indicated only 
about 50% conversion but workup of the reaction and subsequent 1H NMR analysis indicated 
that in fact the TEMPO reaction performed better, with approximately 78% conversion 
compared to 56% for the oxidation with Bobbitt’s salt. 
 
Scheme 35: the synthesis of α-D-glucuronyl fluoride 29 via two different oxidation conditions 
Purification of the two sugar samples was then carried out using small-scale anion-exchange 
chromatography to determine how pure the products were after the first pass. As the reaction 
products were expected to contain significant quantities of organic material a methanol wash 
was included to remove such material prior to elution of the glucuronyl fluoride 29. 
An acetate salt (likely ammonium acetate) was observed to be present in the fractions 
containing the glucuronyl fluoride from the TEMPO/BAIB reaction, most likely from the 
reduction of iodobenzene diacetate 106 during the oxidation reaction, in addition to some 
minor aromatic impurities212. One possible pathway is outlined in scheme 36.  
 
Scheme 36: a possible reduction pathway for BAIB in the TEMPO oxidation 
The hydroxylamine 97 formed via the deprotonation step in figure 22 can substitute at the 
iodine centre in 106, with the loss of acetic acid, to afford the linked intermediate 109. The lone 
pair on the nitrogen atom can then eliminate the iodobenzene acetate moiety, reforming the 
oxoammonium species 96 (the active catalyst) and leading to the loss of acetate and 
iodobenzene 110, two possible contributors to the impurities observed. 
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A small amount of acetate impurities was observed in the glucuronyl fluoride fractions for the 
reaction with Bobbitt’s salt. As the sugars were purified one after another with the same column 
it appears that regeneration of the column is required for optimum purification. Otherwise, no 
impurities were observed.  
At this point there was little to separate the two methods, with one having higher conversions 
but slightly more impurities and the other having a cleaner end product but with lower 
conversion. Therefore, both methods were used in the synthesis of 18O-labelled glucuronyl 
fluoride and were carried out under strictly anhydrous conditions to maximise the relative 
concentration of 18O-water to ordinary water. Solid compounds such as the glucosyl fluoride 28, 
BAIB, TEMPO, carbonates etc. were dried under vacuum overnight while the liquids, acetonitrile 
and 2,6-lutidine, were dried overnight on freshly activated 3Å molecular sieves. 
Reactions were performed on 10 mg scale, and upon workup and AEX purification both 1H NMR 
and mass spectral analysis were performed to characterise the products. The approximate 
isolated yields for the two reactions (Bobbitt’s salt vs. TEMPO/BAIB) were 38% and 51% 
respectively – unfortunately some minor irremovable impurities (e.g. aromatic impurities from 
BAIB or 2,6-lutidine) were present in the isolated samples of the sugars.  
While this made quantifying the yield of the sugars impossible, the impurities were not 
expected to pose difficulties for purification of the corresponding glucuronides by WAX SPE. No 
differences between the NMR spectra for the two compounds are observed and map excellently 
onto the NMR spectrum for the unlabelled sugar, as expected. However, the major difference is 
observed when the mass spectra are examined (figure 25).  
(a)  (b)  
Figure 25: the mass spectral patterns for the parent ion of the glucuronyl fluoride product, with 
(a) corresponding to the sugar obtained from oxidation with Bobbitt’s salt and (b) 
corresponding to the sugar obtained from oxidation with TEMPO/BAIB. 
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For the Bobbitt’s salt oxidation, there are three products observed by mass spectrometry and 
the predominant product is singly-labelled glucuronyl fluoride at 72% (m/z = 197 (18O1)) 
compared to 9% (m/z = 199 (18O2)) for the doubly-labelled and 19% (m/z = 195) for the 
unlabelled sugar.  
It is somewhat surprising that any wholly unlabelled sugar is observed at all under the 
conditions, and this might be attributed to a number of factors. One, incomplete drying of the 
reaction components could have led to the retention of some unlabelled water. Two, the 
potential expulsion of a molecule of unlabelled water to form the doubly-labelled sugar could 
have contributed to formation of some of the unlabelled products – obviously not all of them 
due to the percentage difference between the doubly-labelled (9%) and fully unlabelled (19%) 
compounds. 
For the TEMPO/BAIB oxidation there are two products observed, either the doubly-labelled 
(82%; m/z = 199 (18O1)) or singly-labelled sugar (18%; m/z = 197 (18O1)) with no unlabelled 
sugar observed.  
 
Scheme 37: the two oxidation reactions of α-D-glucosyl fluoride 28 to afford the labelled α-D-
glucuronyl fluorides 111 and 112 
A mechanistic rationale can be offered for this outcome. Both oxidation steps occur quite rapidly 
as detailed previously. The key difference lies in the nature of the oxidant.  
In the reaction with Bobbitt’s salt the oxoammonium is already formed and therefore going 
from the alcohol to the aldehyde to the carboxylic acid would be expected to be rapid. 
In contrast the oxidation with TEMPO/BAIB would be comparatively slower as the 
oxoammonium species must be regenerated from catalytic TEMPO (scheme 38). This then 
leads to a longer lifetime of the aldehyde in solution and therefore the greater the chance that 
the original hydroxyl could undergo equilibrium with the solvent (H218O). Thus, Bobbit’s salt 
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favours single incorporation of 18O as opposed to double incorporation, while the TEMPO/BAIB 
system favours double incorporation of 18O. 
Having observed this difference in incorporation of 18O, the glucuronyl fluoride from the TEMPO 
reaction was selected as the sugar of choice for labelling steroids due to the extra mass units 
afforded to the final compound. 
 
 
Scheme 38: the mechanistic rationale for the observation of single vs. double incorporation of 
18O in the oxidation of glucosyl fluoride. Oxidation with Bobbitt’s salt is expected to be 
comparatively faster and follow pathway A, while oxidation with TEMPO/BAIB is expected to 
be comparatively slower and follow pathway B 
3.3 The synthesis of 5α-androstan-3β,17β-diol 3(18O2),17-bis 
glucuronide 113 
While the sugar was being prepared, the synthesis of the bis-glucuronide was also commenced. 
The initial efforts were directed towards the preparation of a labelled glucuronide where the 
labelled moiety is situated at the C17 hydroxyl, with an unlabelled sugar present on the C3 
hydroxyl (figure 26).   
 
Figure 26: the target bis-glucuronide 114 could be prepared from epiandrosterone 35 
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The starting point for the synthesis was epiandrosterone, a steroid that experience has proven 
to be very useful synthetically due to the excellent reactivity of the C3 alcohol for both direct 
glucuronylation and other chemistries. To install the labelled sugar at the C17 alcohol, 
protection of the C3 alcohol was required, and this had previously been achieved by reaction 
with succinic anhydride in pyridine at reflux to afford the 5α-androstan-3β,-17β-diol 3-
hemisuccinate 115 in excellent yields (scheme 39)213. The C17 alcohol was then reduced with 
sodium borohydride to afford the C17 alcohol 116 solely as the β-isomer, again in very high 
yield. No α-configured hydroxyl was observed in the reaction due to the steric demands placed 
by the neighbouring methyl group. 
 
Scheme 39: the synthesis of the hemisuccinate 115 from epiandrosterone 35 by esterification 
with succinic anhydride then reduction with sodium borohydride 
The resulting hemisuccinate diol 116 would be reacted under glucuronylsynthase conditions to 
afford the 17-glucuronide 117 and the expected mixture of glucuronide and starting material 
would be subjected to lithium hydroxide-mediated hydrolysis of the hemisuccinate. This would 
yield a neutral steroid diol 119 and a glucuronide 118 with the free C3 alcohol, a mixture that 
can be purified via SPE, with the pure glucuronide then ready for a second glucuronylation step 
(scheme 40). 
This approach was to be performed with both the labelled and unlabelled sugar for comparison 
of NMR spectra and characterisation purposes. Reaction with normal glucuronyl fluoride 
afforded what appeared to be quantitative conversion to the 17-glucuronide, a very pleasing 
outcome considering the expected low conversions as seen previously (see section 2.2.3). 
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Scheme 40: the synthetic plan towards synthesis of glucuronide 118 using a hemisuccinate 
approach with the key differentiation step taking place via lithium hydroxide deprotection of 
the hemisuccinate 117 
Before conducting the hydrolysis of the hemisuccinate 117, 5α-androstan-3β,-17β-diol 3-
hemisuccinate 116 was used as a model substrate to determine the optimum hydrolysis 
conditions. Initial experiments with potassium hydroxide and ethanol achieved quantitative 
conversion to the steroid diol 119 but this could not be replicated, likely owing to the 
evaporation of solvent during the course of the experiment. Other methods using sodium 
hydroxide, ammonium hydroxide and hydrazine acetate also failed to afford the desired 
product. Ultimately, the hydrolysis was found to proceed consistently when lithium hydroxide 
was used as the base (50 equivalents) in tetrahydrofuran/water (scheme 41).  
 
Scheme 41: the hydrolysis of 5α-androstan-3β,17β-diol 3-hemisuccinate 116 by lithium 
hydroxide, showing the expected covalent bond between the carboxylate and lithium with 
hydroxide-promoted hydrolysis of the hemisuccinate ester 
The solvent could be changed to methanol to account for the increased polarity of the 
glucuronide conjugate, with no reduction in yield of the steroid diol 119. A possible explanation 
for this is that lithium is a small ion in solution (a “hard” Lewis acid according to HSAB 
theory214) and the resulting binding to oxygen (a “hard” Lewis base) is strong enough such that 
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the bond is partially covalent, which would “mask” the carboxylate’s charge at the end of the 
hemisuccinate chain. The lack of electrostatic repulsion would then allow the incoming 
hydroxide to react at the ester centre unimpeded.  
However, attempts to apply this method to the glucuronide derivative failed. This then 
necessitated the development of an alternative route where the labelled glucuronide would now 
be appended to the C3 hydroxyl (scheme 42) with the unlabelled sugar attached at the C17 
hydroxyl. This approach would reduce the number of steps to three in total and would generate 
three different labelled glucuronides along the way. Additionally, the type of sugar could be 
alternated for a different labelling pattern if so desired.  
 
Scheme 42: the retrosynthetic analysis for the synthesis of 5α-androstan-3β,17β-diol 
3,17(18O2)-bis-glucuronide 113 from epiandrosterone 35 
In the event, epiandrosterone 35 was reacted with α-D-(18O2)-glucuronyl fluoride 111 to afford 
the labelled glucuronide 121, with quantitative conversion by 1H NMR (this was part of the 
reason for choosing to place the sugar here instead of at C17). Comparisons with the proton 
NMR of unlabelled epiandrosterone 3-glucuronide 36 synthesised concurrently revealed no 
differences as expected. Pleasingly the mass spectrum showed that the additional mass units are 
retained in their respective ratios in the labelled glucuronide.  
Subsequent reduction with sodium borohydride proceeded to near completion. The key peaks 
corresponding to the 17-ketone – the pair of doublet of doublets at 2.10-2.02 ppm and 1.98-1.96 
ppm were still visible by 1H NMR with their integrations corresponding to about ~8% left of the 
starting ketone (for the labelled glucuronide – the unlabelled glucuronide proceeded to 
complete conversion). This could be resolved by simply resubmitting the steroid to the 
reduction conditions, resulting in complete conversion to the desired 17β-hydroxyl compound. 
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The challenging step is the synthesis of the 17-glucuronide 113 due to the hindered nature of 
the alcohol as a result of the neighbouring methyl group. Glucuronylation of the two mono-
glucuronides (labelled 120 and unlabelled 122) was performed using the standard 
glucuronylsynthase procedure and intriguingly a different conversion was observed for both 
reactions (scheme 43). This may be simply put down to the small scale of the reactions as only 
estimates of material (<1 mg) could be used to prepare the subsequent glucuronylation 
reactions. This discrepancy is expected to disappear if the reactions could be performed on 
larger scales that would allow for accurate determination of the amount of starting glucuronide. 
 
Scheme 43: differing conversions were for observed for the synthesis of bis-glucuronides (120 
to 113, 31%) and (122 to 123, 60%) 
Around this time other colleagues within the research group were developing methods for the 
solid-phase purification of similar compounds (e.g. bis-glucuronides) using C18 cartridges. One 
method, developed by Natasha Anderson, appeared to be particularly useful towards this goal. 
This involved pre-conditioning the cartridge with methanol and water (as for the WAX protocol; 
see section 2.2.1), then loading the glucuronide mixture as a solution in water on to the 
cartridge. Elution of the bis-glucuronide is achieved first with 20% aqueous MeOH followed by 
elution of the mono-glucuronide with 100% MeOH (figure 27). 
Ultimately, both bis-glucuronides were synthesised in three steps from epiandrosterone 35 in 
excellent conversions up to the final glucuronylation step. The 1H NMR spectra of both 
compounds displayed no particular difference between them. For example, the anomeric 
protons H20 and H26 are observed at shifts of δ 4.41 and 4.35 ppm with integrations of one 
proton each (figure 28). Additionally, the sugar region at δ ~3.4 to 3.2 ppm is now much more 
complex due to the presence of two slightly chemically different glucuronyl moieties. As 
described previously the glucuronyl fluoride 29 showed no difference in the 1H NMR between 
the labelled and unlabelled versions and this characteristic also carries over to the glucuronides, 
whereby no difference in the spectra are observed. 
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Figure 27: the C18 SPE purification procedure for isolation of pure glucuronide from a mono- 
and bis-glucuronide mixture (note: this occurs after WAX SPE) 
 
 
Figure 28: an example 600 MHz 1H NMR spectrum of 5α-androstan-3β,17β-diol 3,17-bis-
glucuronide 123 showing the key peaks for the anomeric protons and the sugar region (inset) 
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Table 4: the mass spectrum fragmentation pattern for the labelled bis-glucuronide 113 
m/z  Proposed ion m/z  Proposed ion 
647 (M(18O2)–H)– 113 C5H5O3– 
645 (M(18O1)–H)– 97 C5H5O2– 
471 (M(18O2)–gluc–H)– 79 HOCH2C(18O2)– 
467 (M-gluc–H)– 62 unidentified 
323 (M(18O2)–2H)2–   
314 (M(18O2)–H2O–2H)2–   
 
 
Figure 29: the low-resolution negative-mode ESI spectrum for unlabelled bis-glucuronide 123 
However, in the mass spectra for the two bis-glucuronides the labelled sugar presented a much 
more obvious difference. For example the molecule ion for ([M–NH4]–) is m/z = 643 for the 
unlabelled bis-glucuronide 123 but there are two peaks for the labelled bis-glucuronide 113 at 
m/z = 645 ([M(18O1)–NH4]–) and 647  ([M(18O2)–NH4]–). While the unlabelled bis-glucuronide 
123 displayed only a single peak for the loss of a glucuronyl moiety from either end (m/z = 467 
([M–(C6H8O6)–NH4]–), the labelled bis-glucuronide 113 displayed two peaks as a result of loss of 
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the glucuronyl moiety from either end due to the labelling on one of the sugars (m/z = 467 and 
471 for loss of the labelled and unlabelled glucuronyl moieties respectively). The relevant peaks 
for the labelled glucuronide 113 are displayed in table 4. 
 
Figure 30: the low-resolution negative-mode ESI spectrum for the labelled glucuronide 113 
Both spectra display a cluster of peaks from m/z = 113 to 62 that arise from fragmentation of 
the glucuronic acid 29 as described by Fabregat et al., indicating that using these peaks as a way 
of identifying the glucuronide would not be a viable approach (figures 29 & 30)215. It should be 
noted that the difference in intensities between the two spectra could arise from differences in 
sample concentration or in-source ion fragmentation variation216. 
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3.4 Conclusions and future work 
In summary, the synthesis of an 18O-labelled steroid glucuronide (and the corresponding 
unlabelled bis-glucuronide) was accomplished in three steps from epiandrosterone with 
purification of the final bis-glucuronide performed by either reverse-phase silica 
chromatography or C18-based solid phase extraction. An alternative method for the synthesis of 
17-labelled glucuronides has been detailed as well, although it was not successful at the time. A 
synthesis of the unlabelled bis-glucuronide was also achieved, with both bis-glucuronides 
characterised by 1H NMR and mass spectrometry. 
By 1H NMR no differences were observed between the labelled and unlabelled bis-glucuronides 
but the shift in m/z between the two glucuronides could be identified as a result of the labelling 
afforded by the labelled glucuronyl fluoride 111, though there were discrepancies in peak 
intensities. However, further studies by collision-induced dissociated (CID) MS/MS could 
improve the accuracy of these measurements by overcoming in-source fragmentation errors for 
more reliable analysis217. 
A new method for the synthesis of the α-D-glucuronyl fluoride 29 was also developed utilising 
TEMPO and BAIB in sodium bicarbonate/carbonate buffer at pH 9 to afford a bis-labelled 
glucuronyl fluoride. Upon examination of the mass spectra of the glucuronyl fluoride products 
of the oxidations with H218O, a significant difference in the uptake of 18O was observed, with the 
conclusion that the oxidation with Bobbitt’s salt appears to be faster than oxidation with 
TEMPO and BAIB. The origin of this difference in reactivity is likely due to the relative 
concentrations of the oxoammonium species present in solution – Bobbitt’s salt 100, used 
stoichiometrically, contains a pre-formed oxoammonium, while in the TEMPO oxidation the 
oxoammonium must be continuously regenerated by the co-oxidant BAIB. The slower oxidation 
allows for a greater lifetime of the expected aldehyde hydrate, which can then undergo 
equilibration with labelled water leading to double incorporation. 
However, there remain some challenges to overcome with this labelling approach. While the 
successful incorporation of 18O into the glucuronyl fluoride 29 is pleasing to observe, it should 
be noted that the mixed incorporation for both oxidation systems could prove to be 
problematic. It may be the case that mixed incorporation is simply unsuitable for applications 
where only single incorporation is desired.  
In addition, while not explicitly shown, both samples appear to contain some unlabelled 
glucuronyl fluoride 29 (m/z = 195). There is the potential for this unlabelled material to 
interfere with the capacity of such a compound to act as an internal standard, whereby even 1% 
of unlabelled material could lead to false positives. These problems could potentially be 
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resolved through further refinement of the reaction conditions but should these complications 
persist, alternatives may be required. 
For example, replacing glucose 93 with a per-deuterated derivative in scheme 29 may be a 
useful and practical alternative, although potentially costly depending on the scale of material 
required. However, this would still be a simpler alternative to the acquisition of labelled 
glucuronides as there is only a single source of labelling.  
This study paves the way for future work towards the development of an alternative labelling 
approach for glucuronides, in which the glucuronylsynthase protocol developed in chapter 2 
can play a particularly important role in the synthesis of labelled glucuronides. 
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Chapter 4: Kinetics of the synthase and hydrolysis of the 
glucuronyl fluoride 29 
4.1 Introduction 
As described previously in section 2.2 the glucuronylsynthase protocol was revised from 
Wilkinson’s work in an effort to improve the synthesis of glucuronides for analytical 
applications. This involved adding tert-butanol in a final concentration of 10% v/v to the 
reaction conditions as a way to solubilise the hydrophobic steroid substrates and to improve 
enzyme activity. This was a successful approach with a broad range of steroids able to be 
accessed by the synthase protocol and also demonstrated a significant improvement over the 
previous conditions in the synthesis of glucuronides of epiandrosterone 35 and 
dehydroepiandrosterone 19, for example. 
The actual contribution of tert-butanol towards activating the enzyme remained uncertain. 
Substrate inhibition for CMO-DHEA 33 was observed at 21 °C in the absence of tert-butanol but 
for all reactions at 37 °C with tert-butanol no apparent substrate inhibition was observed based 
on initial rate data acquired with increasing substrate concentrations. Indeed, as Wilkinson 
observed, substrate concentrations of up to 10 mM for CMO-DHEA 33 could be tolerated by the 
glucuronylsynthase with no apparent deleterious effect on initial rates of the enzyme. However, 
no detailed studies including or excluding tert-butanol at either 21 °C or 37 °C were performed, 
which left the question of tert-butanol’s contribution to activation of the enzyme unanswered. 
To resolve this question a study of the Michaelis-Menten kinetics of the glucuronylsynthase with 
respect to these two variables would be performed. The changes to the specificity constant 
kcat/KM, the Michaelis constant KM and the catalytic turnover constant kcat would be expected to 
reveal possible mechanisms through which tert-butanol is acting on the enzyme. For example, it 
may affect the binding affinity of the steroid substrate (as the steroids are known to be highly 
soluble in tert-butanol), which would be borne out in a higher observed KM for the steroid 
substrate. Additionally, it would be interesting to observe at which point substrate inhibition 
disappears as a result of the change in the two variables. 
To perform these kinetics experiments, measurements of activity with and without tert-butanol 
were required and this required a steroid that would be sufficiently water-soluble without 
organic co-solvent. In Wilkinson’s work a number of steroid derivatives were prepared in an 
effort to improve the water solubility of the steroids by exploiting the expected charged nature 
of the substituents (figure 31).  
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Figure 31: the steroid derivatives synthesised in an effort to improve the solubility of the 
steroids in aqueous conditions. Shown in brackets are the maximum (soluble) concentrations 
reached in sodium phosphate buffer (100 mM, pH 7.5) 
Of these derivatives, DHEA O-(carboxymethyl)oxime 33 was the standout with greatly 
improved aqueous solubility over the other two derivatives, which led to its use in studies on 
the kinetics of the E504G glucuronylsynthase155.  
4.2 Synthesis of CMO-DHEA 33 and CMO-DHEA 3-glucuronide 34 
A previous synthesis of CMO-DHEA 33 was reported by Philomin et al. where DHEA 19 was 
reacted with O-(carboxymethyl)hydroxylamine hydrochloride 126, using pyrrolidine as a 
catalyst for the condensation reaction, to afford the resulting CMO-DHEA 33 in 88% yield 
(scheme 44)218. This reaction works well and was used by Wilkinson but the experimental 
procedure requires careful attention to anhydrous conditions and a lengthy workup for optimal 
results. 
 
Scheme 44: the synthesis of CMO-DHEA 33 (yield from Wilkinson) 
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In search of a method that permitted faster and simpler access to the desired steroid, the 
literature was examined and a method found in the work of Rosenfeld et al. as illustrated in 
scheme 45219. The parent steroid is dissolved in ethanol followed by the addition of O-
(carboxymethyl)hydroxylamine hemihydrochloride 126 dissolved in sodium hydroxide (3 
equivalents with respect to the parent steroid), and the reaction is heated at 80-85 °C for 4 h 
until completion. 
 
Scheme 45: the synthesis of CMO-DHEA 33 using Rosenfeld et al.’s procedure 
This is an operationally simpler approach without requiring strictly anhydrous conditions and 
the reaction is complete after 4 h. In fact, upon cooling the reaction mixture to room 
temperature the steroid is observed to precipitate out of solution and a simple filtration affords 
pure CMO-DHEA in 58% yield that is identical by 1H NMR to the material obtained using the 
pyrrolidine-catalysed procedure. An additional crop (again identical by 1H NMR) of CMO-DHEA 
can be obtained by concentrating the filtrate and extracting with ethyl acetate and aqueous 
hydrochloric acid, for an overall yield of 80%, which is comparable to the previous method. 
Stereochemically, the product obtained through this method is expected to possess the same 
stereochemistry at the oxime due to the adjacent quartnery carbon at C13, which would enforce 
the formation of the E-isomer over the Z-isomer. 
Now that the synthesis of the steroid was complete, all that remained was synthesis of the 
corresponding CMO-DHEA 3-glucuronide 34 to obtain product for a calibration curve. This is 
accomplished with the glucuronylsynthase reaction (which has been performed on 10 mg scale 
before) but with a twist – the conventional solid-phase extraction method used (WAX) is unable 
to separate the starting material and product glucuronide. As explained in section 2.2.1, the 
WAX purification separates compounds based on their chemical properties – weak anions (such 
as carboxylate) will be retained while neutral compounds will be removed in a methanol wash, 
for example. However, since CMO-DHEA contains a carboxylic acid the glucuronide cannot be 
purified in this way. 
To resolve this issue a reverse-phase column was used instead, relying on the significant 
differences in polarities of the two compounds for purification. Unfortunately the first attempt, 
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using 10 mg of glucuronide, using a solvent system developed by Wilkinson (25% aqueous 
acetonitrile + 1% formic acid), failed to purify the glucuronide and led to loss of all material. 
A second attempt was performed on a reaction mixture with 9 mg of the parent steroid, where a 
6 cc WAX cartridge was refitted with the required reverse-phase silica. The solvent system was 
changed to 1:1 MeOH:H2O to avoid the use of formic acid that could potentially hydrolyse the 
glucuronide if left in solution. Fractions were collected in 0.5 mL portions and it was observed 
that separation of glucuronide and starting material was successful.  
In practice, the glucuronide eluted quite rapidly and after the flowthrough fractions it was 
already observed in the next 2-3 fractions. However, there remained some glucuronide that co-
eluted with the starting material and no solvent system could be found to resolve this issue. 
Fortunately a sufficient quantity of pure glucuronide was obtained to obtain a calibration curve 
for CMO-DHEA 3-glucuronide 34 at concentrations of 0, 20, 50, 100, 200 500 and 1000 μM. 
4.3 Method development 
For the kinetics experiments a suitable solvent system had to be developed for HPLC separation 
of glucuronide from parent steroid. A previous method had been developed by Wilkinson (2010, 
PhD thesis) but the composition – pH 2 sodium phosphate buffer – was deemed to be too acidic 
to take advantage of the chemical differences between the two compounds (with regards to the 
carboxylates, two for the glucuronide vs one for the parent steroid).  
Instead, ammonium acetate was selected as the buffer component as a commonly used buffering 
agent in the McLeod group. Initial experiments were performed using pH 6 ammonium acetate 
buffer (100 mM) and it appeared that the parent steroid retained quite strongly on the column, 
leading to longer run times. A change to pH 7.5 and a reduction in concentration to 10 mM 
ammonium acetate improved elution times but it became clear that the glucuronide product 
was eluting a great deal faster and as a result different solvent compositions were trialled to 
obtain an elution time under 15 mins for the parent steroid, for quicker runs, while keeping the 
glucuronide away from the solvent front, which would obscure any useful signals.  
The mobile phase was to consist of some percentage of methanol to buffer and a range of 30-
80% v/v methanol was examined. Finally, an isocratic solvent composition of 45:55 
MeOH:buffer (10 mM, pH 7.5) was settled on, where the glucuronide was sufficiently separated 
from the solvent front to consistently provide a distinct peak and the parent steroid eluted 
sufficiently rapidly such that each run could be completed within 15 mins, with the parent 
steroid eluting in about 10-12 mins, while the glucuronide would elute at about 2.5-3 mins. 
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4.4 Kinetics of the E504G glucuronylsynthase 
4.4.1 Effect of tert-butanol concentration on the initial rate of the E504G synthase 
An initial set of experiments focused on varying the concentration of tert-butanol and observing 
the effect this had on the initial rate of the synthesis of CMO-DHEA 3-glucuronide 34. With the 
substrate concentration set at 2 mM, the concentration of tert-butanol was then varied from 0% 
up to 20% v/v at 37 °C. As in Wilkinson’s initial rate experiments, the concentration of the 
glucuronyl fluoride 29 was kept at a saturating concentration of 1 mM throughout153. The 
results are detailed in figure 32 and it was interesting to see that 5% tert-butanol resulted in 
the highest initial rates for the synthase compared to 10%.  
From about 15% and more, the concentration of tert-butanol starts to have a deleterious effect 
on the initial rate, and especially at 20% v/v the initial rate has decreased to approximately 
27% compared to the initial rate in the absence of tert-butanol. This appears to mirror the 
general trend seen in enzyme reactions where organic solvents are used as co-solvents in an 
effort to improve substrate solubility. While improved solubility of the organic substrates is 
often achieved, this is typically accompanied by an adverse effect on the activity and stability of 
the enzyme, often leading to denaturation or decreased specificity220,221. 
 
Figure 32: the effect of tert-butanol concentration on the initial rate of the E504G 
glucuronylsynthase at 37 °C with CMO-DHEA 33 (experiments conducted in triplicate). 
Conditions: CMO-DHEA 33 (2 mM), α-D-glucuronyl fluoride 29 (1 mM), E504G 
glucuronylsynthase (0.2 mg/mL), NaPi (50 mM, pH 7.5), 37 °C. 
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This indicates that a small percentage of tert-butanol co-solvent is sufficient to increase the 
initial rate of the enzyme but more than 10% has a negative impact on the initial rates (and 
correspondingly the overall yield). However, this effect was not yet fully understood and further 
analysis by Michaelis-Menten kinetics was performed to elucidate the nature of this apparent 
activation.  
However, before discussing the study of the Michaelis-Menten kinetics of the 
glucuronylsynthase enzyme, a brief introduction to the model and its theoretical and 
experimental implications will be given below. 
4.4.2 The Michaelis-Menten model  
4.4.2.1 A history of the Michaelis-Menten equation 
The Michaelis-Menten model of enzyme kinetics is one of the most well-known models in 
biochemistry today. Developed by Lenor Michaelis and Maud Menten and reported in 1913, it 
was the first coherent model of enzyme kinetics to explain the behaviour of the invertase 
enzyme (now known as the β-fructofuranosidase enzyme) not just from a theoretical 
standpoint, which others had previously done, but also by supporting the theory with rigorous 
experimental design and evidence222–224. 
Initial efforts to understand enzyme reactions in the late 1800s were hindered by the lack of 
availability of pure enzyme, limited assays etc. Indeed, the development of buffers for the 
purpose of controlling reaction pH had not yet occurred. To further complicate matters, studies 
typically examined the enzyme reaction over its entire time course, which would introduce 
other variables such as the reverse reaction and product inhibition into the mix, rendering 
interpretation of results particularly challenging. 
Studies by O’Sullivan and Thompson on the invertase enzyme, which hydrolyses sucrose to 
glucose and fructose, revealed that the reaction has a particular requirement for the acidity of 
the medium and an optimum temperature, a property unexpected at the time225. Additionally, 
the stability of the enzyme appeared to be greatly improved in the presence of the sucrose 
substrate, which pointed to the existence of an enzyme-substrate complex as a critical aspect of 
the reaction.  
Later work by Brown proposed that the enzyme-substrate (EA) complex affected the kinetics of 
the reaction, namely that the complex had brief existence but had a sufficient lifetime to convert 
substrate to product before breaking down and that only through the formation of this complex 
could any reaction take place at all226. Others, such as Henri, proposed that this complex existed 
as an equilibrium between the free enzyme, enzyme-substrate and enzyme-product complexes. 
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Unfortunately their experiments were hindered by not recognising the importance of pH, which 
allowed objections to be raised against each hypothesis. 
However, once a clear understanding of acidity was developed in the form of the pH scale, it was 
Michaelis and Menten who realised that this could be a possible way to resolve the issue. 
Through the control of pH as well as measuring the initial rates of reaction instead of following 
the reaction time course, they could avoid several of these challenges to obtain more useful 
information about the enzyme reaction. Ultimately they came to similar conclusions as the 
others did, but with a much surer experimental footing, along with a reaction mechanism as 
shown in equation (1). 
𝐸 + 𝐴 ⇌ 𝐸𝐴 → 𝐸 + 𝑃    (1) 
Like Henri, Michaelis and Menten assumed that the initial formation of the EA complex could be 
conceived as an equilibrium between the complex and free enzyme such that an equilibrium 
constant for substrate dissociation could be written down as: 𝑘𝐷 = 𝑒𝑎 𝑥⁄ , where “e” is the 
instantaneous concentration of enzyme, “a” is the instantaneous concentration of substrate and 
“𝑥” is the concentration of the enzyme-substrate complex EA. 
It may be obvious that the instantaneous concentrations of enzyme and substrate are not 
directly measurable. However, they can be expressed in terms of the measurable quantities of 
the initial concentrations of each, 𝑒0 = 𝑒 + 𝑥 and 𝑎0 = 𝑎 + 𝑥. The first observation is that 𝑥 
cannot be larger than e0 and the second is that if a0 is much larger than e0, then it must also be 
much larger than 𝑥. 
This allows the simplification 𝑎0 = 𝑎 (𝑎0 ≫ 𝑥). It then follows that: 
𝑥 = 𝑒𝑎 𝑘𝐷⁄     (2) 
𝑥 = (𝑒0 − 𝑥)𝑎0 𝑘𝐷⁄    (3) 
𝑥 =
𝑎0𝑒0
𝑘𝐷+𝑎0
    (4) 
𝑥 = 𝑒0 (
𝑘𝐷
𝑎0
)⁄ + 1   (5) 
The second step in the reaction, 𝐸𝑆 → 𝐸 + 𝑃, is a first-order reaction and can be represented as 
𝑣 = 𝑘2𝑥 =
𝑘2𝑎0𝑒0
𝑘𝐷+𝑎0
   (6) 
where k2 is the rate constant for this step. These equations then allowed Michaelis and Menten 
to explain the behaviour of the invertase enzyme, which subsequently become widely adopted 
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amongst biochemists and where equation (6) is now referred to as the Michaelis-Menten 
equation. 
4.4.2.2 Steady state formulation by Briggs-Haldane 
In 1925, Briggs and Haldane extended the work of Michaelis and Menten by proposing a 
mechanism in terms of the rate of change of the enzyme-substrate complex for the equation227: 
𝐸 + 𝐴
𝑘1
→ 
𝑘−1
←  
𝐸𝐴
𝑘2
→𝐸 + 𝑃   (7) 
Defining E as “𝑒0 − 𝑥”, A as “𝑎” and EA as “𝑥”, this leads to the rate equation: 
𝑑𝑥
𝑑𝑡
= 𝑘1(𝑒0 − 𝑥)𝑎 − 𝑘−1𝑥 − 𝑘2𝑥 (8) 
This avoided the requirement of assuming whether the first step in the reaction (𝐸 + 𝐴 ⇌ 𝐸𝐴) 
was in equilibrium or not. Briggs and Haldane further argued that a steady state could occur 
when 𝑑𝑥 𝑑𝑡⁄ = 0, that is, when the concentration of the enzyme-substrate complex EA is 
constant. This then leads to an expression for 𝑥: 
𝑥 = 𝑘1𝑒0𝑎
𝑘−1+𝑘2+𝑘1𝑎
    (9) 
Expressing in terms of v by combining equation (6) with equation (9) gives the following 
equation: 
𝑣 = 𝑘2𝑥 =
𝑘2𝑘1𝑒0𝑎
𝑘−1+𝑘2+𝑘1𝑎
   (10) 
𝑣 = 𝑘2𝑒0𝑎𝑘−1+𝑘2
𝑘1
+𝑎
    (11) 
Equation (11) is often described as the correct approach to representing the Michaelis-Menten 
equation. However, there remains the issue that equation (7) assumes that only one type of 
enzyme-bound intermediate exists, the enzyme-substrate complex, and does not take into 
account the possibility for other types, such as enzyme-product complexes (e.g. for product 
inhibition) and so on. For these reasons, the method of Michaelis and Menten, where only initial 
rates of reaction were studied, became widely adopted since the complexities of product 
formation and reverse reactions can simply be avoided as these effects do not occur until later 
in the course of the enzyme reaction. 
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4.4.2.3 The Michaelis-Menten equation and its parameters 
Thus, an even more general way of representing the Michaelis-Menten equation is shown by 
equation (12): 
𝑣 =
𝑘cat𝑒0𝑎
𝐾M+𝑎
    (12) 
Here, k2 is represented by kcat while 
𝑘−1+𝑘2
𝑘1
 is represented by KM, the Michaelis constant. 
Rewriting these constants is important as it recognises that not every enzyme reaction follows 
the traditional two-step Michaelis-Menten mechanism, as kcat is not necessarily always the 
second step of the reaction and nor is KM always equivalent to 
𝑘−1+𝑘2
𝑘1
.  
However, kcat has properties of a first-order rate constant and with the units of reciprocal time 
(s–1), represents the number of times the enzyme-substrate complex EA can turn over substrate 
(i.e. the number of cycles per unit time) and is therefore referred to as the catalytic constant 
(hence the term kcat).  
Additionally, the enzyme concentration is not necessarily known at first, especially when 
studying a new enzyme and it may be convenient to represent 𝑘cat𝑒0 as V or Vmax (equation 13).  
𝑣 =
𝑘cat𝑒0𝑎
𝐾M+𝑎
=
Vmax𝑎
𝐾M+𝑎
   (13) 
It should be pointed out that Vmax used to define the maximum velocity of the enzyme reaction, 
but should be thought in terms of a limit on the maximum velocity rather than as the actual 
maximum observable velocity. 
The Michaelis-Menten equation, plotted as v against a, generates a rectangular hyperbola with 
asymptotes at a = –KM and v = V (figure 33). 
There are three special conditions that have particular meaning in the Michaelis-Menten model. 
At low substrate concentrations, where a ≪ KM (where e0 is constant) such that KM dominates, 
the equation becomes: 
𝑣 =
𝑘cat𝑒0𝑎
𝐾M
=
Vmax𝑎
𝐾M
   (14) 
This shows that at such substrate concentrations, the reaction becomes first-order with respect 
to a and second-order overall. For this reason, the term 𝑘cat 𝐾M⁄  is called the specificity constant 
and represents the ability of the enzyme to turn over a substrate, or its capacity to turn over one 
substrate over another in the same reaction. Graphically, this is represented by the slope 
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Vmax/KM, which allows for the determination of the specificity constant under this set of 
conditions. 
 
Figure 33: a schematic representation of the Michaelis-Menten equation as a plot of V (the y-
axis) against a (the x-axis) for the case Vmax = 1, showing KM (which equals 1 in this case), the 
slope Vmax/KM (which here has the form v = a), and the two asymptotes Vmax and –KM 
For the condition where a = KM, equation (13) simplifies as below: 
𝑣 =
Vmax𝐾M
𝐾M+𝐾M
=
Vmax
2
   (15) 
This allows the definition of KM as the point where the concentration of substrate enables the 
enzyme to reach half the limit of maximum velocity and it is independent of the enzyme 
mechanism that is being examined. In this capacity KM can sometimes be used as a way of 
approximating the binding affinity of a particular substrate – for example, substrates with lower 
KM values bind tighter to the enzyme compared to those with higher KM values, and hence allow 
the enzyme to approach Vmax much more rapidly. 
At high substrate concentrations, where a ≫ KM (where e0 is constant) such that a dominates, 
the equation becomes zero-order with respect to a: 
𝑣 =
𝑘cat𝑒0𝑎
𝑎
= 𝑘cat𝑒0 = Vmax  (16) 
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Hence the sometimes written form for V as Vmax and indeed throughout the study on the kinetics 
of the glucuronylsynthase, Vmax will be the term used. However, it should be noted that v will 
never reach Vmax for any finite value of a and the equality shown in equation (16) is only 
possible as a tends towards infinity, which is not realistic (hence the above discussion about V 
as a limit rather than a definite maximum).  
This simplification has the additional meaning in that all of the active sites on the enzyme are 
presumed to be filled by substrate and therefore the enzyme is said to be saturated at this point. 
The constants of kcat, KM, and kcat/KM are all fundamental properties of the enzyme in reaction 
with a particular substrate and therefore their determination will allow for greater 
understanding of the corresponding enzyme mechanism. 
4.4.2.4 Substrate inhibition and linear plots 
As emphasised in section 1.7 and the introduction to this section, the glucuronsynthase enzyme 
exhibited substrate inhibition at room temperature in the presence of CMO-DHEA 34. Substrate 
inhibition follows the type of mechanism shown in figure 34, where the substrate A binds to the 
enzyme-substrate complex EA to form the substrate-enzyme-substrate complex AEA (described 
by the inhibition constant Ksi) that cannot react further and must involve release of bound 
substrate to continue productive behaviour. The observed behaviour then is a reduction in 
reaction velocity as the substrate concentration is increased (as seen in Wilkinson’s work and in 
figure 3), the opposite behaviour to that seen in standard Michaelis-Menten kinetics. 
 
Figure 34: the mechanistic representation of substrate inhibition 
This type of inhibition is represented by equation (17): 
𝑣 =  
𝑉′𝑎
𝐾′+𝑎(1+
𝑎
𝐾𝑠𝑖
)
  (17) 
Here, Vmax is represented as V’ and KM as K’ due to the fact that these parameters are no longer 
Michaelis-Menten parameters as a result of the (1 + (
𝑎
𝐾𝑠𝑖
)) term. 
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To examine the Michaelis-Menten model in further detail, sometimes the data may be fit to 
alternative models for easier interpretation, obtaining the relevant kinetic parameters, or 
sometimes for a simpler format where the rectangular hyperbola could be difficult to draw 
(especially in the days before computing software could perform the task). To this end 
reciprocal plots are often used to obtain linear functions. The most well-known of these is the 
Lineweaver-Burk plot, or the double reciprocal plot, which is obtained when the data is fitted 
according to the following equation228: 
1
𝑣
=
1
Vmax
+
𝐾M
Vmax
∙
1
𝑎
  (18) 
This produces a plot of 1 𝑣⁄  against 1 𝑎⁄ , which gives the y-intercept as 1 Vmax⁄  and the x-
intercept as the value of −1 𝐾M⁄  (figure 35). However, care is often required when using this 
particular plot as the experimental errors can be greatly distorted – for example, small values of 
𝑣 result in large values of 1 𝑣⁄ , and large values of 𝑣 result in small values of 1 𝑣⁄  and so on. 
Weighting methodology can be used to overcome this problem but it remains a potential source 
of misinterpretation. 
 
Figure 35: a schematic of the Lineweaver-Burk linear plot of 1/v against 1/a for Vmax = 1 and KM 
= 1, showing the slope of the line as KM/Vmax, the y-intercept at 1/Vmax and the x-intercept at –
1/KM 
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Another linear representation of the Michaelis-Menten model is known as the Hanes plot, the 
Woolf plot, or the Hanes-Woolf plot (referred to as such here on in) and modelled according to 
equation (19), which is simply obtained by multiplying equation (18) by a229,230: 
𝑎
𝑣
=
𝑎
Vmax
+
𝐾M
Vmax
  (19) 
This gives a plot of a/v against a (figure 36), which has the y-intercept at KM/Vmax and the x-
intercept at –KM. 
 
Figure 36: a schematic representation of the Hanes-Woolf plot of a/v against a for the case Vmax 
= 1, KM = 1, showing the slope of the line as 1/Vmax, the y-intercept at KM/Vmax, and the x-
intercept at –KM 
The improvement of this representation over the Lineweaver-Burk plot is that the plotted 
errors do not suffer from the reciprocity problem and the errors are usually sensible as a result. 
This type of plot is usually used when a test of the interpretation, derived from the initial 
Michaelis-Menten kinetics plot, is required. For example, should a system display substrate 
inhibition, this can be confirmed through the use of a reciprocal plot, where an obvious 
deviation from the linear fit can be seen. 
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4.4.3 Michaelis-Menten kinetics of the E504G glucuronylsynthase 
Previous work by Wilkinson on the kinetic parameters of the glucuronylsynthase used CMO-
DHEA 33 as the steroid substrate. Experiments were performed with a saturating concentration 
of the glucuronyl fluoride 29 (1 mM) in sodium phosphate buffer (100 mM, pH 7.5) at 21 °C 
while varying the concentration of the steroid substrate. Under these conditions, the 
concentration of glucuronyl fluoride 29 is saturating and therefore the kinetics of this system 
was expected to follow a simple Michaelis-Menten model as described above. 
The resulting data was instead found to fit well (R2 = 0.97) to a substrate inhibition model 
where a second steroid substrate molecule was anticipated to inhibit the synthesis of the 
corresponding glucuronide by binding to the enzyme-substrate complex. However, the errors 
obtained from the non-linear curve fit to the substrate inhibition model were quite substantial, 
with KM and Vmax estimated to be 7 ± 19 mM and 32 ± 87 nmol min–1 [mg protein]–1 respectively. 
Therefore the actual values of KM and Vmax for the glucuronylsynthase enzyme remained 
uncertain155.  
To investigate the Michaelis-Menten kinetics of the synthase in this study, initial rate plots were 
required at different substrate concentrations, preferably from values of about 0.1 KM to 10 KM 
for accurate determination of the various Michaelis-Menten parameters231.  
For example, sufficient measurements at low values of substrate concentration (a ≪ KM) will 
provide information on the specificity constant 𝑘cat 𝐾M⁄  for the enzyme, while measurements at 
high values of substrate concentration (a ≫ KM) will provide information about Vmax. Naturally 
the value of KM is not necessarily known beforehand and therefore a wide range of substrate 
concentrations will be covered, experimental conditions permitting, depending on solubility or 
assay sensitivity. 
To vary the substrate concentration a stock solution of the steroid substrate CMO-DHEA 33 was 
required. As mentioned previously, CMO-DHEA 33 is a steroid derivative of 
dehydroepiandrosterone 19 where the carboxylic acid functionality (pKa ~ 3) is charged at 
neutral pH enhancing aqueous solubility, enabling kinetics experiments to be conducted in the 
absence of tert-butanol, which would be necessary to elucidate the effect of the co-solvent on 
the glucuronylsynthase reaction. Of course, the hydrophobic steroid core has not been altered 
and there remains a limit to the solubility of the steroid in purely aqueous media, as observed 
when attempting to prepare the requisite stock solutions. Indeed, an upper limit of 
approximately 4 mM for CMO-DHEA in sodium phosphate buffer (50 mM, pH 7.5) is observed, 
which necessitated prolonged sonication to fully dissolve the steroid. Further attempts to 
prepare solutions of concentrations greater than 5 mM failed to afford homogenous solutions. 
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With a stock solution of the substrate in hand and having developed an appropriate HPLC 
method, work could proceed on plotting initial rate data against substrate concentration, which 
may or may not show Michaelis-Menten behaviour. As mentioned previously, the variables are 
tert-butanol concentration (0% and 10% v/v) and temperature (21 °C and 37 °C), which gives 
rise to four possible reaction combinations or systems (to be listed as {tBuOH v/v %, 
temperature °C} herein). Additionally, a range of substrate concentrations was covered, with the 
set of 100 μM, 150 μM, 200 μM, 500 μM, 1 mM and 2 mM to be examined. Finally, experiments 
were performed in triplicate to improve experimental accuracy. All experiments used an 
enzyme concentration of 0.2 mg/mL of E504G glucuronylsynthase. 
The initial set of data produced from these experiments indicated that for three of the possible 
combinations exhibited normal Michaelis-Menten kinetics but for the {0%, 21 °C} combination a 
decrease in initial rate was observed towards the higher substrate concentrations, which is 
symptomatic of substrate inhibition similar to what Wilkinson also observed under comparable 
conditions155. Unfortunately, for the two 21 °C experiments the initial rates of reaction proved to 
be so slow that the data for 100 and 150 μM had to be discarded as it was difficult to distinguish 
the product peaks from baseline noise. 
At this point, it was evident from the assembled data that sufficient saturation of the enzyme, 
defined as a > 3 KM, had not yet been reached for the two experiments containing 10% v/v tert-
butanol, which would therefore reduce the accuracy of the values for the various kinetic 
parameters. Additional data was therefore acquired for substrate concentrations of 5 mM and 
10 mM by preparing an alternate stock solution of CMO-DHEA 33 where the solution contained 
tert-butanol to aid in dissolution of the steroid. In this way a stock solution at a concentration of 
20 mM could be achieved by this method, demonstrating the solubilising effect that tert-butanol 
has on steroids, even for solubilised derivatives like CMO-DHEA 33. 
Due to the need to discard the data for the lower concentration ranges for the two experiments 
conducted at 21 °C as a result of poor sensitivity, further initial rate data was acquired 
(particularly for the {0%, 21 °C} combination) at 400, 600, 800 and 1200 µM to improve the 
accuracy of the data. The resulting data for all four reaction combinations is shown below. 
4.4.3.1 Graphical results and calculations 
In figure 37 the first reaction combination of {10%, 37 °C} appears to fit well to the Michaelis-
Menten model with an R2 = 0.99. To aid the reader, the enzyme concentration is estimated to be 
2.9 µM (from the values of enzyme concentration = 0.2 mg/mL, molecular weight of the enzyme 
= 68.4 kDa ~ 68,400 g/mol, and reaction volume = 1 mL). 
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The derived Vmax from the equation fit gives a value of 11.2 ± 0.5 µM min–1, or 56.2 ± 2.3 nmol 
min–1 (mg protein)–1 and a KM of 6.0 ± 0.5 mM, which combine to give a calculated kcat/KM value 
(i.e. obtained from the above values for Vmax and KM) of 10.7 ± 0.9 M–1 s–1, with a corresponding 
kcat value of 0.064 s–1.  
When considering the initial slope for Vmax/KM as given by the blue line, this gives a fitted kcat/KM 
value of 8.4 ± 2.0 M–1 s–1. Here it may be observed that this does not pass through the origin – 
when fitting through the origin the value becomes 9.3 ± 1.0 M–1 s–1. 
 
Figure 37: the Michaelis-Menten curve (red) for the reaction combination {10%, 37 °C} for 
CMO-DHEA 33, including the Vmax/KM slope (blue). Conditions: tert-butanol (10% v/v), E504G 
(0.2 mg/mL), α-D-glucuronyl fluoride 29 (1 mM), NaPi (50 mM, pH 7.5), 37 °C. 
It can be seen from figure 37 that the range of substrate concentrations that could be examined 
does not reach up to 10× KM, and indeed only reaches about 1.7× KM (usually >3× KM is desired). 
While this is a consequence of the limited solubility of the steroid substrate it does affect the 
accuracy of the results. In this instance the value of kcat/KM is likely to be more accurately 
represented by the fitted value rather than the calculated value. However, there is no reliable 
way to extract information about Vmax, kcat and KM from this linear fit and therefore the 
calculated values remain necessary, even though their values must be taken as approximations. 
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Figure 38: the Michaelis-Menten curve (red) for the reaction combination {0%, 37 °C} for CMO-
DHEA 33, including the Vmax/KM slope (blue). Conditions: E504G (0.2 mg/mL), α-D-glucuronyl 
fluoride 29 (1 mM), NaPi (50 mM, pH 7.5), 37 °C. 
On the other hand, in the absence of tert-butanol at 37 °C there is a significant reduction in the 
Vmax and KM of the system, to 2.8 ± 0.1 µM min–1, or 13.9 ± 0.7 nmol min–1 (mg protein)–1 and 637 
± 79 µM respectively (figure 38). The calculated kcat is then found to be 0.016 s–1. The respective 
calculated and fitted kcat/KM values for this system were found to be 24.8 ± 3.3 M–1 s–1 and 21.1 ± 
1.8 M–1 s–1 (or 17.3 ± 0.9 M–1 s–1 when fitting through the origin). 
In this system the range of substrate concentrations covered up to 3.1× KM. While not as 
desirable as values of 5× or 10× KM, this does allow for greater confidence in the calculated 
values for Vmax and KM. However, there remains the discrepancy between the calculated and 
fitted values for kcat/KM, which would likely be attributed to the lower initial rate, increasing the 
error at lower substrate concentrations. 
As seen in figure 39, lowering the temperature for the system {10%, 21 °C} appears to have a 
similar effect on Vmax, with the calculated value found to be 2.8 ± 0.1 µM min–1, or 14.0 ± 0.6 
nmol min–1 (mg protein)–1, which gives rise to a kcat value of 0.016 s–1, essentially the same as for 
the {0%, 37 °C} reaction combination.  
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A very interesting change in KM is found with the calculated value at 3.3 ± 0.3 mM suggesting 
that something similar to the {10%, 37 °C} system may be occurring, as both systems exhibit a 
high KM value. The corresponding calculated and fitted kcat/KM values are 4.9 ± 0.5 M–1 s–1 and 
3.2 ± 0.3 M–1 s–1 (3.5 ± 0.2 M–1 s–1 when fitted through the origin), which are much lower than 
the previous two reaction combinations. 
Here, the range of substrate concentrations covered up to 3.1× KM. Like the previous reaction 
system this allows for some confidence in the accuracy of the calculated values. 
 
Figure 39: the Michaelis-Menten curve (red) for the reaction combination {10%, 21 °C} for 
CMO-DHEA 33, including the Vmax/KM slope (blue). Conditions: tert-butanol (10% v/v), E504G 
(0.2 mg/mL), α-D-glucuronyl fluoride 29 (1 mM), NaPi (50 mM, pH 7.5), 21 °C. 
Shown in figure 40 is the final reaction combination {0%, 21 °C}, which is similar to the 
conditions studied in Wilkinson’s work described above. The most obvious point of difference 
between this system and the preceding three is that the data appears to fit to a substrate 
inhibition model (R2 = 0.96) rather than the typical Michaelis-Menten model. The calculated 
value for Vmax was found to be 1.2 ± 0.3 µM min–1, or 6.1 ± 1.4 nmol min–1 (mg protein)–1, with a 
calculated kcat value of 0.007 s–1. The calculated value for KM was found to be 1.3 ± 0.4 mM, lower 
than both reaction systems containing tert-butanol but higher than the other reaction system 
without tert-butanol {0%, 37 °C}. 
0
0.5
1
1.5
2
2.5
0 2000 4000 6000 8000 1 10
4
1.2 10
4
Michaelis-Menten plot for:
CMO-DHEA (10%, 21 
o
C)
FGlu (1 mM), E504G (0.2 mg/mL)
incl. V
max
/K
M
 slope
Initial rate (uM/min) for 10%, 21 oC
Vmax/KM
y = -0.006654 + 0.0006629x   R
2
= 0.9569 
In
it
ia
l 
ra
te
 (

M
/m
in
) 
fo
r 
1
0
%
, 
2
1
 o
C
Concentration (M)
y = V
max
*[S]/(K
M
+[S])
ErrorValue
0.10952.797Vmax
289.23264KM
NA0.177Chisq
NA0.9831R
2
 
Plot of initial rates against concentration 
for the glucuronylsynthase reaction of 
CMO-DHEA 33 at 21 °C (10% v/v tBuOH) 
Concentration (µM) 
In
it
ia
l r
at
e 
(µ
M
/m
in
) 
Chapter 4: Kinetics of the synthase and hydrolysis of the glucuronyl fluoride 29 
102 
 
The calculated kcat/KM value was found to be 5.4 ± 0.4 M–1 s–1, compared to the fitted value of 2.8 
± 0.1 M–1 s–1. The discrepancy here is unusually large, which could be attributed to the 
calculated kcat/KM value being dependent on a calculated KM obtained from a substrate range of 
1.6× KM. In addition, there is the matter of the linear fit not passing through the origin. If the 
linear fit is instead plotted through the origin, then the resulting fitted value becomes 3.7 ± 0.2 
M–1 s–1, which is higher but still not as close to the calculated value as desired. This is 
attributable to the difficulty of acquiring data at low substrate concentrations, especially in the 
case of a low initial rate (as seen for the case at 37 °C in the absence of tert-butanol), resulting in 
less data points and consequently a poorer data set. 
Therefore, the calculated values for the various Michaelis-Menten parameters for this reaction 
system can only be taken as approximations and here the fitted value for kcat/KM is taken to be a 
more accurate representation of this parameter. Again the limited solubility of the substrate 
would have contributed to this reduced accuracy. 
 
Figure 40: the Michaelis-Menten curve (red) for the reaction combination {0%, 21 °C} for CMO-
DHEA 33, including the Vmax/KM slope (blue). Conditions: E504G (0.2 mg/mL), α-D-glucuronyl 
fluoride 29 (1 mM), NaPi (50 mM, pH 7.5), 21 °C. 
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For the fourth reaction combination {0%, 21 °C), a Hanes-Woolf plot is presented in figure 41, 
confirming the pattern of substrate inhibition illustrated in the Michaelis-Menten plot in figure 
40. The blue line represents the expected linearity of the plot but the deviation of the data 
points at higher substrate concentrations shows that substrate inhibition is indeed present in 
this system. 
 
Figure 41: the Hanes-Woolf plot for CMO-DHEA 33 at 21 °C without tert-butanol, showing 
substrate inhibition due to a deviation (red) from the expected linearity (blue) 
A summary of the important calculated and fitted Michaelis-Menten parameters for this study 
are collated in table 5. 
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Table 5: compilation of the relevant parameters derived from Michaelis-Menten modelling of 
the E504G glucuronylsynthase with CMO-DHEA 33 
Reaction 
combinationa 
Calculatedb 
Vmax 
(nmol/min/[
mg protein]) 
Calculatedb 
KM (µM) 
Calculatedc 
kcat/KM  
(M–1 s–1) 
Fittedd 
kcat/KM  
(M–1 s–1) 
Ksi (µM) 
(1) 37 °C, 10% 56.2 ± 2.3 5981 ± 483 10.7 ± 0.9 9.3 ± 1.0d - 
(2) 37 °C, 0% 13.9 ± 0.7 637 ± 79 24.8 ± 3.3 17.3 ± 0.9d - 
(3) 21 °C, 10% 14.0 ± 0.6 3264 ± 289 4.9 ± 0.5 3.5± 0.2d - 
(4) 21 °C, 0% 6.1 ± 1.4 1270 ± 376 5.4 ± 0.4 3.2 ± 0.2d 1065 ± 371 
(5) Wilkinson’s 
system155 
32 ± 87 7000 ± 
19000 
5.3 4.3 100 ± 100 
aPresented in the form of (temperature, tert-butanol concentration v/v %). bObtained via non-
linear fitting to the Michaelis-Menten equation. cCalculated from the parameters obtained via 
non-linear fitting. dObtained via linear fit to first few points of substrate concentration. Due to 
low initial rates at low substrate concentrations these values differ from the calculated value of 
Vmax/KM. dErrors obtained via the LINEST function in Microsoft Excel 2013. 
4.4.3.2 The effect of increasing temperature 
An initial inspection of the graphical information presented in section 4.4.2.1 might indicate 
that tert-butanol acts to relieve substrate inhibition (for example, compare reaction systems (3) 
and (4). However, a more detailed examination suggests that the story is not so clear-cut. 
When only temperature is increased (i.e. (2) vs (4)) a 2.3-fold increase in Vmax (and hence kcat) is 
observed, similar to the effect of tert-butanol above, but a corresponding 50% reduction in KM 
suggests that the steroid is actually binding more strongly at higher temperatures. 
Additionally, there is a dramatic 5.4-fold increase in the fitted specificity constant kcat/KM 
between (2) and (4), which arises as a result of an increase in Vmax and a decrease in KM. This 
suggests that increasing temperature alone has a much more significant effect than tert-butanol 
alone at lower substrate concentrations. 
There is also an increase in temperature between (1) and (3), where a 4.0-fold increase in Vmax 
is observed. Intriguingly there is also a 1.8-fold increase in KM, in contrast to the change 
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observed for (2) vs (4). This then leads to a 2.9-fold increase in the fitted specificity constant, 
mirroring the hypothesis drawn previously.  
There is virtually no difference in Vmax between reaction systems (2) and (3), suggesting that, 
alone, temperature and tert-butanol enhance the rate at higher substrate concentrations to 
similar degrees, at least in comparison with (4). Interestingly the KM is 5.1-fold lower for (2) 
than in (3), which suggests that tert-butanol significantly affects the binding affinity of the 
steroid substrate. These two parameters then combine to give rise to a 5.1-fold increase in the 
(calculated) specificity constant kcat/KM for (2) over (3), showing that a temperature increase 
alone exerts a much more significant rate-enhancing effect at lower substrate concentrations 
than sole addition of tert-butanol. 
However, when considering that (1) and (3) both contain tert-butanol, this analysis suggests 
that an increase in temperature has more of a rate-enhancing effect than tert-butanol at both 
lower and higher substrate concentrations. 
4.4.3.3 The effect of adding tert-butanol 
When only tert-butanol (i.e. comparing (3) vs (4)) is added to the reaction at 21 °C, a 2.4-fold 
increase in Vmax is observed, suggesting that there is a rate-enhancing effect of tert-butanol at 
higher substrate concentrations.  
There is also a 2.6-fold increase in the value of KM, suggesting that the steroid is not binding as 
tightly in the enzyme active pocket. Incidentally, the apparent absence of substrate inhibition 
between (3) and (4) could arise as a result of this lower binding affinity, which would be 
expected to affect both KM and Ksi, which would lend more evidence to the possibility that tert-
butanol is affecting the binding affinity of the steroid substrate. It should be noted that the 
steroid substrate is also greatly solubilised by tert-butanol, which would also contribute to this 
reduction in binding affinity. 
Interestingly, the fitted specificity constant (kcat/KM) exhibits only a modest 1.1-fold increase 
between the two systems suggesting that for reactions at lower substrate concentrations the 
two reaction systems give rise to similar reaction rates and hence the effect of tert-butanol is 
much less remarkable.  
On the other hand, when only tert-butanol is added to the reaction at 37 °C (i.e. comparing (1) 
vs (2)) a 4.0-fold increase in Vmax is observed, the same as that seen for (1) vs (3), which 
involved a temperature increase. However, the value of KM increases dramatically at 37 °C, with 
a 9.4-fold increase from (2) to (1). This is much higher than seen for (4) to (3), which suggests 
that higher temperatures appear to increase the effect that tert-butanol has on the binding 
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affinity of the steroid substrate. These parameters then translate to a 1.9-fold reduction in the 
specificity constant (kcat/KM) from (1) to (2), implying that tert-butanol has a negative effect on 
the rate at lower substrate concentrations. 
All in all, it appears that while tert-butanol does have a rate-enhancing effect on the 
glucuronylsynthase reaction, particularly at higher substrate concentrations, the rate-enhancing 
effect of temperature appears to dominate. Throughout this analysis it was apparent that tert-
butanol was exerting some deleterious effect on the binding affinity of the steroid substrate and 
an examination of the literature for instances where tert-butanol was used as a co-solvent was 
performed to find further clues on the effect of tert-butanol on enzyme systems. It should be 
pointed here that tert-butanol also improves the solubility of other steroid substrates (i.e. those 
without a solubilising group such as the O-(carboxymethoxyl)oxime), consequently promoting 
the synthase reaction. This effect operates independently of any kinetic effects as discussed 
here. 
4.4.3.4 The effect of tert-butanol on other enzyme systems 
Pesheck and Lovrien found that tert-butanol reduced substrate inhibition (Ksi) in the hydrolysis 
of phenolphthalein glucuronide 127 by E. coli β-glucuronidase by 5-fold232. Additionally, they 
observed an increase in Vmax (2.6-fold) and KM (1.6-fold) and this correlated well with the 
kinetics data obtained in this work indicating that an increase in KM (and hence poorer substrate 
binding affinity) is accompanied with an increase in the overall reaction velocity. However, no 
discussion of the mechanism of action of tert-butanol was offered.  
Bowers and Johnson observed that tert-butanol could be used to elute tightly retained steroid 
substrates from immobilised E. coli β-glucuronidase in their effort to develop a streamlined 
glucuronidase system for analytical applications233. This hinted that tert-butanol could be 
binding and consequently displacing the steroid in the enzyme active site of the synthase. 
Alternatively, this “displacement” could also arise simply from the increased solubility of the 
steroid in tert-butanol. 
It was reported by Fishman and Green that glucuronyl transfer from phenolphthalein 
glucuronide 127 to tert-butanol to form tert-butanol glucuronide 128 could be achieved by the 
transglycosylation activity of mammalian β-glucuronidase enzymes in 15% yield, highlighting 
the possibility that tert-butanol is a useful alcohol acceptor, albeit with a non-bacterial enzyme 
(scheme 46)234. It should be pointed out that the concentration of tert-butanol stated in 
Fishman and Green’s report approximates to about 12% v/v, which is very similar to the 
concentration of tert-butanol in the glucuronylsynthase protocol. Thus if tert-butanol was a 
suitable alcohol acceptor then it would make sense for it to bind well in the active site. 
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Scheme 46: the transglycosylation of tert-butanol by β-glucuronidase with phenolphthalein 
glucuronide 127 carried out by Fishman and Green 
It is assumed with a high degree of confidence that tert-butanol is unreactive under the 
glucuronylsynthase conditions. For example, it would might be expected that epiandrosterone 
35 would out-compete tert-butanol for reaction with α-D-glucuronyl fluoride 29 as it is a more 
reactive secondary alcohol substrate, but in the case of methyltestosterone 48, a much poorer 
substrate, it would be expected that if tert-butanol could act as an alcohol acceptor then this 
would be where most of such a glucuronide would be observed. However, no evidence for the 
formation of tert-butanol glucuronide 128 had ever been observed either in the NMR spectra or 
in the mass spectra in all glucuronylsynthase reactions to date. 
4.4.3.5 Is tert-butanol a possible inhibitor? 
It may be the case that tert-butanol is also acting as a type of inhibitor, binding in the active site 
but not reacting productively with the α-D-glucuronyl fluoride 29 and thereby inhibiting the 
synthesis of the glucuronide product. The basis for this comes from the observation that tert-
butanol appears to uniformly increase KM and reduce the specificity constant kcat/KM in all cases, 
which is suggestive of inhibitor-like behaviour. 
There are several modes of inhibition (aside from substrate inhibition) that are known for 
enzyme systems. The first of these is competitive inhibition, where a competing substrate (the 
inhibitor) binds to the active site and blocks access by the other substrate at the same site.  
The mechanistic representation of competitive inhibition is shown in figure 42. Here, enzyme E 
may not only combine with the substrate A to form the enzyme-substrate complex EA, but may 
instead combine with the inhibitor I to form the enzyme-inhibitor complex EI with Kic as the 
competitive inhibition constant for this step. However, in this scenario the inhibitor is unable to 
bind the enzyme-substrate complex EA. Thus the inhibitor competes with the substrate for 
binding with the enzyme. 
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Figure 42: the mechanistic representation of competitive inhibition 
This type of inhibition is represented by equation (20), where as the result of the introduction 
of inhibitor the kinetic parameters take on apparent values: 
𝑣 =  
𝑉𝑎𝑝𝑝𝑎
𝐾M
𝑎𝑝𝑝
+𝑎
 (20) 
The observational outcome of this type of inhibition is that while there is no difference in the 
value of Vmax, an increase in KM is observed (as represented by equation 22), where the inhibitor 
is represented by “i”. These two parameters are thus referred to as apparent Vmax (𝑉𝑎𝑝𝑝) and 
apparent KM (𝐾M
𝑎𝑝𝑝
).  
𝑉𝑎𝑝𝑝 = 𝑉  (21) 
𝐾M
𝑎𝑝𝑝 = 𝐾𝑀(1 +
𝑖
𝐾𝑖𝑐
) (22) 
This consequently affects the specificity constant (in equation 23), where there is a reduction as 
a result of the increase in 𝐾M
𝑎𝑝𝑝
: 
𝑉𝑎𝑝𝑝
𝐾M
𝑎𝑝𝑝 =
𝑉/𝐾
1+
𝑖
𝐾𝑖𝑐
  (23) 
A second type of inhibition is known as uncompetitive inhibition, where the inhibitor is only able 
to bind to the enzyme-substrate complex and not the free enzyme (hence the term 
uncompetitive, with respect to the substrate).  
The mechanistic representation of this type of inhibition is shown in figure 43. Here, the 
enzyme E and substrate A are free to combine to form the enzyme-substrate complex EA but 
here the inhibitor I is now able to bind to this complex to form the enzyme-substrate-inhibitor 
complex EAI with the corresponding uncompetitive inhibition constant Kiu. Thus, the inhibitor 
does not compete with the substrate for binding to the free enzyme and is uncompetitive in this 
regard. 
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Figure 43: the mechanistic representation of uncompetitive inhibition 
This type of inhibition leads to a change in both Vmax and KM, which are depicted by equations 
(24) and (25): 
𝑉𝑎𝑝𝑝 =
𝑉
1+
𝑖
𝐾𝑖𝑢
  (24) 
𝐾M
𝑎𝑝𝑝 =
𝐾M
1+
𝑖
𝐾𝑖𝑢
  (25) 
However, with these changes to both 𝑉𝑎𝑝𝑝 and 𝐾M
𝑎𝑝𝑝
, no change in the specificity constant is 
expected as the 𝑖 𝐾𝑖𝑢⁄  term cancels out.  
A third type of inhibition is known as mixed inhibition, where the inhibitor may bind to the 
enzyme regardless of whether substrate is bound or not.  
This type of inhibition is represented mechanistically by figure 44. This type of inhibition, as 
the designation indicates, is a mixture of competitive and uncompetitive inhibition with the 
difference being that the inhibitor is capable of binding to the free enzyme and the enzyme-
substrate complex, with the corresponding inhibition constants Kic and Kiu. Additionally, the 
enzyme-inhibitor complex EI is not necessarily a dead-end and indeed the substrate would be 
expected to be able to bind to this as well to form the enzyme-substrate-inhibitor complex EAI. 
However, should there be a preference of the inhibitor for one mode over the other then the 
mode of inhibition would become either competitive or uncompetitive inhibition. 
 
Figure 44: the mechanistic representation of mixed inhibition 
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One subtlety of this mechanistic representation should pointed out. While there is the potential 
for a situation where Kic = Kiu, this is not an absolute necessity and indeed the Kic–to–Kiu ratio 
can exist along a spectrum. The former is called pure non-competitive inhibition, which is a 
special case of mixed inhibition. 
Mathematically, this mechanism gives rise to a change in both 𝑉𝑎𝑝𝑝 and 𝐾M
𝑎𝑝𝑝
 as represented by 
equations (26) and (27): 
𝑉𝑎𝑝𝑝 =
𝑉
1+
𝑖
𝐾𝑖𝑢
  (26) 
𝐾𝑀
𝑎𝑝𝑝 =
𝐾M(1+
𝑖
𝐾𝑖𝑐
)
1+
𝑖
𝐾𝑖𝑢
 (27) 
However, for pure non-competitive inhibition, the two terms for the inhibition constants cancel 
out to leave 𝐾M
𝑎𝑝𝑝 = 𝐾M. The change in the specificity constant is therefore, in both cases, 
dependent on the competitive inhibition rate constant to give: 
𝑉𝑎𝑝𝑝
𝐾M
𝑎𝑝𝑝 =
𝑉/𝐾
1+
𝑖
𝐾𝑖𝑐
  (28) 
It is evident from the kinetics data that tert-butanol exhibits the following trends: an increase in 
Vmax, a significant increase in KM and therefore a reduction in binding affinity of the steroid, a 
reduction in the specificity constant Vmax/KM and a significant increase in kcat. These trends and 
indirect literature evidence all appear to suggest that tert-butanol has some characteristics of a 
competitive inhibitor. Of course, tert-butanol is not necessarily an inhibitor and there remains 
the issue of reconciling the increases in Vmax, as a competitive inhibitor is not expected to affect 
the Vmax parameter. This increase in Vmax instead suggests an activating effect of tert-butanol on 
the enzyme. 
4.4.3.6 The effect of other organic solvents on enzyme systems 
Indeed, organic co-solvents in general have been recognised as having activating effects on 
various enzymes in mixed solvent systems and there have been several reviews of such enzyme 
reaction systems. By the time of Butler’s review of such systems, it was already known that 
organic co-solvents display a great many different effects on enzymes, such as competition with 
substrates for binding, affecting enzyme conformation equilibria, and stabilising or destabilising 
the enzyme, to name a few235.  
There is a great disparity in the effects of various organic co-solvents in the literature, as might 
be expected, but the generalisation identified by Butler is that organic co-solvents compete with 
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substrates (sometimes strongly) for binding leading to an observed increase in KM, something 
observed in this study with the glucuronylsynthase and tert-butanol. 
In another review, Khmelnitsky et al. noted that the general rule for the activation effect 
observed for organic co-solvents arises from consequent conformational changes in the enzyme 
as a result of a change in the composition of the solvent medium236. 
With regards to the observed alleviation of substrate inhibition (see table 5, compare (3) with 
(4)), a physical chemical explanation was indirectly offered by Maurel, who noted that organic 
co-solvents likely affect the formation of “icebergs” around hydrophobic substrates, where 
formation of such bodies in the absence of co-solvent is an entropically unfavourable process237.  
The concept of “icebergs” was first floated by Frank and Evans in 1945 as a tool for resolving 
some of the thermodynamic questions surrounding the solvation of small, non-polar solutes in 
water, such as argon, where the resulting entropy of solvation was negative, implying some sort 
of local ordering around the solute akin to that found in ice crystals (hence the term 
“iceberg”)238.  
However, a rigorous description of the structure of this “iceberg” was never fully expounded but 
the simplicity of the concept and its evocative image “captured the imagination…of scientists 
working in the field of aqueous solutions”239. Unfortunately, the search for experimental 
confirmation of such a local iceberg or ice-like structure proved to be unsuccessful. While the 
theory lacked evidence and stronger theoretical backing, the physical chemistry of local 
ordering of water molecules around a small hydrophobic solute remains the subject of much 
interest. 
Recently Galamba observed that water molecules do exhibit some slight local ordering around 
hydrophobic solutes, which has a significant effect on enhancing the tetrahedral ordering of 
water in the first hydration shell240.  
Additionally, Rezus and Bakker found that there is a dynamic effect of local ordering around a 
hydrophobic solute, where some 20% of the water molecules in the solvation shell of methanol 
(used to represent methyl groups) are practically immobilised, a consequence of the “decrease 
in configurational space available to water molecules” in solvating hydrophobic solutes241. 
However, this remains somewhat controversial with conflicting experimental evidence 
suggesting that there is only a mild slow down rather than full immobilisation and remains a 
hotly debated topic (see Galamba, 2014, J. Phys. Chem. B and references therein)242. 
Rezus and Bakker pointed out that this immobilisation does not resemble an ice-like ordered 
state, but rather the dynamics of the water molecules were “ice-like” and the actual hydrogen 
Chapter 4: Kinetics of the synthase and hydrolysis of the glucuronyl fluoride 29 
112 
 
bond network that they observed still resembled the disordered state in the bulk water 
solution. 
These findings then require a slight adjustment to Maurel’s interpretations. It should be said 
that while there is no local ice-like structure around the hydrophobic solute, there indeed exists 
some form of localised ordering of water molecules around a hydrophobic solute through a 
slowing down of water molecules in the hydration shell of the hydrophobic solute. 
Continuing on from Maurel’s studies, he noted that binding of the substrate to the enzyme active 
site involved favourable interactions between the nonpolar functionalities on both the substrate 
and the enzyme, which would lead to dissipation of this “iceberg”, an entropically favourable 
process, which constitutes the driving force for binding of the substrate to the enzyme. 
Maurel also observed that the organic co-solvents studied appeared to be able to solvate the 
hydrophobic substrate directly, bypassing or at least reducing formation of the entropically 
unfavourable “iceberg”, which leads to a reduction in the binding affinity (and consequently a 
higher KMapp) of the substrate as there is less of an entropic benefit to be gained from binding 
with the enzyme active site237. However, to provide a clearer picture of what is happening the 
iceberg model must be supplanted by more modern experimental evidence on the nature of 
tert-butanol, in particular, in aqueous solution. 
Interestingly the nature of the hydration shell around tert-butanol in aqueous solutions has 
been discussed at some length in the literature. For example, it is known that tert-butanol starts 
to self-aggregate in aqueous mixtures when the mole fraction is 𝑥 ⪎ 0.03-0.04243–245, which 
results from a weak hydration shell that is a consequence of the hydrophobicity afforded by the 
tert-butyl group. 
For example, Sinibaldi et al. found that trimethylamine-N-oxide (TMAO), which has a much 
larger dipole moment than tert-butanol, was surrounded by a much more robust hydration shell 
(smaller hydration radius and greater hydration number) that prevented self-aggregation243. 
They thus concluded that the hydrophobic component of tert-butanol was critical to this self-
aggregation. This self-aggregation also reduced the viscosity of the overall aqueous solution and 
therefore allowed the tert-butanol solute to flow more freely than the TMAO counterpart. 
In particular, at higher concentrations of tert-butanol (reaching up to 𝑥 ~ 0.1 or 4 M) the 
hydration shell around the molecule appears to be more populated by other tert-butanol 
molecules rather than water, again pointing to the self-aggregation of tert-butanol in aqueous 
solution246. For reference, the concentration of tert-butanol used here (10% v/v ~ 1 M) 
corresponds to a mole fraction of approximately 𝑥 ~ 0.03246. 
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This could then suggest that the steroid substrate is being mostly solvated by tert-butanol 
molecules with a few water molecules in the hydration shell. Additionally, tert-butanol itself is 
also solvated mostly by other tert-butanol molecules with some water molecules filling the 
remaining space in the hydration shell. The two types of hydration shells would then allow the 
steroid substrate to flow more freely in aqueous solution.  
The release of water molecules from the hydration shell when the steroid substrate 
enters/binds in the enzyme active site would, as Maurel suggests, be an entropically favourable 
process but because there are fewer molecules to release, the entropic benefit is reduced. This, 
combined with the greater fluidity of the steroid substrate in solution could then be contribute 
to the increase in KM seen in this study. This thus suggests a physical mechanism by which tert-
butanol alleviates substrate inhibition by CMO-DHEA 33.  
One final point by Maurel noted that the effect of organic co-solvent on KMapp is an 
intermolecular effect, while the effect on kcat is more likely an intramolecular effect (e.g. in the 
active site) and therefore varies from enzyme to enzyme237. 
4.4.3.7 The conformational effect of tert-butanol on glucuronylsynthase 
Having observed the significant changes in rates when both tert-butanol and temperature are 
combined, it was suggested that tert-butanol may be affecting the conformation of the enzyme. 
A study performed by Shu-Ann Chan in the Ollis group (unpublished results) revealed that the 
glucuronylsynthase enzyme is unstable in 20% v/v tert-butanol at 30 °C over the course of 12 h, 
with an observed half-life of 1.8 h and concomitant degradation of the secondary structure of 
the enzyme. This was surprising, not for the instability of the enzyme in the presence of organic 
co-solvent, but because the observed half-life was so short, when the glucuronylsynthase 
reaction proceeds well without any apparent deleterious effects. 
However, it was noted that the presence of α-D-glucuronyl fluoride 29 was key as previous 
studies by Chan had shown that the sugar was essential for improving the stability of the 
glucuronylsynthase. Indeed, in the presence of α-D-glucuronyl fluoride 29 no change in the 
secondary structure of the enzyme was observed even after overnight incubation. However, 
information on the effect of tert-butanol on enzyme conformation remained unavailable. 
To investigate this, a study was performed to examine the effect that tert-butanol has on the 
quaternary structure of the enzyme, at least at a concentration of 10% v/v, using size-exclusion 
chromatography with a Superdex 200 column. The structure of the E. coli β-glucuronidase was 
recently reported by Wallace et al. showing the enzyme as a tetramer that arises from an 
asymmetric dimer of two monomers, which then afford the tetramer by crystallographic 
symmetry247. 
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This size-exclusion chromatography would then lead to discrimination between the sizes of the 
various oligomeric states of the enzyme e.g. whether a dimeric form dominates or the 
tetrameric form is predominant. While information on the activity of the various quaternary 
structures remained unknown, this study could provide some information on whether a change 
in quaternary structure occurs at all and the consequent effects on the enzyme as a result. 
In size-exclusion chromatography the resin beads have various sized pores, which facilitate 
partition of solutes into the bead-based stationary phase in a size-dependent fashion. For 
example, smaller solutes will partition to a greater extent than larger solutes and so will have a 
greater elution volume as a result. In this study the difference in size of the various eluted 
products may then be correlated to the quaternary structure, be it monomeric, dimeric etc. With 
the aid of UV detection, the proteins were tracked in terms of the volume of solvent required to 
elute each one.  
In order to describe the behaviour of the solute in a size-exclusion column, three parameters are 
used. These are Ve (the volume required to elute the solute), V0 (the void volume, the volume of 
the interstitial liquid at the point when the first solute begins to elute) and Vi (the fraction of 
inner volume of the column available to the solute). All three parameters must be determined 
experimentally as they are not intrinsic to the column248. 
For Sephadex and Superdex gels, blue dextran is often used as a marker for the interstitial liquid 
due to the fact that it is excluded from the beads entirely. In this cases, Ve for blue dextran is a 
good approximation for V0248,249. 
These parameters are combined in equation 29 for the distribution coefficient Kd of the solute, 
which describes the behaviour of the solute on the column: 
𝐾𝑑 =
𝑉𝑒−𝑉0
𝑉𝑖
  (29) 
However, Vi is usually difficult to determine due to the fact that some of this inner volume will 
be occupied by the resin as well as the solute and therefore it is often much simpler to consider 
the available value of Kd, or Kav, to characterise the behaviour of the solute. This is represented 
by equation (30): 
𝐾𝑎𝑣 =
𝑉𝑒−𝑉0
𝑉𝑇−𝑉0
~
𝑉𝑒−𝑉0
𝑉𝑠𝑎𝑙𝑡−𝑉0
 (30) 
Here, VT is the total volume of the column, while Vsalt is the volume at which salts start to elute 
from the column. V0 is often ~30-35% of VT depending on the nature of the gel used. The 
remaining column volume is then available for protein resolution but this is often about 80% 
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the remainder of VT, which approximates to about 52-56% of VT248. Here, Vsalt can also be useful 
as a marker of the end of elution, where the salt begins to elute from the column (and as the 
smallest component it would be expected that no further protein would be expected to elute). 
This can be a better parameter for the determination of Kav to avoid overestimating the end-
point of solute elution. 
A plot of Kav against the logarithm of molecular weights of some protein standards then gives a 
selectivity curve, calibrating the column. The values of Kav for the solute in question are then 
compared to the calibration curve to determine the molecular weights of the solutes at their 
points of elution. 
Show in figure 45 are the selectivity curves for the two sets of conditions that were investigated 
in this study, differing only by the presence or absence of tert-butanol. The protein standards 
used here were blue dextran (2000 kDa), β-amylase from sweet potato (200 kDa), alcohol 
dehydrogenase from yeast (150 kDa), and bovine serum albumin (66 kDa). There is a slight 
difference between the two curves, likely a result of the effect of tert-butanol on the mobile 
phase.  
There are two sets of plots shown, one set for blue dextran (blue and red) and one set for the 
other protein standards (green and purple). As is evident the inclusion of blue dextran in the 
second set of data would significantly affect the R2 evaluation. As mentioned previously blue 
dextran is a useful marker of the void volume of the column and exclusion of the compound 
from the gel resin is to be expected. This implies that the resolution of this system is better for 
the range of molecular weights from 200 kDa to 66 kDa onwards and is poorer for higher 
molecular weight solutes, such as tetramers, although of course this would be clearer with the 
inclusion of other higher molecular weight standards such as ferritin (440 kDa) and 
thyroglobulin (669 kDa). 
Using the elution volumes provided in figures 46 and 47, the corresponding values of Kav to 
each significant elution peak were calculated and the results, along with the calculated value for 
molecular weights in kDa, are displayed in table 6. 
 
Chapter 4: Kinetics of the synthase and hydrolysis of the glucuronyl fluoride 29 
116 
 
 
Figure 45: the selectivity curves for protein size against elution volume, with or without tert-
butanol (10% v/v). Conditions: NaPi (50 mM, pH 7.5), sodium chloride (150 mM), 4 °C. 
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Figure 46: the size exclusion UV chromatogram for E504G glucuronylsynthase without tert-
butanol with elution volumes marked (in mL). Conditions: E504G glucuronylsynthase (0.2 
mg/mL), NaPi (50 mM, pH 7.5), NaCl (150 mM), 4 °C. 
 
Figure 47: the size exclusion UV chromatogram for E504G glucuronylsynthase in the presence 
of tert-butanol with elution volumes marked (in mL). Conditions: tert-butanol (10% v/v), 
E504G glucuronylsynthase (0.2 mg/mL), NaPi (50 mM, pH 7.5), NaCl (150 mM), 4 °C. 
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Table 6: the calculated Kav and molecular weights for each elution peak of the E504G 
glucuronylsynthase  
Without tert-butanol With tert-butanol (10% v/v) 
Elution 
volume (mL) 
Kav Calculated 
molecular 
weight (kDa) 
Elution 
volume (mL) 
Kav Calculated 
molecular 
weight (kDa) 
65.1 0.260 217.6 75.9 0.485 210.5 
113.6 1.059 66.4 123.8 1.363 54.1 
120.7 1.176 55.8 142.2 1.700 32.1 
124.4 1.237 51.0    
146.5 1.601 29.7    
 
Given that the E. coli β-glucuronidase comprises four monomeric subunits at 68.4 kDa each, the 
calculated molecular weights for the enzyme of ~210-217 kDa is unfortunately inconclusive as 
to whether it is a trimer or a tetramer, although it is certainly closer to the expected value for 
the trimer (205.2 kDa) compared to the tetramer (273.6 kDa)250. However, it should be noted 
that these molecular weights lie outside the weights examined for the selectivity curve and 
therefore both oligomeric forms should still be considered. The molecular weight as calculated 
from the last elution peak in both chromatograms does not appear to correspond to the 
expected monomer size and are likely artefacts of the column, or even perhaps monomer that 
has become further partitioned during chromatography resulting in an elution peak that gives 
an apparent calculated molecular weight of 30-32 kDa. 
An inspection of the areas under the peaks for figure 46 shows that the first two elution peaks 
correspond to 45% and 1.7% of the total area under the peaks, demonstrating a strong bias 
towards the higher molecular weight form (although the next elution peak contributes to 28% 
of the total area). For figure 47, the first two elution peaks correspond to 94% and 4.8% of the 
total area under the peaks. This is a much more dramatic shift in the molecular weight bias. 
These two pieces of information suggest that in the presence of tert-butanol the enzyme further 
favours aggregated forms over non-aggregated or monomeric states, perhaps to minimise 
unfavourable interactions with the organic co-solvent.  
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Perhaps the shift in quaternary state of the enzyme contributes to the observed changes in KM 
for the where the aggregate form binds the steroid less effectively than the monomer, although 
this remains speculative. It may also be the case that this shift could account for the observed 
increases in Vmax, where the aggregate is more active that the monomer. However, Wilkinson 
found that, at least in the absence of tert-butanol, at 21 °C there is no discernible effect of the 
enzyme concentration on the reaction rate (figure 48)155. In that study the absolute (blue) and 
relative (red) velocity of the glucuronylsynthase was plotted against the concentration of the 
enzyme for the synthesis of 2-phenylethanol glucuronide 40 (section 1.6, figure 2). This 
showed that either a) there is no variation in the enzyme’s activity due to increased enzyme 
concentration or that b) the enzyme’s catalytic activity remains constant across different 
aggregation states. 
 
Figure 48: the dependence of the activity of the glucuronylsynthase on the concentration of the 
glucuronylsynthase for the synthesis of 2-phenylethanol glucuronide 40 as a measure of 
absolute velocity (blue) and relative velocity (red). Conditions: 2-phenylethanol 39 (94 mM), 
FGlu 29 (1 mM), NaPi (50 mM, pH 7.5), 21 °C. 
It remains to be seen whether this holds true in the presence of tert-butanol. However, based on 
the conclusions drawn from the studies in this section, such as temperature having more of an 
impact than tert-butanol on the Michaelis-Menten kinetics of the enzyme, the effect may very 
well be modest. 
Ultimately it seems that the effect that tert-butanol has on the glucuronylsynthase reaction 
appears to be largely based on increasing the solubility (and therefore the concentration) of the 
steroid substrate in aqueous solution, thereby facilitating access to the substrate. While there is 
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indeed a contribution to the initial rate of the reaction with CMO-DHEA 33, particularly at 
higher substrate concentrations, this effect is not particularly useful considering that most 
steroids, particularly in the absence of solubilising groups such as for CMO-DHEA 33, would 
likely not be soluble at such concentrations. 
4.5 Hydrolysis of the α-D-glucuronyl fluoride 29 
The hydrolysis of the α-D-glucuronyl fluoride 29 was investigated by Wilkinson when it was 
discovered that further equivalents of sugar improved the yield of the glucuronide. The sugar 
was heated in a solution of D2O and the appearance of peaks corresponding to the hydrolysed 
sugar was tracked over a period of 21 h by 1H NMR spectroscopy. This revealed that the half-life 
of the uncatalysed hydrolysis of the glucuronyl fluoride 29 was 148 h or ~6.2 d, which is 
substantially longer than the entire glucuronylsynthase reaction.  
It was discovered later that excess sugar was instead competing for active site binding and thus 
reducing product inhibition by the glucuronide product on the glucuronylsynthase reaction. 
However, the question of sugar stability was not fully answered as the experiment was 
performed under non-buffered conditions. This is important as the hydrolysis of the sugar 
liberates hydrogen fluoride, which could conceivably affect the rate of hydrolysis of the sugar. 
Thus, though the α-D-glucuronyl fluoride 29 was known to be susceptible to hydrolysis, just 
how fast this hydrolysis was (and whether it was a relevant consideration for optimising the 
glucuronylsynthase protocol) remained an open question. 
4.5.1 Introduction and previous work 
The hydrolysis of the α-D-glucuronyl fluoride 29 was to be investigated in sodium phosphate 
buffered conditions to more closely replicate the glucuronylsynthase conditions. The use of 
phosphate is important as there is literature evidence for phosphate-mediated hydrolysis of 
similar compounds, such as α-D-glucosyl fluoride 28. Indeed, the glucosyl fluoride has been 
studied quite extensively as it was and remains used as a glycosyl donor for glucosyl transferase 
reactions for the preparation of oligosaccharides148,251.  
In 1981 Jung and Mayer reported and confirmed previous studies that α-D-glucosyl fluoride 28 
is a suitable glycosyl donor for dextransucrases and during their studies observed spontaneous 
hydrolysis with nucleophilic buffers. This led to the use of lower concentrations of phosphate 
buffer. However, this observation was not investigated further by the authors, though it was 
studied in more detail by others as detailed below252. 
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Studies on the lifetimes of other oxonium ions in solution by Amyes and Jencks led to a 
extrapolation by Banait and Jencks that suggested the lifetime of such an ion for the glucosyl 
system is approximately on the order of ~10–12 s, an exceedingly small yet significant lifetime in 
water253,254. This is important as the lifetime of the oxonium ion 129 would then lead to 
products that could reveal information about the mechanism of hydrolysis.  
For example, should the lifetime of this oxonium ion 129 be significant enough, a mixture of 
inversion and retention hydrolysis products (e.g. 93) would be observed, which is usually a 
hallmark of SN1-type reactions (scheme 47).  
 
Scheme 47: the uncatalysed hydrolysis of α-D-glucosyl fluoride 28, where the oxonium ion 129 
has a sufficient lifetime to affect the stereochemical outcome to yield α/β-D-glucose 93 
On the other hand, if the hydrolysis reaction were to proceed via an SN2 mechanism, which 
involves concurrent association of the nucleophile and dissociation of the leaving group, this 
would lead to predominantly inversion products e.g. α-D-glucosyl fluoride 28 to β-D-glucosyl 
azide 130 (scheme 48). This would require that the oxonium ion exist only transiently and not 
as a distinct species. Through isotope effect studies, the mechanism (in particular, for strong 
nucleophiles) was suggested to occur via an “exploded” transition state where both bond 
association and dissociation is weak, generating a substantial partial positive charge at the 
anomeric carbon (figure 49). This “carbocation” does not have a real lifetime like the oxonium 
ion as both bonding events occur concurrently throughout. 
 
Scheme 48: reaction of α-D-glucosyl fluoride 28 with sodium azide, a strong nucleophile, 
leading to an SN2 reaction to form β-D-glucosyl azide 130 
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Figure 49: the exploded transition state model for SN2 reactions, where a substantial positive 
charge exists at the reaction centre, while the incoming and leaving groups develop a partial 
negative charge, due to weak bond association and dissociation 
Indeed, Banait and Jencks found two key pieces of evidence that indicated that hydrolysis at the 
anomeric centre occurs by an SN2 mechanism in the presence of strong nucleophiles, namely 
that there was a linear dependence between the pseudo-first order rate constant for the 
hydrolysis of the α-D-glucosyl fluoride 28 and the concentration of nucleophile. Additionally, the 
observation of exclusive (>99%) inversion products such as azide 130254 also strongly indicated 
an SN2 mechanism. The second-order rate constant for hydrolysis of the glucosyl fluoride 28 by 
azide ion was found to be 5.5 × 10–6 M–1 s–1, two orders of magnitude faster than for water, 
observed to be 1.6-2.7 × 10–8 M–1 s–1. Very recently, Chan et al. used transition-state structure 
modelling of the reaction of glucosyl fluoride 28 with azide ion and found that indeed an 
“exploded” transition state model agreed well with data acquired via 18O-kinetic isotope effect 
experiments255. 
Interestingly, poorer nucleophiles such as methanol and ethanol were not able to trap the 
oxonium ion 129 at all in aqueous solvent mixtures and instead the only product observed was 
glucose. This was suggested to be due to the development of positive charge at the anomeric 
carbon that precedes the SN1-type reaction, where the presence of water molecules act to 
stabilise this charge compared to other alcohols. 
One observation of Banait and Jencks that would be investigated during the course of the study 
of the hydrolysis of the α-D-glucuronyl fluoride 29 was that uncharged amines were poor 
nucleophiles and did not give rise to hydrolysis rates above background rates. This was also 
suggested to be a consequence of the development of positive charge at the anomeric carbon, 
whereby anionic nucleophiles present could stabilise this charge while uncharged amine 
nucleophiles could not and therefore would not react as favourably254. 
In a second study published at the same time, Banait and Jencks reported on the general-base 
and general-acid catalysed hydrolysis of the α-D-glucosyl fluoride 28156. General-acid and 
general base mechanisms are different from specific acid and specific base mechanisms in that 
complete protonation or deprotonation events that are a hallmark of the latter two are not 
observed in the former two, usually due to lower dissociation of the relevant species in solution 
(scheme 49). 
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Instead the protonation or deprotonation steps occur during the course of the reaction and is 
usually a termolecular process – all three species, the general acid/base, the nucleophile, and 
the electrophile, must be close in space for the reaction to proceed at any significant rate. For 
example, in specific acid or base catalysis, a strong proton or hydroxide source (e.g. H2SO4, 
NaOH) is usually required, whereas in general acid or base catalysis, weaker acids and bases can 
partake in catalysis (e.g. acetate, phosphate; scheme 49). 
 
Scheme 49: a) the specific base catalysis of hydroxide for the acetylation of ethanol with acetic 
anhydride 131, and b) the general base catalysis for the acetylation of ethanol with acetic 
anhydride 131 to give ethyl acetate 132 
In their study Banait and Jencks noted that the relative nucleophilicity of the catalyst species 
also played a part. Bulky phosphates and phosphonates readily participated in general base 
catalysis alone without nucleophilic substitution, whereas the less bulky acetate reacted via 
nucleophilic substitution as well. Further evidence that charge stabilisation (of the developing 
positive charge at the anomeric carbon) by the anionic catalyst was observed when methanol 
reacted with α-D-glucosyl fluoride 28 in the presence, but not the absence, of phosphate 
buffer156. 
For the general base-catalysed hydrolysis of α-D-glucosyl fluoride 28 by dibasic phosphate 
buffer, they proposed that the reaction is a concerted mechanism, rather than one involving first 
loss of fluoride then addition by water to the oxonium ion 129, as this occurs in the absence of 
general base catalysis (scheme 50).  
 
Scheme 50: Banait and Jencks’ proposed SN2 mechanism of general base catalysed hydrolysis of 
α-D-glucosyl fluoride 28 by dibasic phosphate to give D-glucose 93 
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This was reinforced by the observation of an increase in the rate of disappearance of the 
glucosyl fluoride 28 in the presence of phosphate, something that would not occur if fluoride 
were to leave first as general base catalysis by phosphate would not affect this step. 
The calculated second-order rate constant for the general base-catalysed hydrolysis of α-D-
glucosyl fluoride 28 by dibasic phosphate buffer was found to be 6.1 × 10–6 M–1 s–1 at 30 °C, 
where the acid:base ratio (monobasic to dibasic phosphate) was 1:9, a 1.1-fold increase over the 
rate of SN2 hydrolysis by azide ion (5.5 × 10–6 M–1 s–1) as seen above. This showed that general 
base catalysis is both significant and rapid, at a rate comparable to those of strong nucleophiles. 
However, while the hydrolysis of α-D-glucosyl fluoride 28 is well described there is a 
comparative lack of literature on the hydrolysis of the α-D-glucuronyl fluoride 29, though this 
may be attributed to the glucuronyl fluoride 29 being less used in glycosyl transferase reactions 
and that protected glucuronyl donors are normally considered less reactive than their glucosyl 
counterparts, as noted in section 1.5. However, the rate of hydrolysis of the glucuronyl fluoride 
29 remains an open question and it may very well be that the free carboxylate anion could 
exhibit some measurable effect on hydrolysis. For example, the carboxylate anion may stabilise 
the oxonium ion (by some unknown mechanism) leading to a potential increased rate of 
hydrolysis. 
4.5.2 Hydrolysis of the α-D-glucosyl fluoride 28 
Initial attempts to measure the initial rate of hydrolysis of the α-D-glucuronyl fluoride 29 
involved the development of a fluoride quenching assay where the fluorescence of a zirconium 
complex 133 would be quenched by release of fluoride, which has a high affinity for the metal 
ion (scheme 51)256. The binding of fluoride would then release the sulfoflavone 134 and thus 
“quenching” the fluorescence of 133. 
 
Scheme 51: the proposed fluoride quenching assay for determination of fluoride concentration 
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Unfortunately it appeared that for low fluoride concentrations (e.g. 10-50 μM), which would be 
expected to be critical to initial rate measurements, the errors were significant enough that poor 
precision would likely result from using this approach. 
Instead an alternative method for detection fluoride concentration in solution was developed 
using a fluoride selective electrode, which was found to be more sensitive to the change in 
fluoride concentrations in solution with correspondingly much greater precision, so the fluoride 
selective electrode was used for the rest of the study. 
Calibration curves of sodium fluoride were prepared in each of the buffer systems. A carefully 
temperature-controlled water bath was required to ensure minimal temperature variation, but 
also operationally a non-standard floatation device, prepared from polystyrene packaging was 
required for performing these measurements. Experiments were performed in plastic falcon 
tubes (to avoid fluoride etching of glassware) that were fitted inside the floatation device. 
Measurements of fluoride release were then taken over the time course of the experiments and 
during the hydrolysis of the first 5-10% of glucosyl fluoride 28 and glucuronyl fluoride 29. This 
allowed for the determination of initial rates of hydrolysis of the sugars in various buffer 
systems. 
The first phase of this study examined the hydrolysis of the glucosyl fluoride 28 in sodium 
phosphate buffer under the typical glucuronylsynthase conditions (e.g. 37 °C, with and without 
tert-butanol etc.). This data would then allow for comparison with Banait & Jencks’ results to 
see if there are any significant differences that arise – for example, Banait & Jencks conducted 
their experiments at 30 °C, while the experiments in this study were performed at 37 °C. 
Additionally, a comparison with their data would show if the fluoride selective electrode 
approach is sufficient for accurate results. 
The first aspect of these experiments involved using a background measurement of hydrolysis 
in buffer (at 2 mM sodium phosphate buffer as a minimum baseline to buffer the sugar) and 
comparing this baseline rate to the rate of hydrolysis of the sugar at a much higher 
concentration of buffer. This would then reveal whether the buffer indeed has an effect in 
hydrolysing the sugar or not. The buffer concentration used in this approach was 100 mM, a 50-
fold increase over the baseline concentration. 
Hydrolysis experiments on the glucosyl fluoride 28 were thus performed in sodium phosphate 
buffer at 37 °C, with or without tert-butanol. An additional set of experiments was performed in 
Tris buffer, to see if an amine-based buffer would affect the rate of hydrolysis. As discussed 
previously, Banait and Jencks proposed that amines are poor stabilisers of the developing 
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charge at the anomeric centre, which consequently gave hydrolysis rates comparable to 
background rates. It would therefore be interesting to see if this behaviour is replicated in a 
different set of buffer conditions, or if some discernible change in rate of hydrolysis occurs. The 
resulting data for this is displayed in figure 50. 
As expected, the phosphate buffer does indeed exert a noticeable effect on the rate of hydrolysis 
of the glucosyl fluoride 28, with a 1.4-fold increase over the baseline rate.  
Amine-based nucleophiles exerted no increased rate of hydrolysis compared to background 
rates in Banait & Jencks, and this appears to have also been mirrored with the Tris buffer 
system, which displayed no increase over the background rate of hydrolysis of the glucosyl 
fluoride 28 in sodium phosphate buffer. 
However, the addition of tert-butanol to the system reveals a visually striking result, where the 
rate of hydrolysis of the glucosyl fluoride appears to have been dampened quite dramatically. 
Indeed, comparing the rates of hydrolysis between the two corresponding sets of data shows a 
1.9-fold and 1.4-fold reduction for the 2 mM and 100 mM concentrations respectively.  
Specifically, the combined first-order rate constant of hydrolysis for the glucosyl fluoride 28 in 
the absence of tert-butanol at 100 mM phosphate concentration was found to be 5.7 × 10–9 s–1. 
In the presence of tert-butanol, the first-order rate constant decreases to 4.1 × 10–9 s–1. 
Additionally it appears, at least at first glance, that there may in fact be a slight increase to the 
rate of hydrolysis by phosphate as a result of the introduction of tert-butanol. 
However, upon comparing the difference in the contribution of phosphate-catalysed general 
base hydrolysis to the combined first-order rate constants between the two systems, this 
increase is found to be an illusion. The contribution of phosphate to the general base-catalysed 
hydrolysis of the glucosyl fluoride 28 in the absence of tert-butanol is an additional 1.58 ± 0.25 
× 10–9 s–1. In the presence of tert-butanol, the contribution of phosphate is 1.85 ± 0.14 × 10–9 s–1, 
a difference of 0.27 ± 0.29 × 10–9 s–1, which is not statistically significant. 
In comparison to Banait and Jencks’ data, it becomes immediately apparent that the rate 
constants obtained in this study are significantly lower than those found by Banait and Jencks, 
by a few orders of magnitude. In this case a direct quantitative comparison cannot be performed 
as their data was acquired using a system where the ionic strength of the solution was adjusted 
to 2 M with potassium chloride, and where their second-order rate constants were normalised 
to the second-order rate constant of chloride-mediated solvolysis (i.e. 𝑘Cl−), which would be 
expected to have a significant bearing on the rate of solvolysis of the sugar254.  
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Figure 50: the effect of various types of buffer systems on the rate of hydrolysis of α-D-glucosyl 
fluoride 28 (1 mM). Conditions: pH 7.5, 37 °C. 
In this study the line of inquiry was more concerned with acquiring data in a setting that 
resembled the actual glucuronylsynthase conditions rather than hydrolytic behaviour at an 
arbitrary ionic strength. It should be pointed out here that solvolysis will be used in place of 
hydrolysis where the reaction does not necessarily involve water (e.g. MeOH, Cl– as in Banait 
and Jencks). 
However, qualitative comparisons are still possible. In this study, it was found that anionic 
phosphate indeed increases the rate of hydrolysis of the α-D-glucosyl fluoride 28, a conclusion 
also reached by Banait and Jencks. Perhaps the main comparison that can be made is in both 
systems the addition of an alcohol as co-solvent reduces the absolute rate of hydrolysis.  
For example, Banait and Jencks observed that increasing the percentage of methanol 
concentration (H2O-to-MeOH) from 0% to 90% reduces the first-order rate constant of 
solvolysis for α-D-glucosyl fluoride 28 from 1.5 × 10–6 s–1 to 3.2 × 10–8 s–1. In the system studied 
here the first-order rate constant also decreases in the presence of tert-butanol (as seen above).  
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Unfortunately there was no study of the effect of organic solvent on the rate of hydrolysis of the 
sugar in a buffered system. While methanol was used in their study of general base-catalysed 
solvolysis of the sugar, it was in pursuit of understanding how phosphate buffer affects the 
product distribution of solvolysis to afford glycoside, rather than specifically examining the 
effect of organic solvent on the rate of phosphate-catalysed hydrolysis.  
To summarise for the glucosyl fluoride 28: in this work it has been found that phosphate buffer 
indeed exerts a significant and detectable increase on the rate of hydrolysis of the glucosyl 
fluoride 28. It has also been observed that an absolute reduction in the rate of hydrolysis is seen 
when tert-butanol is added to the system. 
This then poses the question: through what mechanism could tert-butanol be achieving these 
changes in rates of hydrolysis? 
A possible explanation could be offered when considering the hydrolysis of the glucosyl fluoride 
28 in terms of SN1 and SN2 mechanisms.  
The background rate, represented by the hydrolysis data acquired at a phosphate concentration 
of 2 mM, is expected to be predominantly SN1, where the reaction rate depends solely on the 
concentration of sugar substrate. As Banait and Jencks have described, this hydrolysis 
mechanism involves loss of fluoride to generate a carbocation at the anomeric carbon, which is 
charge-stabilised by the presence of nearby water molecules. The addition of tert-butanol, a less 
polar molecule than water, would be expected to reduce the polarity of the bulk solution. This 
then leads to poorer stabilisation of this carbocation and consequently the SN1 hydrolysis 
mechanism becomes much less favourable. 
The phosphate-catalysed hydrolysis of the glucosyl fluoride 28, represented by the hydrolysis 
data acquired at a phosphate concentration of 100 mM, was shown by Banait and Jencks to be 
an SN2-type reaction, where the charge is distributed throughout the “exploded” transition state, 
rather than as a discrete carbocation257. The consequent reduction in polarity of the bulk 
solution would therefore destabilise the charged start and end points of the reaction (i.e. the 
charged phosphate molecule and fluoride anion), while the charge-distributed transition state is 
consequently less affected.  
Therefore, the reduction in polarity of the bulk solution would also accelerate, in relative terms, 
the SN2 reaction. This would then account for the apparent observed increase in the 
contribution of phosphate-catalysed hydrolysis of the glucosyl fluoride 28 in the presence of 
tert-butanol. 
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The half-life of the glucosyl fluoride 28 under the first set of conditions (100 mM NaPi, no tert-
butanol) was found to be ~32 h. In the presence of tert-butanol, this was found to be extended 
to ~45 h, showing that the likely effect that tert-butanol has on reducing the polarity of the bulk 
solution is the predominant factor controlling the hydrolysis of the sugar. 
4.5.3 Hydrolysis of the α-D-glucuronyl fluoride 29 
The second phase of this study examined the hydrolysis of the glucuronyl fluoride 29 under the 
same set of conditions to examine the effect of phosphate buffer on the rate of hydrolysis of the 
sugar. As before, experiments were performed using a background hydrolysis rate obtained at a 
2 mM concentration buffer and comparing this to the rate of hydrolysis in 100 mM buffer in the 
system. The results of this study are presented in figure 51. 
 
Figure 51: the rates of hydrolysis of the α-D-glucuronyl fluoride 29 (1 mM) in sodium 
phosphate buffer, with and without tert-butanol. Conditions: pH 7.5, 37 °C. 
From this data, it is immediately evident that a higher concentration of sodium phosphate buffer 
does not appear to increase the rate of hydrolysis of the glucuronyl fluoride 29 in any significant 
manner and indeed appears to show no significant deviation from the baseline level of 
hydrolysis.  
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This could potentially be explained by a charge repulsion model, where the carboxylic acid 
functionality exists as a carboxylate anion. This would then interact unfavourably with any 
nearby phosphate molecules, consequently hindering the involvement of phosphate in the 
hydrolysis of the sugar and rendering the hydrolysis of the glucuronyl fluoride 29 more or less 
dependent on the SN1 aspect of the hydrolysis mechanism rather than the SN2 aspect. It might 
also be expected that the charged carboxylate functionality could serve to stabilise the 
developing charge on the nearby anomeric carbon. 
While not discussed here, in the studies by Banait and Jencks they observed that the primary 
alcohol in the glucosyl fluoride 28 could in fact form the cyclic 1,6-anhydroglucose 135 in basic 
conditions (scheme 52)254. This indicates that the carboxylate functionality could quite easily 
exert a repulsive effect around the anomeric carbon, thereby negating the effect of phosphate on 
the rate of hydrolysis. 
 
Scheme 52: the formation of 1,6-anhydroglucose 135 by reaction of glucosyl fluoride with 
hydroxide  ion as observed by Banait & Jencks 
Interestingly the addition of tert-butanol to the system results only in a slight decrease in the 
rate of hydrolysis, with an approximately 1.2-fold and 1.1-fold reduction (2 mM vs 2 mM + 10% 
v/v tert-butanol etc.). 
This is a striking observation that is in contrast to the hydrolysis data found for the glucosyl 
fluoride 28, in which the addition of tert-butanol led to a sharp reduction in the overall rate of 
hydrolysis of the sugar. An explanation for this observation might be found again in the 
carboxylate moiety. 
It would be expected that just as the carboxylate functionality could hinder nearby phosphate 
molecules from participating in general base-catalysed hydrolysis, it could also affect the 
polarity of the local medium surrounding the glucuronyl fluoride 29. While tert-butanol would 
reduce the polarity of the bulk solution, the charged carboxylate moiety could essentially 
insulate the sugar by locally counterbalancing the effect of tert-butanol, resulting in only a mild 
perturbation of the rate of hydrolysis. 
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The half-life of the glucuronyl fluoride 29 under both sets of conditions, with and without tert-
butanol, were found to be ~52 and ~59 h respectively. This showed that the hydrolysis of the 
sugar by buffer alone in the glucuronylsynthase conditions would not be a significant problem 
for reaction yields. 
An additional survey of various buffers at 100 mM concentrations was performed to see if other 
buffers could possibly provide lower rates of hydrolysis, as a way to improve upon the current 
set of buffer conditions even further. The buffers chosen for this small study were sodium 
phosphate (NaPi; with or without tert-butanol), MOPS, TES and Tris buffers, which all had an 
effective buffer range around pH 7.5, and all experiments were performed at 37 °C.  
The results of these experiments are presented in figure 52. The three new buffers tested 
displayed no significant rate reductions compared to sodium phosphate, and in fact showed 
some slight increases over the phosphate system. Thus, it appears that the sodium phosphate 
buffer system remains the choice buffer system for the glucuronylsynthase reaction, with a 
slight improvement offered by the inclusion of tert-butanol. 
 
Figure 52: the effect of other buffers such as Tris, TES and MOPS on the initial rate of hydrolysis 
of the α-D-glucuronyl fluoride 29 (1 mM) as compared to NaPi. Conditions: pH 7.5, 37 °C. 
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4.6 Conclusions and future work 
In summary, the Michaelis-Menten kinetics of the E504G glucuronylsynthase, using CMO-DHEA 
33 as the substrate, was investigated in relation to the effects of tert-butanol and temperature.  
It was observed that substrate inhibition, present at 21 °C in the absence of tert-butanol, 
disappeared upon either addition of the organic co-solvent or an increase in temperature. 
Further analysis of the data revealed that temperature had the most pronounced rate-
enhancing effects, through increases to kcat and the specificity constant kcat/KM. 
It was found that tert-butanol also exerted a rate-enhancing effect on Vmax, indicating that tert-
butanol appears to be more beneficial at higher substrate concentrations. However, it did not 
show any particular improvement over the effects of temperature in this or the other kinetics 
parameters. In fact, the most prominent effects of tert-butanol were observed to be a uniform 
increase in KM (poorer substrate binding affinity) and a reduction in the specificity constant 
(poorer reactivity at lower substrate concentrations).  
This was proposed to be due to the looser hydration shell due to the presence of tert-butanol in 
aqueous solution, which would then reduce entropic benefits associated with substrate binding 
(such as release of water molecules from the hydration shell) to the enzyme active site.  
In combination with the known solubilising effect that tert-butanol has on steroid substrates in 
general, an effect that operates independently of kinetic effects, this then suggested that the 
organic co-solvent may play a more important role in solubilising the steroid substrate rather 
than exerting some significant rate-enhancing effect on the glucuronylsynthase rate. 
Having considered the effect of organic solvents on other enzyme systems, there may be the 
potential for the development of complementary solvent systems for the glucuronylsynthase 
reaction. As seen in section 2.2, the synthesis of some steroid glucuronides was hindered due to 
their poor solubility, even with 10% v/v tert-butanol. Therefore the development of alternative 
synthase conditions involving two-phase systems (e.g. ethyl acetate/water) may help overcome 
these solubility problems, particularly in the case of the cholestanes (as an example), or indeed 
even near pure organic solvent systems, where enzyme rigidity allows for the rescue of some (if 
not all) activity235,258,259. As an example, almond β-D-glucosidase was used to synthesise the 
corresponding β-D-glucosides in a mixture of water-organic solvent, such as tert-butanol, where 
a mixture of 10:90 resulted in the highest yield of product260. 
Experiments on the hydrolysis of the glucosyl fluoride 28 and glucuronyl fluoride 29 revealed 
some intriguing information concerning the rates of general base-catalysed hydrolysis by 
phosphate buffer. For the glucosyl fluoride 28, it was found that phosphate buffer increases the 
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rate of hydrolysis, mirroring literature evidence. The addition of tert-butanol to the system 
displayed a sharp drop in the overall rate of hydrolysis, a possible consequence of the reduction 
in polarity of the bulk solution.  
On the other hand the glucuronyl fluoride 29 did not appear to suffer any increase in the rate of 
general base-catalysed hydrolysis by phosphate buffer. This was suggested to be caused by the 
pendant carboxylate functionality on the glucuronyl fluoride 29, which would be charged at pH 
7.5 and therefore be involved in unfavourable charge-charge repulsion with the negatively-
charged phosphate. The hydrolysis of the glucuronyl fluoride 29 would then be more dependent 
on the SN1-type hydrolysis mechanism rather than any general base-dependent catalysis. 
The addition of tert-butanol displayed a much milder reduction in the rate of hydrolysis of the 
sugar. This was suggested to be attributable to the carboxylate functionality exerting a possible 
insulating effect on the local medium around the sugar, counterbalancing the reduction in 
polarity of the bulk solution by tert-butanol. 
It would be interesting to measure the polarity of the various buffer systems used in this study 
to attempt to correlate them with the observed effects on the rates of hydrolysis of the sugars. 
It would also be very interesting to examine the effect that the enzyme has on the rate of 
hydrolysis of the sugars, the glucuronyl fluoride 29 in particular. Based on Wilkinson’s work on 
relieving product inhibition, the sugar is known to bind tightly to the enzyme. Here, water 
would be expected to be present in high concentrations. For example, the apparent KMapp 
observed by Wilkinson for the glucuronyl fluoride 29 (with a fixed concentration of alcohol 
acceptor 2-phenylethanol 39) was found to be 15.0 ± 1 µM, much lower than those seen for the 
CMO-DHEA 33 substrate in the enzyme kinetics study. 
Initial attempts in this work to measure this resulted in apparently rapid hydrolysis of the 
sugar, but this was performed with enzyme preparations that displayed some hydrolytic activity 
as described in section 2.2.3. No experiments on enzyme-mediated hydrolysis of the glucuronyl 
fluoride 29 were performed since the new protocol for enzyme expression was developed and 
so this remains an open question. Indeed, this may provide a better indicator of the stability of 
the glucuronyl fluoride 29 under the glucuronylsynthase conditions as the data gathered thus 
far suggests that the glucuronyl fluoride 29 does not experience any particularly serious general 
base-catalysed hydrolysis by phosphate. Whether the enzyme could significantly alter the 
conclusions reached here remains unknown. 
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Ultimately, the effect of tert-butanol on the glucuronylsynthase and corresponding yields has 
been found to be largely dependent on the ability of the organic co-solvent to dissolve the 
steroid rather than providing any particularly noteworthy improvements to the enzyme 
reaction. 
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Chapter 5: Experimental 
5.1 General experimental 
5.1.1 Equipment 
Melting points were determined using an Optimelt Automated Melting Point System100 and are 
uncorrected. 
Optical activity was measured on a Perkin-Elmer Polarimenter 241MC set at the 589.3 sodium D 
line, in a 1.00 dm cell. Data is expressed as [α]TD +/- R (c, S), where T is the temperature (°C), R 
is the calculated rotation (10–1 deg cm2 g–1), and S is the solvent used. 
Infrared absorption (IR) spectra were obtained using a Perkin-Elmer Spectrum One FTIR 
spectrometer. The compounds were dried as a thin film onto sodium chloride plates (NaCl). 
Significant absorbance bands are reported in wavenumbers (cm–1) and are described by the 
abbreviations: br = broad, vs = very strong, s = strong, m = medium, w = weak. Where 
applicable, bands are also assigned their respective functional group. 
1H Nuclear Magnetic Resonance (1H NMR) spectra were obtained on a Mercury 400 (400 MHz), 
Bruker Avance 400 (400 MHz), Bruker Avance 600 (600 MHz), or Bruker 800 (800 MHz) at 300 
K unless otherwise stated. Chemical shift data is expressed in ppm relative to δTMS = 0, using 
residual protons in deuterated solvent as an internal reference. The data is reported as chemical 
shift (δ), relative integral, multiplicity (s = singlet, d = doublet, dd = doublet of doublets, ddd = 
doublet of doublet of doublets, m = multiplet), coupling constants(s) (J Hz), and assignment. All 
multiplicities and coupling constants are apparent. Where necessary, COSY, HSQC & HMBC 
experiments were performed to complete assignments.  
13C Nuclear Magnetic Resonance (13C NMR) spectra were obtained on a Mercury 400 (100 MHz), 
Bruker Avance 400 (100 MHz), Bruker Avance 600 (150 MHz), or Bruker 800 (200 MHz) at 300 
K with complete proton decoupling unless otherwise stated. Chemical shift data is expressed in 
ppm relative to δTMS = 0, using deuterated solvent as an internal reference. The data is reported 
as chemical shift (δ) and assignment. Heteronuclear 13C– 19F coupling, where present, are 
denoted with multiplicity (d = doublet) and coupling constant (J Hz). 
Low resolution mass spectrometry (LRMS) was recorded on a Micromass ZMD ESI-Quad mass 
spectrometer, using using positive (+ESI) or negative (–ESI) electro-spray ionisation. Data is 
expressed as observed mass (m/z) and assignment. 
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High resolution mass spectroscopy (HRMS) was recorded on a Waters LCT Premier XE mass 
spectrometer, using positive (+ESI) or negative (–ESI) electro-spray ionisation and on a VG 
autospec mass spectrometer using electron impact (EI) ionisation. Data is expressed as 
observed mass (m/z) and assignment. 
Analytical thin layer chromatography (TLC) was performed using 0.2 mm thick, aluminium-
back, pre-coated silica gel plates (Merck Silica gel 60 F254). Compounds were visualised by short 
and long wavelength ultra-violet fluorescence and/or by staining with 5% sulphuric acid in 
methanol or basic permanganate (40 g of potassium carbonate, 6 g of potassium permanganate, 
600 mL water, and 5 mL of 10% w/v sodium hydroxide) with heating where required. 
Normal-phase flash column chromatography was performed using Merck Silica gel 60 (230 – 
400 mesh ASTM), under a positive pressure of nitrogen, with the indicated solvents. Solvent 
compositions were mixed volume per volume (v/v) as specified. 
Anion exchange column chromatography was performed using Dowex 1x8, 200–400, Mesh Cl 
resin. All solutions were made from milliQ water and the resin was re-conditioned before every 
use. The resin was re-conditioned with 1 M hydrochloric acid (10 column volumes, pH = 1), then 
water until neutral, 1 M sodium hydroxide (10 column volumes, pH = 14), then water until 
neutral, 1 M ammonium bicarbonate (10 column volumes), then finally water until neutral (10 
column volumes). All ion washings were done using gravity; water washes were carried out 
under a positive pressure of nitrogen. 
Reverse-phase column chromatography was performed using Grace Davisil C18 silica (cat 
#633NC18E) under a positive pressure of nitrogen, with the indicated solvents. Solvent 
compositions were mixed volume per volume (v/v) as specified. 
High-performance liquid chromatography with ultraviolet detection (HPLC-UV) was performed 
on a Waters 2695 Separations module equipped with the Waters Alliance Series Column Heater 
and Waters 2996 Photodiode Array (PDA) detector. Data acquisition and processing was 
performed with the Waters Empower 2 software. 
Solid-phase extraction was performed using an Agilent Bond Elut Certify II 200 mg, 3 cc, 40 μM 
pore size (12102080), Oasis Weak-Anion Exchange (WAX) 60 mg, 3 cc, 60 μM pore size 
(186002492) or 500 mg, 6 cc, 60 μM pore size (186004647), Oasis MAX 60 mg, 3 cc, 30 μM pore 
size (186000367), or Oasis Certified Sep-Pak C18 500 mg, 3 cc (186004619). 
Evaporation or solvent removal under reduced pressure refers to evaporation using a rotary 
evaporator connected to a vacuum pump. Removal of residual solvent when necessary was 
achieved by evacuation (0.1-0.2 mm Hg) with high stage oil sealed vacuum pump. 
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Lyophilisation refers to the sublimation of residual solvent, achieved by freezing the liquid 
within a containing round-bottom flask in a bath of liquid nitrogen and subjecting it to high 
vacuum overnight. 
Molecular sieves refers to 3Å or 4Å 1.6 mm pellets, Sigma-Aldrich. Activation was achieved by 
subjecting oven-dried molecular sieves to seven cycles (30 seconds per cycle) of high 
microwave irradiation. Care was taken to remove red-hot pellets. 
All solvents and reagents were dried and purified when necessary. ‘Hexanes’ refers to hexanes 
(b.p. 65 – 69 °C), ‘pet. ether’ refers to petroleum ether (b.p. 40 – 60 °C), and ‘brine’ refers to 
saturated aqueous sodium chloride solution. Moisture sensitive reactions were carried out 
under a dry inert atmosphere of nitrogen. Reaction temperatures were controlled using ice (0 
°C) cooling baths or oil heating baths (> room temperature). Room temperature ranges from 18-
25 °C. Typical concentrations of E504G glucuronylsynthase ranged from ~2 – 7.15 mg/mL. 
5.1.2 Biochemical solutions 
The following recipes for biochemical solutions are made as a solution in milliQ water with the 
percentage concentration as grams per 100 mL (w/v %) unless otherwise stated. 
Concentrations are stated as the final concentration in solution. 
Binding buffer: sodium dihydrogen phosphate (20 mM), sodium chloride (0.5 M), imidazole (20 
mM), milliQ water, adjusted to pH 7.4. 
Bromophenol blue loading buffer (BPB): bromophenol blue (0.05%), glycerol (75%), Tris buffer 
(pH 8.0, 2.5 mM), milliQ water. 
Eluting buffer: sodium dihydrogen phosphate (20 mM), sodium chloride (0.5 M), imidazole (500 
mM), milliQ water, adjusted to pH 7.4. 
Glycine running buffer: Tris buffer (0.25 M), glycine (1.92 M), sodium dodecyl sulfate (SDS, 
1.0%), milliQ water, adjusted to pH 8.3. 
Glycine SDS-PAGE resolving gel (15%): acrylamide (15%), Tris buffer pH 8.8 (0.38 M), sodium 
dodecyl sulfate (SDS, 0.1%), ammonium persulfate (APS, 0.075%), milliQ water, N,N,N’,N’- 
tetramethylethylenediamine (TEMED, 0.125%). 
Glycine SDS-PAGE stacking gel (5%): acrylamide (4.5%), Tris buffer pH 6.8 (0.12 M), sodium 
dodecyl sulfate (SDS, 0.1%), ammonium persulfate (APS, 0.06%), milliQ water, N,N,N’,N’-
tetramethylethylenediamine (TEMED, 0.1%). 
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Luria Burtani (LB) media: tryptone (1%), yeast extract (0.5%), sodium chloride (1%), milliQ 
water, autoclaved. 
Luria Burtani (LB) agar media: agar (1.5%), tryptone (1%), yeast extract (0.5%), sodium 
chloride (1%), milliQ water, autoclaved. 
Luria Burtani with kanamycin (LBkan) media: tryptone (1%), yeast extract (0.5%), sodium 
chloride (1%), milliQ water, autoclaved, then kanamcyin (0.005%). 
Phosphate buffered saline (PBS) buffer: sodium chloride (0.8%), potassium chloride (0.02%), 
sodium monohydrogen phosphate (0.144%), potassium dihydrogen phosphate (0.024%), milliQ 
water, adjusted to pH 7.4, autoclaved. 
Terrific Broth: glycerol (0.4% v/v), yeast extract (2.4%), tryptone (1.2%), milliQ water, 
autoclaved, then potassim phosphate buffer (pH 7.2, 10%) and kanamcyin (0.005%). 
2x YT: sodium chloride (0.5%), yeast extract (1.0%), tryptone (1.6%), milliQ water, autoclaved, 
then kanamcyin (0.005%). 
YenB media: yeast extract (0.75%), nutrient broth (0.8%), milliQ water. 
5.2 Expression of E504G glucuronylsynthase 
The following details a modified procedure for the expression of the E504G glucuronylsynthase 
based on Wilkinson’s original protocol153. Method development was performed by Shu-Ann 
Chan of the Ollis research group. 
5.2.1 Protein SDS-PAGE 
Gels were freshly prepared each time. For the two gels (running & stacking) the components 
were added in the order of: milliQ water, Tris buffer (pH 8.8), SDS, ammonium persulfate (after 
defrosting), acrylamide and then TEMED added in the fume hood. The final solution was swirled 
well but gently then transferred to the casting setup by pipette (5 mL). Approximately 1 cm of 
space was left for the stacking gel. The running gel was allowed to set (approximately 0.5-1 h) 
before the stacking gel was prepared in the same fashion. Gels were cast with either 10 or 15 
lanes and samples were typically loaded with volumes of 5 or 10 μL.  
Protein samples were typically prepared as a 1-in-2 or 1-in-4 dilution with β-mercaptoethanol 
and bromophenol blue loading buffer then heating at 90 °C for approximately 5 mins. The gel 
was run in a Wide Mini Sub Cell electrophoresis tank at a constant voltage (180 V) or constant 
current (20 mA) until the dye was approximately 0.5 cm from the baseline. 
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A low-molecular weight standard was used to provide bands corresponding to β-galactosidase 
(116.25 kDa), phosphorylase b (97.4), serum albumin (66.2), ovalbumin (45) and carbonic 
anhydrase (31). Other bands were not visible. 
Visualisation was performed by first washing the gel thrice with distilled water (microwave, 1 
min each), then using BioRad Coomassie Blue G-250 stain (either fresh or 1x used) to stain for 
1-2 h with shaking. The stain was then removed and poured into the appropriate container and 
the gel de-stained (typically overnight) with distilled water, with shaking. 
5.2.2 Transformation 
Electro-competent E. coli host cells (50 μL, BW25142) were thawed on ice before the addition of 
concentrated pJ401(+)-E504G vector (1 μL). The mixture was left to stand for 1 min before 
being transferred into a 0.2 mm electrode cuvette (electroporation) and subjected to an electric 
field (2.5 kV, 5 ms) using a BioRad Micropulser Electroporator. YenB media (2x 500 μL) was 
immediately added to the cells and the solution then incubated for 1 h (37 °C, 120 rpm). 
5.2.3 Selection 
Freshly transformed cells (500 μL) were plated onto LBkan agar selection plates with strict 
aseptic technique. The plate was then incubated overnight at 37 °C (16 h). 
5.2.3.1 Preparation of selection plates 
Freshly autoclaved LBkan agar selection media (500 mL) was allowed to cool to approximately 
50-60 °C in a lamina flow fume hood at which point kanamycin (500 μL solution in milliQ water, 
50 mg/mL), X-Gluc 74 (40 mg in a solution of 500 μL DMSO, filter-sterilised) and IPTG (1 mL of 
a 0.5 M solution in milliQ water) were added and the media mixed carefully before being poured 
into plastic Petri dishes (approximately ~20-25). The agar selection media were then allowed to 
solidify before use (approximately 0.5-1 h). 
5.2.4 Expression & induction 
A colony of transformed E. coli pJ401 BW25142 cells was chosen from an LBkan agar selection 
plate to inoculate an aliquot of LBkan solution media (10 mL) that was incubated overnight at 37 
°C (16 h) with shaking (160 rpm). 
This culture was used to inoculate a sterile LBkan solution media (1 L) and the larger culture 
incubated at 37 °C with shaking (160 rpm). At A600 = ~0.6-0.8 (2.5-3 h), cells were induced with 
IPTG (ci = 0.5 M, 1 mL, 500 μmol) and the culture incubated at 30 °C overnight (16 h) with 
shaking (120 rpm). 
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The cells were harvested by centrifugation (5000 rpm, 15 min, 4 °C). The pellet was typically 
split between four falcon tubes, then resuspended in PBS buffer (30 mL each) and centrifuged 
under the same conditions. The supernatant was discarded and the cell pellets (typically 2-4 g) 
were stored at -80 °C until required. 
5.2.5 Cell lysis 
A bacterial cell pellet was allowed to warm on ice before suspension in binding buffer (typically 
10-15 mL per gram, maximum 30 mL) then subjected to lysis by sonication (6 min, 50% pulse 
power, 5 ms pulses). The crude lysate was then centrifuged (30,000 g, 30 min, 4 °C), the 
supernatant collected and immediately subjected to purification. 
5.2.6 Purification 
A GE Healthcare HisTrapTM column was pre-conditioned with water (25 mL) then binding buffer 
(25 mL) before the crude supernatant was loaded on to the column via a plastic syringe fitted 
with a 0.45 μM membrane filter. If the volume exceeded 30 mL, the loading step was split into 
two with an intermediate binding buffer wash (15 mL). Once the sample was fully loaded on to 
the column, a binding buffer wash was performed (25 mL) followed by elution, firstly with 1:1 
binding buffer : eluting buffer (50 mL, as 10 x 1 mL then 4 x 10 mL fractions), then 100% eluting 
buffer (15-20 mL). 
Sample purity was assessed by protein SDS-PAGE analysis. Aliquots (20 μL) were taken for: 
crude lysate (before centrifugation), crude lysate (after centrifugation), sample loading 
flowthrough, binding wash, selected elution fractions and final eluting buffer wash.  
After use, the HisTrapTM column was washed with water (20 mL) and aqueous ethanol (20%, 20 
mL) before being stored at 4 °C. 
The appropriate fractions containing enzyme were combined and transferred into sodium 
phosphate buffer (50 mM, pH 7.5) using centrifugal filtration tubes (50 mL) and centrifugation 
(4000 rpm, 4 °C) until the estimated concentration of imidazole was about ≤1 μM (typically 7-8 
rounds). The enzyme solutions were combined and diluted with further sodium phosphate 
buffer up to typically 20 mL. A sample of the final flow-through was used for determination of 
protein concentration. 
5.2.7 Protein concentration determination 
Enzyme concentrations were determined via a NanoDropTM ND-1000 spectrophotometer. The 
sample pedestal was cleaned with milliQ water then milliQ water (1.5 μL) was used to set up the 
system. A blank measurement (1-1.5 μL) was performed using the sample obtained previously 
then measurements were performed on the enzyme sample (1.5 μL) in triplicate, using the 
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following values for molecular weight (68.4 kDa) and extinction coefficient (140.70 x 103 M–1 
cm–1 – estimated via the ProtParam online tool, http://web.expasy.org/protparam/). 
5.3 Synthesis of α-D-glucuronyl fluoride 
5.3.1  1,2,3,4,6-Penta-O-acetyl-β-D-glucopyranoside 26261 
 
Acetic anhydride (100 mL, 1.06 mol) was added to D-glucose 93 (20.0 g, 0.111 mol) and sodium 
acetate (16.0 g, 0.195 mol) and the solution heated to 100 °C for 2.5 h. The mixture was cooled 
to room temperature and poured onto ice with stirring to give a colourless suspension in water. 
The solid was filtered, washed with ice-cold water (10 L), dried, and stored overnight in a 
desiccator over potassium hydroxide. Recrystallisation from hot methanol (10 mL per gram of 
crude) afforded the title compound 26 as small colourless needles (16.9 g, 39%, α:β 1:100). 
Rf 0.32 (9:1 CHCl3:EtOH); [α]20D +5.0 (c 4.6, CHCl3) [lit.261 [α]23D +4.5 (c 4.6, CHCl3)]; mp: 129–
130 °C (lit.261: 130–131 °C); IR (NaCl): 2924 (C-H), 1755 (C=O), 1435, 1368, 1218, 1075, 1037, 
910 cm–1 ; 1H NMR (400 MHz, CDCl3): δ 5.71 (1H, d, JH1-H2 8.4, H1), 5.25 (1H, t, JH2-H1≈JH2-H3 9.6, 
H2), 5.15-5.10 (2H, m, H3, H4), 4.29 (1H, dd, 2JH6a-H6b 12.4, 3JH5-H6a 4.4, H6a), 4.11 (1H, dd, 2JH6a-H6b 
12.4, 3JH5-H6b 2.0, H6b), 3.83 (1H, ddd, JH4-H5 9.8, JH5-H6a 4.3, JH5-H6b 2.2, H5), 2.17-2.01 (15H, m, 5 x 
Ac); 13C NMR (100 MHz CDCl3): δ 170.6 (C=O), 170.1 (C=O), 169.4 (C=O), 169.3 (C=O), 169.0 
(C=O), 91.72 (C1), 72.8, 70.3, 70.0, 67.8, 61.5, 20.8 (2 x CH3), 20.7 (3 x CH3); LRMS (+ESI) m/z 
413 ([M+Na]+); HRMS (+ESI) m/z calcd. for C16H22O11Na ([M+Na]+) 413.1060, found 413.1060. 
5.3.2  2,3,4,6-Tetra-O-acetyl-α-D-glucopyranosyl fluoride 94262 
 
 
Hydrogen fluoride-pyridine (70%, 20 mL) was added to 1,2,3,4,6-penta-O-acetyl-β-D-
glucopyranoside 26 (12.03 g, 0.03 mol) dissolved in dry dichloromethane (20 mL) at room 
temperature under a nitrogen atmosphere. The reaction was stirred for 6 h at room 
temperature then poured into a solution of diethyl ether (50 mL) and aqueous potassium 
fluoride (10% w/v, 200 mL). The organic layer was collected and the aqueous layer washed 
with ether:hexane 3:1 (4x 80 mL). The organic layers were combined and washed with aqueous 
potassium fluoride (10% w/v, 4x 100 mL), saturated sodium bicarbonate (100 mL) and brine 
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(50 mL). The solvent was dried over anhydrous magnesium sulphate, filtered, and evaporated 
under reduced pressure at 40 °C. The resulting gum-like residue was dissolved in chloroform, 
adsorbed onto silica gel, and dry-loaded onto a normal-phase flash silica column. Elution with 
chloroform:ethyl acetate (9:1) afforded the title compound 94 as a colourless solid (7.66 g, 
71%). 
Rf 0.52 (9:1 CHCl3:EtOAc); [α]20D +80.3 (c 3, CHCl3) [lit.262 [α]20D +90.1 (c 3, CHCl3)]; Rf 0.43 (9:1 
chloroform : ethyl acetate); mp: 98–104 °C (lit.262: 108 °C); IR (NaCl): 2963 (C-H), 1751 (C=O), 
1369, 1221, 1161, 1042, 924, 772 cm–1 ; 1H NMR (400 MHz, CDCl3): δ 5.75 (1H, dd, JH1-F 52.8, JH1-
H2 2.8, H1), 5.50 (1H, t, JH3-H4≈JH4-H5 10.0, H4), 5.15 (1H, t, JH2-H3≈JH3-H4 10.0, H3), 4.96 (1H, ddd, JH2-
F 24.2, JH1-H2 2.8, JH2-H3 10.4, H2), 4.31-4.13 (3H, m, H5, H6), 2.10 (3H, s, Ac), 2.09 (3H, s, Ac), 2.04 
(3H, s, Ac), 2.02 (3H, s, Ac); 13C NMR (100 MHz, CDCl3): δ 170.6 (C=O), 170.1 (C=O), 170.0 (C=O), 
169.5 (C=O), 103.8 (d, 1JC1-F 228.4, C1), 70.4 (d, 2JC2-F 24.8, C2), 69.8 (d, 3JC3-F 4.4, C3), 69.6 (C5), 
67.4 (C4), 61.2 (C6), 20.7 (CH3), 20.6 (3 x CH3); LRMS (+ESI) m/z 373 ([M+Na]+); HRMS (+EI) 
m/z calcd. for C14H19O9F ([M]+) 350.1013, found 350.1021. 
5.3.3  α-D-Glucopyranosyl fluoride 28263 
 
Sodium methoxide (1.0 mL, 1M, 1.0 mmol) was added drop-wise to 2,3,4,6-tetra-O-acetyl α-D-
glucopyranosyl fluoride 94 (1.76 g, 9 mmol) dissolved in dry methanol (49 mL) on ice under 
nitrogen atmosphere. The reaction was stored overnight (18 h) at 4 °C then quenched by the 
addition of silica gel (6 g). The solvent was evaporated under reduced pressure at 30 °C and the 
resulting colourless residue wet-loaded onto a normal-phase flash silica column. Elution with 
ethyl acetate:ethanol (5:2) afforded the title compound 28 as a colourless solid (0.87 g, 95%). 
Rf 0.48 (7:2:1 EtOAc:MeOH:H2O); [α]20D +104 (c 1.1, H2O) [lit.263 [α]24D +97.6 (c 1.5, H2O)]; Rf 
0.33 (5:2 ethyl acetate : ethanol); mp: 128–157 °C (lit.263: 112–119 °C); IR (NaCl): 3373 (vs br, 
OH), 2937 (w, C-H), 1341, 1164, 1109, 1088, 1031 cm–1; 1H NMR (400 MHz, D2O): δ 5.71 (1H, 
dd, JH1-F 53.6, JH1-H2 2.8, H1), 3.91-3.51 (6H, m, H2, H3, H4, H5, H6); 13C NMR (100 MHz, D2O): δ 
107.3 (d, JC1-F 221.4, (C1), 74.1, (C5), 72.3 (C3), 71.0 (d, 2JC2-F 24.8, C2), 68.4 (C4), 60.0 (C6); 
LRMS (+ESI) m/z 205 ([M+Na]+); HRMS (+ESI) m/z calcd. for C6H11O5FNa ([M+Na]+) 205.0488, 
found 205.0486; Elemental analysis: calcd. for C6H11O5F: C, 39.56; H, 6.09; F, 10.43. Found: C, 
39.49; H, 6.22; F, 10.22. 
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5.3.4  α-D-Glucopyranuronyl fluoride 29, ammonium salt200 
 
TEMPO (42 mg, 0.269 mmol) was added to α-D-glucopyranosyl fluoride 28 (1.00 g, 5.49 mmol) 
dissolved in milliQ water (55 mL) on ice (~4 °C). The pH was adjusted to 9 with sodium 
hypochlorite before the drop-wise addition of sodium hypochlorite (1.313 M, 8.4 mL, 11.03 
mmol). The addition of sodium hypochlorite was maintained at such a rate that the pH of the 
reaction remained about 9.5 ± 0.5. After the addition of sodium hypochlorite, the pH of the 
reaction was maintained at 9.4 ± 0.2 by the addition of sodium hydroxide (0.5 M) until the pH 
steadied. Upon completion (by TLC; 3 h), the pH of the solution was lowered to 7 by the addition 
of hydrochloric acid (0.5 M) and the crude reaction subjected to anion exchange column 
chromatography (Dowex®, 1x8, 200-400 mesh, HCO3– form). The column was eluted with 
milliQ water (4 column volumes) then 50 mM ammonium bicarbonate (2 column volumes), 
followed by 0.1 M ammonium bicarbonate (6 column volumes to elute the majority of the title 
compound), then by 0.2 M ammonium bicarbonate until complete elution of the target 
compound. Fractions were combined and concentrated under reduced pressure at 30 °C and the 
resulting white residue redissolved in milliQ water and concentrated under reduced pressure at 
30 °C three times, followed by lyophilisation overnight, to afford the title compound 29 as a 
white solid (1.01 g; 86%). Recrystallisation was performed via dissolution of the title compound 
in boiling 70% aqueous ethanol (5 mL per gram of product) then immediate refrigeration at 4 
°C to afford the pure title compound 29 as colourless crystals (369 mg, 74% from 501 mg). 
Rf 0.03 (7:2:1 EtOAc:MeOH:H2O), 0.45 (5:2:1 EtOAc:MeOH:H2O); [α]20D +57.4 (c 1, H2O) [lit.153 
[α]24D +46.6 (c 1.1, H2O)]; mp: 120–138 °C (lit.125: 112–119 °C); IR (NaCl): 3205 (s, O-H), 2937 
(m, C-H), 1600 (CO2–), 1417 (CO2–), 1312, 1161, 1109, 1076, 1033, 1010 cm–1; 1H NMR (400 
MHz, D2O): 5.71 (1H, d, JH1-F 53.4, JH1-H2 2.7, H1), 4.09 (1H, d, JH5-H4 10.2, H5), 3.77 (1H, t, JH3-H4 ≈ 
JH3-H2 9.5, H3), 3.67 (1H, ddd, JH2-F 26.1, JH2-H3 9.8, JH2-H1 2.7, H2), 3.59 (1H, t, JH4-H5 ≈ JH4-H3 9.3, H4); 
13C NMR (100 MHz, D2O): δ 175.5 (C6), 107.1 (d, JC1-F 222.6, C1), 74.0 (C5), 72.2 (C3), 71.0 (C4), 
70.8 (d, JC2-F 25.2, C2); LRMS (-ESI) m/z 195 ([M–NH4]–); HRMS (-ESI) m/z calcd. for C6H8O6F 
([M-NH4]–) 195.0305, found 195.0305. 
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5.4 Synthesis of steroid glucuronides 
5.4.1 Development of the solid-phase extraction protocol 
Stock solutions of dehydroepiandrosterone 19 and dehydroepiandrosterone 3-glucuronide 21 
were made up separately in 20 mM sodium phosphate buffer (pH 7.5) containing 10% v/v tert-
butanol. For the purpose of this section “crude reaction” is defined as an equivolume mixture of 
dehydroepiandrosterone 19 and dehydroepiandrosterone 3-glucuronide 21 solutions. TLC 
development was carried out in 7:2:1 EtOAc:MeOH:H2O and stained with 5% v/v H2SO4 in 
MeOH with heating. 
5.4.1.1 The Waters Oasis WAX solid-phase extraction cartridge (3 mL, 60 μm pore size) 
Protocol 1: Waters Oasis WAX extraction protocol 
The Waters Oasis WAX SPE cartridge was pre-conditioned with methanol (1 mL) followed by 
milliQ water (3 mL). The crude reaction was loaded onto the cartridge and washed with 
aqueous formic acid (2% v/v, 3 mL), methanol (3 mL), then ammonium hydroxide in methanol 
(5% v/v, 3 mL). 
Protocol 2: Waters Oasis WAX extraction protocol (modified) 
The Waters Oasis WAX SPE cartridge was pre-conditioned with methanol (1 mL) followed by 
milliQ water (3 mL). The crude reaction was loaded onto the cartridge and washed with 
aqueous formic acid (2% v/v, 3 mL), milliQ water (3 mL), methanol (3 mL), then ammonium 
hydroxide in methanol (5% v/v, 3 mL). 
Protocol 3: Australian Racing Forensic Laboratory extraction protocol 
The Waters Oasis WAX SPE cartridge was pre-conditioned with methanol (1 mL) followed by 
milliQ water (3 mL). The crude reaction was loaded onto the cartridge and washed with sodium 
hydroxide (0.1 M, 3 mL), sodium phosphate buffer (50 mM, 3 mL, pH 7.5), milliQ water (3 mL), 
methanol (3 mL), and finally 1:1 MeOH : EtOAc + 2% v/v formic acid (3 mL). 
5.4.1.2 The Bond Elut Certify II solid-phase extraction cartridge (3 mL, 200 mg) 
Protocol 4: Waters Oasis MAX extraction protocol (modified) 
The Bond Elut Certify II SPE cartridge was pre-conditioned with methanol (1 mL) followed by 
milliQ water (3 mL). The crude reaction was loaded onto the cartridge and washed with 
aqueous ammonium hydroxide (5% v/v, 3 mL), milliQ water (3 mL), methanol (3 mL), then 
formic acid in methanol (2% v/v, 3 mL). 
 
Chapter 5: Experimental 
145 
 
Protocol 5: Australian Racing Forensics Laboratories extraction protocol 
The Bond Elut Certify II SPE cartridge was pre-conditioned with methanol (1 mL) followed by 
milliQ water (3 mL). The crude reaction was loaded onto the cartridge and washed with sodium 
hydroxide (0.1 M, 3 mL), sodium phosphate buffer (50 mM, 3 mL, pH 7.5), milliQ water (3 mL), 
methanol (3 mL), and finally 1:1 MeOH : EtOAc + 2% v/v formic acid (3 mL). 
Protocol 6: Bond Elut Certify II recommended protocol 
The Bond Elut Certify II SPE cartridge was pre-conditioned with methanol (1 mL) followed by 
0.1 M sodium acetate buffer (pH 7.0, 3 mL). The crude reaction (adjusted to pH ~6) was loaded 
onto the cartridge and washed with 1:1 H2O : MeOH (2x 3 mL), EtOAc (2 mL), then 3:1 hexane : 
EtOAc + 1% v/v acetic acid (2x 3 mL). 
5.4.2 Solid-phase extraction of a glucuronylsynthase reaction 
5.4.2.1 Extraction of the enzyme-catalysed dehydroepiandrosterone 3-glucuronide 21 
reaction 
Protocol 1: Waters Oasis WAX extraction protocol (modified) 
The SPE cartridge was pre-conditioned with methanol (1 mL) followed by milliQ water (3 mL). 
The crude reaction (2.5 mL) was loaded onto the cartridge and washed with aqueous formic 
acid (2% v/v, 3 mL), milliQ water (3 mL), methanol (3 mL), then ammonium hydroxide in 
methanol (5% v/v, 3 mL). 
Protocol 2: Australian Racing Forensics Laboratories WAX extraction protocol 
The SPE cartridge was pre-conditioned with methanol (1 mL) followed by milliQ water (3 mL). 
The crude reaction (2.5 mL) was loaded onto the cartridge and washed with sodium hydroxide 
(0.1 M, 3 mL), sodium phosphate buffer (50 mM, 3 mL, pH 7.5), milliQ water (3 mL), methanol 
(3 mL), and finally 1:1 MeOH : EtOAc + 2% v/v formic acid (3 mL). 
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5.4.3 Quantification of the glucuronylsynthase protocol for steroid glucuronides 
5.4.3.1  General method A (conversion by 1H NMR analysis): Epiandrosterone 
3-glucuronide 36, ammonium salt165 
 
To epiandrosterone 35 (1.00 mg, 3.44 μmol) dissolved in tert-butanol (500 μL) and sodium 
phosphate buffer (3.22 mL, 50 mM, pH 7.5) was added E504G glucuronylsynthase (ci = 1.07 
mg/mL, 924 μL, cf = 0.2 mg/mL) and α-D-glucuronyl fluoride 29 (3.89 mg, 18.2 μmol, 5 equiv.) 
dissolved in sodium phosphate buffer (344 μL, 50 mM) and the reaction incubated at 37 °C for 2 
d without agitation. The reaction was then subjected to solid-phase extraction. An Oasis WAX 
SPE cartridge (60 mg, 3 mL) was pre-conditioned with methanol (1 mL) and milliQ water (3 
mL). The crude reaction was loaded onto the cartridge and washed with aqueous formic acid (3 
mL, 2% v/v), milliQ water (3 mL), and then with saturated aqueous ammonium hydroxide in 
methanol (9 mL, 5% v/v). The appropriate fractions were combined and the solvent removed 
under reduced pressure at 30 °C to afford a mixture of epiandrosterone 35 and epiandrosterone 
3-glucuronide ammonium salt 36 with a 90% conversion as determined by 600 MHz 1H NMR 
integration of the H3 protons. 
5.4.3.2  General method B (synthesis) 
The reaction was carried out as for method A on a larger scale with epiandrosterone 35 (5.03 
mg, 1.73 μmol). The reaction was then subjected to solid-phase extraction. An Oasis WAX SPE 
cartridge (500 mg, 6 mL) was pre-conditioned with methanol (5 mL) and milliQ water (15 mL). 
The crude reaction was loaded onto the cartridge and washed with aqueous formic acid (15 mL, 
2% v/v), milliQ water (15 mL), methanol (15 mL) to elute free steroid, and finally with 
saturated aqueous ammonium hydroxide in methanol (30 mL, 5% v/v) to elute the steroid 
glucuronide. The appropriate fractions were combined and the solvent removed under reduced 
pressure at 30 °C to afford epiandrosterone 3-glucuronide ammonium salt 36 as a white solid 
(6.8 mg, 84%). 
Rf 0.44 (7:2:1 EtOAc:MeOH:H2O); 1H NMR (600 MHz, CD3OD): δ 4.41 (1H, d, JH20–H21 8.0, H20), 
3.78 (1 H, m, H3), 3.55 (1H, d, JH24–H23 9.5, H24), 3.43 (1H, t, JH23–H24 ≈ JH23–H22 9.2, H23), 3.39 (1H, 
t, JH22–H23 ≈ JH22–H21 8.9, H22), 3.18 (1 H, t, JH21–H22 ≈ JH21–H20 8.4, H21), 2.43 (1 H, dd, J 19.3, 8.7), 
2.06 (1H, dt, J 19.3, 9.4) 1.97–1.91 (2H, m), 1.83 (1H, m), 1.75–1.49 (7H, m), 1.40–1.28 (5 H, m), 
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1.23 (1H, m), 1.15 (1H, m), 1.06–1.01 (2H, m), 0.88 (3H, s, CH3), 0.87 (3H, s, CH3), 0.75 (1H, m); 
13C NMR (150 MHz, CD3OD): δ 224.0 (C17), 176.7 (C25), 101.8 (C20), 78.5 (C3), 77.8 (C22), 75.4 
(C24), 74.9 (C21), 73.7 (C23), 55.8, 52.6, 45.9, 38.1, 36.8, 36.6, 36.3, 35.1, 32.7, 32.0, 30.2, 29.7, 
22.6, 21.5, 14.1 (CH3), 12.6 (CH3), one carbon overlapping or obscured; LRMS (–ESI) m/z 465 
([M−NH4]−); HRMS (–ESI) m/z calcd. for C25H37O8 ([M−NH4]−) 465.2488, found 465.2488. 
5.4.3.3  Testosterone 17-glucuronide 12, ammonium salt153 
 
Testosterone 17‐glucuronide ammonium salt 12 was prepared from testosterone 13 (1.07 mg, 
3.72 μmol) by method A with a 50% conversion as determined by 400 MHz 1H NMR integration 
of the H17 protons. Re-purification by method B afforded pure testosterone 17‐glucuronide 
ammonium salt 12. 
Rf 0.26 (7:2:1 EtOAc:MeOH:H2O); 1H NMR (400 MHz, CD3OD) δ 5.71 (1H, s, H4), 4.35 (1H, d, JH20-
H21 7.8, H20), 3.83 (1H, t, JH17-H16 8.6, H17), 3.51 (1H, d, JH24-H23 9.6, H24), 3.43 (1H, t, JH23-H24 ≈ JH23-
H22 9.1, H23), 3.36 (1H, t, JH22-H23 ≈ JH22-H21 8.8, H22), 3.20 (1H, t, JH21-H22 ≈ JH21-H20 8.4, H21), 2.48 
(2H, m), 2.33-2.26 (2H, m), 2.12-2.01 (3H, m), 1.90-1.86 (1H, m), 1.75-1.57 (5H, m), 1.53-1.49 
(1H, m), 1.34-1.21 (2H, m), 1.24 (3H, s, CH3), 1.07-0.94 (3H, m), 0.90 (3H, s, CH3); LRMS (–ESI) 
m/z 463 ([M−NH4]–); HRMS (–ESI) m/z calcd. for C25H35O8 ([M−NH4]–) 463.2332, found 
463.2331. 
5.4.3.4  Epitestosterone 17-glucuronide 57, ammonium salt264 
 
Epitestosterone 17‐glucuronide ammonium salt 57 was prepared from epitestosterone 41 (1.00 
mg, 3.45 μmol) by method A with a 28% conversion as determined by 600 MHz 1H NMR 
integration of the H17 protons. Re-purification by method B afforded pure epitestosterone 17‐
glucuronide ammonium salt 57. 
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Rf 0.33 (7:2:1 EtOAc:MeOH:H2O); 1H NMR (600 MHz, CD3OD): δ 5.70 (1H, s, H4), 4.24 (1H, d, 
JH20–H21 7.7, H20), 3.99 (1H, d, JH17–H16 5.5, H17), 3.50–3.43 (2H, m), 3.37 (1H, t, JH22–H23 ≈ JH22–H21 
8.8, H22), 3.18 (1H, t, JH21–H22 ≈ JH21–H20 7.2, H21), 2.52–2.44 (2H, m), 2.32–2.27 (2H, m), 2.10 (1H, 
m), 2.01 (1H, m), 1.93 (1H, m), 1.85–1.68 (4H, m), 1.65–1.56 (3H, m), 1.51 (1H, m), 1.26 (1H, m), 
1.24 (3H, s, CH3), 1.11 (1H, m), 1.02–0.87 (2H, m), 0.78 (3H, s, CH3); LRMS  (–ESI) m/z 463 
([M−NH4]–); HRMS (–ESI) m/z calcd. for C25H35O8 ([M−NH4]–) 463.2332, found 463.2332. 
5.4.3.5  Methyltestosterone 17-glucuronide 61, ammonium salt265 
 
Methyltestosterone 17‐glucuronide ammonium salt 61 was prepared from methyltestosterone 
48 (1.04 mg, 3.43 μmol) by method A with low conversion (<5%) as determined by 400 MHz 1H 
NMR analysis that indicated the absence of the anomeric glucuronide proton. Re-purification by 
method B afforded trace product presumed to be methyltestosterone 17‐glucuronide 
ammonium salt 61. Insufficient product was available for 1H NMR analysis. 
LRMS (–ESI) m/z 477 ([M−NH4]–); HRMS (–ESI) m/z calcd. for C26H37O8 ([M−NH4]–) 477.2488, 
found 477.2488. 
5.4.3.6  Nandrolone 17-glucuronide 38, ammonium salt264 
 
Nandrolone 17‐glucuronide ammonium salt 38 was prepared from nandrolone 37 (0.99 mg, 
3.62 μmol) by method A with 64% conversion as determined by 400 MHz 1H NMR integration of 
the H17 protons. Re-purification by method B afforded pure nandrolone 17‐glucuronide 
ammonium salt 38.  
Rf 0.26 (7:2:1 EtOAc:MeOH:H2O); 1H NMR (400 MHz, CD3OD): δ 5.80 (1H, s, H4), 4.36 (1H, d, 
JH19–H20 8.0, H19), 3.84 (1H, t, JH17–H16  8.6, H17), 3.52 (1H, d, JH23–H22 9.2, H23), 3.43 (1H, t, JH22–H23 
≈ JH22–H21 9.0, H22), 3.36 (1H, t, JH21–H22 ≈ JH21–H20 8.8, H21), 3.20 (1H, t, JH20–H21 ≈ JH20–H19 8.8, H20), 
Chapter 5: Experimental 
149 
 
2.50 (1H, m), 2.39–2.01 (7H, m), 1.89–1.84 (2H, m), 1.69–1.27 (7H, m), 1.12–1.04 (2H, m), 0.92 
(3H, s, H18), 0.89–0.86 (1H, m); LRMS (–ESI) m/z 449 ([M−NH4]–); HRMS (–ESI) m/z calcd. for 
C24H33O8 ([M−NH4]–) 449.2175, found 449.2174. 
5.4.3.7  Boldenone 17-glucuronide 58, ammonium salt266 
 
Boldenone 17‐glucuronide ammonium salt 58 was prepared from boldenone 47 (2.09 mg, 7.31 
μmol) by method A with an 8% conversion as determined by 400 MHz 1H NMR integration of 
the H17 protons. Re-purification by method B afforded pure boldenone 17‐glucuronide 
ammonium salt 58.  
Rf 0.26 (7:2:1 EtOAc:MeOH:H2O); 1H NMR (600 MHz, CD3OD): δ 7.30 (1H, d, JH1−H2 10.1, H1), 6.21 
(1H, d, JH2–H1 10.1, H2), 6.06 (1H, s, H4), 4.34 (1H, d, JH20–H21 7.8, H20), 3.83 (1H, t, JH17–H16 8.6, 
H17), 3.49 (1H, d, JH24–H23 9.7, H24), 3.43 (1H, t, JH23–H24 ≈ JH23–H22 9.2, H23), 3.36 (1H, t, JH22–H23 ≈ 
JH22–H21 8.5, H22), 3.20 (1H, t,  JH21–H22 ≈ JH21–H20 9.0, H21), 2.57 (1H, m), 2.41 (1H, m), 2.13–1.99 
(3H, m), 1.80–1.72 (2H, m), 1.67 (1H, m), 1.59 (1H, m), 1.37–1.22 (8H, m), 1.09 (1H, m), 0.94 
(3H, s, CH3); LRMS (–ESI) m/z 461 ([M−NH4]–);  HRMS (–ESI) m/z calcd. for C25H33O8 ([M−NH4]–
) 461.2175, found 461.2175.  
5.4.3.8  Androstanolone 17-glucuronide 59, ammonium salt267 
 
Androstanolone 17‐glucuronide ammonium salt 59 was prepared from androstanolone 42 
(1.10 mg, 3.80 μmol) by method A with a 13% conversion as determined by 400 MHz 1H NMR 
integration of the H17 protons. Re-purification by method B afforded pure androstanolone 17‐
glucuronide ammonium salt 59.  
Rf 0.52 (7:2:1 EtOAc:MeOH:H2O); 1H NMR (600 MHz, CD3OD): δ 4.35 (1H, d, JH20–H21 7.8, H20), 
3.84 (1H, t, JH17–H16 8.7, H17), 3.49 (1H, d, JH24–H23 9.6, H24), 3.43 (1H, t, JH23–H24 ≈ JH23−H22 9.3, H23), 
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3.36 (1H, t, JH22–H23 ≈ JH22–H21 9.0, H22), 3.19 (1H, t, JH21–H22 ≈ JH21–H20 8.5, H21), 2.48 (1H, m), 2.36 
(1H, t, J = 14.5), 2.23–2.16 (2H, m), 2.12–1.98 (4H, m), 1.73 (1H, m), 1.63–1.41 (5H, m), 1.38–
1.29 (3H, m), 1.27–1.22 (2H, m), 1.06 (3H, s, CH3), 1.03 (1H, m), 0.95–0.89 (1H, m), 0.86 (3H, s, 
CH3), 0.80 (1H, m); LRMS (–ESI) m/z 465 ([M−NH4]–);  HRMS (–ESI) m/z calcd. for C25H37O8 
([M−NH4]–) 465.2488, found 465.2487.  
5.4.3.9  Mesterolone 17-glucuronide 60, ammonium salt264 
 
Mesterolone 17‐glucuronide ammonium salt 60 was prepared from mesterolone 45 (2.05 mg, 
6.72 μmol) by method A with a 12% conversion as determined by 600 MHz 1H NMR integration 
of the H17 protons. Re‐purification by method B afforded pure mesterolone 17‐glucuronide 
ammonium salt 60.  
Rf 0.20 (7:2:1 EtOAc:MeOH:H2O); 1H NMR (600 MHz, CD3OD): δ 4.35 (1H, d, JH21–H22 7.8, H21), 
3.85 (1H, t, JH17–H16 8.6, H17), 3.49 (1H, d, JH25–H24 9.7, H25), 3.43 (1H, t, JH24–H25 ≈  JH24–H23 9.2, 
H24), 3.36 (1H, t, JH23–H24 ≈ JH23–H22 9.0, H23), 3.20 (1H, t, JH22–H23 ≈ JH22–H21 8.5, H22), 2.82 (1H, m), 
2.35 (1H, t, J 14.2), 2.16 (1H, m), 2.09 (1H, m), 2.00–1.96 (2H, m), 1.80 (1H, m), 1.72–1.22 (11H, 
m), 1.17 (3H, s, CH3), 1.07–1.00 (2H, m), 0.91–0.86 (7H, m); LRMS (–ESI) m/z 479 ([M−NH4]–); 
HRMS (–ESI) m/z calcd. for C26H39O8 ([M−NH4]–) 479.2645, found 479.2645. 
5.4.3.10 Dehydroepiandrosterone 3-glucuronide 21, ammonium salt153 
 
Dehydroepiandrosterone 3-glucuronide ammonium salt 21 was prepared from 
dehydroepiandrosterone 19 (1.02 mg, 3.54 μmol) by method A with an 87% conversion as 
determined by 600 MHz 1H NMR integration of the H6 protons. Synthesis by method B (5.03 mg 
of the parent steroid) afforded pure dehydroepiandrosterone 3-glucuronide ammonium salt 21 
as a colourless solid (7.6 mg, 94%).  
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Rf 0.26 (7:2:1 EtOAc:MeOH:H2O); 1H NMR (600 MHz, CD3OD): δ 5.42 (1H, d, JH6-H7 4.9, H6), 4.41 
(1H, d, JH20-H21 7.8, H20), 3.66 (1H, m, H3), 3.56 (1H, d, JH24-H23 9.30, H24), 3.44 (1H, t, JH23-H24 ≈ 
JH23-H22 9.1, H23), 3.40 (1H, t, JH22-H23 ≈ JH22-H21 8.9, H22), 3.19 (1H, t, JH21-H22 ≈ JH21-H20 8.3, H21), 
2.47-2.43 (2H, m), 2.27 (1H, t, J 12.3), 2.14-2.06 (2H, m), 2.00-1.94 (2H, m), 1.89 (1H, m), 1.79 
(1H, m), 1.72-1.51 (6H, m), 1.37-1.32 (1H, m), 1.30-1.25 (1H, m), 1.13 (1H, m), 1.07 (3H, s, CH3), 
1.07-1.02 (1H, m), 0.90 (3H, s, CH3); 13C NMR (150 MHz, CD3OD): δ 223.9 (C17), 176.8 (C25), 
142.2 (C5), 122.1 (C6), 102.2 (C20), 79.4 (C3), 77.9 (C22), 76.4 (C24), 75.0 (C21), 73.8 (C23), 
53.0, 51.8, 39.6, 38.5, 38.0, 36.7, 32.8, 31.9, 30.5, 22.8, 21.5, 19.9 (CH3), 13.9 (CH3), two carbons 
overlapping or obscured; LRMS (–ESI) m/z 463 ([M−NH4]–);  HRMS (–ESI) m/z calcd. for 
C25H35O8 ([M−NH4]–) 463.2332, found 463.2336.  
5.4.3.11 Methandriol 3-glucuronide 56, ammonium salt164 
 
Methandriol 3-glucuronide ammonium salt 56 was prepared from methandriol 44 (1.01 mg, 
3.33 μmol) by method A with a 32% conversion as determined by 600 MHz 1H NMR integration 
of the H6 protons. Synthesis by method B (10.0 mg of the parent steroid) afforded pure 
methandriol 3-glucuronide ammonium salt 56 as a colourless solid (2.4 mg, 15%).  
Rf 0.20 (7:2:1 EtOAc:MeOH:H2O); 1H NMR (600 MHz, CD3OD): δ 5.38 (1H, d, JH6–H7 5.2, H6), 4.40 
(1H, d, JH21–H22 7.8, H21), 3.65 (1H, m, H3), 3.56 (1H, d, JH25–H24 9.4, H25), 3.43 (1H, t, JH24–H25 ≈ 
JH24–H23 9.1, H24), 3.40 (1H, t, JH23–H24 ≈ JH23–H22 8.9, H23), 3.19 (1H, t, JH22–H23 ≈ JH22–H21 8.4, H22), 
2.43 (1H, m), 2.25 (1H, m), 2.02–1.97 (2H, m), 1.90–1.84 (2H, m), 1.68–1.47 (8H, m), 1.35–1.22 
(3H, m), 1.19 (3H, s, CH3), 1.12 (1H, m), 1.05 (3H, s, CH3), 0.95 (1H, m), 0.86 (3H, s, CH3); 13C 
NMR (150 MHz, CD3OD): δ 176.9 (C26), 142.1 (C5), 122.5 (C6), 102.2 (C21), 82.3 (C17), 79.5 
(C3), 77.9 (C23), 76.3 (C25), 75.0 (C22), 73.8 (C24), 52.5, 51.8, 46.6, 39.6, 39.3, 38.6, 38.0, 34.2, 
32.9, 32.8, 30.6, 26.1 (CH3), 24.4, 21.9, 19.9 (CH3), 14.5 (CH3); LRMS (–ESI) m/z 479 ([M−NH4]–);  
HRMS (–ESI) m/z calcd. for C26H39O8 ([M−NH4]–) 479.2645, found 479.2646.  
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5.4.3.12 Pregnenolone 3-glucuronide 69, ammonium salt166 
 
Pregnenolone 3-glucuronide ammonium salt 69 was prepared from pregnenolone 68 (1.04 mg, 
3.28 μmol) by method A with a 36% conversion as determined by 600 MHz 1H NMR integration 
of the H6 protons. Synthesis by method B (5.02 mg of the parent steroid) afforded pure 
pregnenolone 3-glucuronide ammonium salt 69 as a colourless solid (2.0 mg, 26%).  
Rf 0.36 (7:2:1 EtOAc:MeOH:H2O); 1H NMR (600 MHz, CD3OD): δ 5.38 (1H, d, JH6–H7 5.0, H6), 4.41 
(1H, d, JH22–H23 7.8, H22), 3.65 (1H, m, H3), 3.57 (1H, d, JH26–H25 9.2, H26), 3.43 (1H, t, JH25–H26 ≈ 
JH25–H24 9.1, H25), 3.38 (1H, t, JH24–H25 ≈ JH24–H23 8.9, H24), 3.19 (1H, t, JH23–H24 ≈ JH23–H22 8.3, H23), 
2.65 (1H, t, JH17–H16 9.0, H17), 2.44 (1H, m), 2.25 (1H, m), 2.17–2.12 (4H, m), 2.07 (1H, m), 2.02–
1.95 (2H, m), 1.89 (1H, m), 1.72–1.48 (8H, m), 1.26–1.22 (2H, m), 1.13 (1H, m), 1.04–1.00 (4H, 
m), 0.63 (3H, s, CH3); 13C NMR (150 MHz, CD3OD): δ 212.4 (C20), 175.9 (C27), 142.1 (C5), 122.5 
(C6), 102.4 (C22), 79.6 (C3), 77.8 (C24), 76.4 (C26), 75.0 (C23), 73.6 (C25), 64.7 (C17), 58.1, 
51.5, 45.1, 39.9, 39.6, 38.5, 37.9, 33.2, 32.9, 31.6, 30.6, 25.5, 23.8, 22.2, 19.8 (CH3), 13.6 (CH3); 
LRMS (–ESI) m/z 491 ([M−NH4]–);  HRMS (–ESI) m/z calcd. for C27H39O8 ([M−NH4]–) 491.2645, 
found 491.2649. 
5.4.3.13 Androsterone 3-glucuronide 54, ammonium salt93 
 
Androsterone 3-glucuronide ammonium salt 54 was prepared from androsterone 43 (0.96 mg, 
3.31 μmol) by method A with low conversion (<5%) as determined by 400 MHz 1H NMR 
analysis that indicated the absence of the anomeric glucuronide proton. Re-purification by 
method B afforded trace product presumed to be androsterone 3-glucuronide ammonium salt 
54. Insufficient product was available for 1H NMR analysis. 
Rf 0.59 (7:2:1 EtOAc:MeOH:H2O); LRMS (–ESI) m/z 465 ([M−NH4]–);  HRMS (–ESI) m/z calcd. 
for C25H37O8 ([M−NH4]–) 465.2488, found 465.2488.  
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5.4.3.14 Etiocholanolone 3-glucuronide 55, ammonium salt165 
 
Etiocholanolone 3-glucuronide ammonium salt 55 was prepared from etiocholanolone 46 (2.07 
mg, 7.14 μmol) by method A with a 25% conversion as determined by 600 MHz 1H NMR 
integration of the H3 protons. Synthesis by method B (5.10 mg of the parent steroid) afforded 
pure etiocholanolone 3-glucuronide ammonium salt 55 as a colourless solid (1.6 mg, 20%).  
Rf 0.44 (7:2:1 EtOAc:MeOH:H2O); 1H NMR (600 MHz, CD3OD): δ 4.42 (1H, d, JH20–H21 7.8, H20), 
3.81 (1H, m, H3), 3.56 (1H, d, JH24–H23 9.3, H24), 3.43 (1H, t, JH23–H24 ≈ JH23–H22 9.0, H23), 3.40 (1H, t, 
JH22–H23 ≈ JH22–H21 8.9, H22), 3.18 (1H, t, JH21–H22 ≈ JH21–H20 8.3, H21), 2.44 (1H, m), 2.08 (1H, m), 
1.98–1.91 (2H, m), 1.90–1.83 (2H, m), 1.78 (1H, m), 1.66–1.64 (2H, m), 1.59–1.52 (4H, m), 1.46 
(1H, m), 1.41–1.23 (7H, m), 1.04–1.00 (1H, m), 0.98 (3H, s CH3), 0.87 (3H, s, CH3); 13C NMR (150 
MHz, CD3OD): δ 224.2 (C17), 102.1 (C20), 79.5, 77.8, 75.0, 73.7, 65.0, 52.8, 44.7, 43.6, 42.1, 36.8, 
36.3, 36.0, 35.1, 33.0, 28.0, 27.6, 26.5, 23.8, 22.8, 21.2, 14.2, C25 not observed, one carbon 
overlapping or obscured; LRMS (–ESI) m/z 465 ([M−NH4]–);  HRMS (–ESI) m/z calcd. for 
C25H37O8 ([M−NH4]–) 465.2488, found 465.2488. 
5.4.3.15 d5-Etiocholanolone 3-glucuronide 80, ammonium salt164 
 
d5-Etiocholanolone 3-glucuronide ammonium salt 80 was prepared from d5-etiocholanolone 79 
(1.00 mg, 3.38 μmol) by method B as a colourless solid. 
Rf 0.41 (7:2:1 EtOAc:MeOH:H2O); 1H NMR (600 MHz, CD3OD): δ 4.41 (1H, d, JH20–H21 7.8, H20), 
3.55 (1H, d, JH24–H23 9.4, H24), 3.43 (1H, t, JH23–H22 ≈ JH23–H24 9.2, H23), 3.40 (1H, t, JH22–H21 ≈ JH22–H23 
8.8, H22), 3.18 (1H, t, JH21–H20 ≈ JH21–H22 8.5, H21), 2.44 (1H, dd, J 19.4, 8.4), 2.08 (1H, m), 1.98–
1.90 (2H, m), 1.83 (1H, d, J 14.3), 1.76 (1H, m), 1.66 (1H, m), 1.59–1.51 (4H, m), 1.44 (1H, m), 
1.41–1.22 (6H, m), 0.98 (3H, s, CH3), 0.87 (3H, s CH3); LRMS (–ESI) m/z 470 ([M−NH4]–);  HRMS 
(–ESI) m/z calcd. for C25H32D5O8 ([M−NH4]–) 470.2802, found 470.2800. 
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5.4.3.16 Estrone 3-glucuronide 62, ammonium salt268 
 
Estrone 3-glucuronide ammonium salt 62 was prepared from estrone 22 (1.00 mg, 3.68 μmol) 
by method A with a 33% conversion as determined by 600 MHz 1H NMR integration of the H2 
and H4 protons. Re-purification by method B afforded pure estrone 3-glucuronide ammonium 
salt 62. 
Rf 0.38 (7:2:1 EtOAc:MeOH:H2O); 1H NMR (600 MHz, CD3OD): δ 7.19 (1H, d, JH1–H2 8.6, H1), 6.89 
(1H, d, JH2–H1 8.6, H2), 6.84 (1H, s, H4), 4.84 (1H, H19 assigned by COSY cross peak analysis) 3.73 
(1H, d, JH23–H22 9.5, H23), 3.55–3.47 (3H, m), 2.90–2.86 (2H, m), 2.49 (1H, dd, J 18.9, 8.7 Hz), 2.42 
(1H, m), 2.27 (1H, m), 2.14 (1H, m), 2.09–2.01 (2H, m), 1.90 (1H, m), 1.67 (1H, m), 1.62–1.56 
(2H, m), 1.54–1.49 (3H, m), 0.93 (3H, s, CH3); 13C NMR (150 MHz, CD3OD): δ 223.8 (C17), 176.5 
(C24), 157.3 (C3), 138.8, 135.0, 127.2 (C1), 118.1 (C4), 115.7 (C2), 102.8 (C19), 77.9, 76.6 (C23), 
74.8, 73.7, 51.7, 45.4, 39.8, 36.8, 32.8, 30.6, 27.7, 27.1, 22.5, 14.3, one carbon overlapping or 
obscured; LRMS (–ESI) m/z 479 ([M−NH4]–); HRMS (–ESI) m/z calcd. for C26H39O8 ([M−NH4]–) 
479.2645, found 479.2646.  
5.4.3.17 Estradiol 3-glucuronide 136, ammonium salt268, estradiol 17-glucuronide 
137, ammonium salt269 and estradiol 3,17-bis-glucuronide 63, ammonium salt270 
 
A mixture of estradiol 3-glucuronide ammonium salt 136, estradiol 17-glucuronide ammonium 
salt 137 and estradiol 3,17-bis-glucuronide ammonium salt 63 was prepared from estradiol 51 
(1.04 mg, 3.82 μmol) by method A with an 88% conversion as determined by 600 MHz 1H NMR 
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integration of the H1, H2, H4, H17, H19 and H23 protons. Re-purification by method B afforded 
a mixture of estradiol 3-glucuronide ammonium salt 136, estradiol 17-glucuronide ammonium 
salt 137 and estradiol 3,17-bis-glucuronide ammonium salt 63 in a 1.0:1.6:1.1 ratio as 
determined by 600 MHz 1H NMR integration of the H1, H2, H4, H17, H19 and H23 protons. 
Rf 0.38 and 0.00 (7:2:1 EtOAc:MeOH:H2O); 1H NMR (600 MHz, CD3OD, key signals only): δ 7.18 
(d, JH1–H2 8.6, 136 and 63 H1), 7.07 (d, JH1–H2 8.5, 137 H1), 6.88 (d, JH2–H1 8.6, 136 and 63 H2), 
6.81 (s, 136 and 63 H4), 6.53 (d, JH2–H1 8.4, 137 H2), 6.47 (s, 137 H4), 4.82 (136 and 63 H19 
assigned by COSY cross peak analysis), 4.40 (d, JH25–H26 7.8, 137 and 63 H25), 3.91 (t, JH17–H16 8.5, 
137 and 63 H17), 3.72 (d, JH23–H22 9.2, 136 and 63 H23), 3.66 (t, JH17–H16 8.6, 136 H17), 0.89 (s, 
137 and 63 CH3), 0.78 (s, 136 CH3); LRMS (–ESI) m/z 623 (42%) ([M−NH4]–, 63), 447 (100%), 
([M−NH4]–, 136 & 137); HRMS (–ESI) m/z calcd. for C30H39O8 ([M−NH4]– 136) 623.2340, found 
623.2343; calcd. for C24H31O8 ([M−NH4]–, 137 & 63) 447.2019, found 447.2020. 
5.4.3.18 Lithocholic acid 3-glucuronide 64, bis-ammonium salt271 
 
Lithocholic acid 3-glucuronide bis-ammonium salt 64 was prepared from lithocholic acid 49 
(0.99 mg, 2.63 μmol) by method A with a low conversion (<5%) as determined by 400 MHz 1H 
NMR analysis. Purification by Oasis WAX SPE could not be performed due to the presence of the 
carboxylic acid on the parent steroid. 
Rf 0.40 (7:2:1 EtOAc : MeOH : H2O); 1H NMR (400 MHz, CD3OD, key signals only):  4.41 (1H, d, 
JH25-H26 7.6, H25), 3.81 (1H, m, H3); LRMS (-ESI) m/z 573 ([M+Na−NH4]–), 551 ([M−2NH4]–); 
HRMS (-ESI) m/z calcd. for C30H48O9 ([M−2NH4]–) 552.3298, found 552.3295. 
5.4.3.19 Coprostanol 3-glucuronide 66, ammonium salt272 
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Coprostanol 3‐glucuronide ammonium salt 66 was prepared from coprostanol 50 (0.98 mg, 
2.52 μmol) by method A with a low conversion (<5%) as determined by 400 MHz 1H NMR 
analysis that indicated the absence of the anomeric glucuronide proton. Re-purification by 
method B afforded trace product presumed to be coprostanol 3‐glucuronide ammonium salt 66. 
Insufficient material was available for 1H NMR analysis. 
Rf 0.50 (7:2:1 EtOAc:MeOH:H2O); LRMS (–ESI) m/z 563 ([M−NH4]–); HRMS (–ESI) m/z calcd. for 
C33H53O8 ([M−NH4]–) 563.3948, found 563.3948. 
5.4.3.20 Cholest-5-ene-3β,25-diol 3-glucuronide 65, ammonium salt164 
 
Cholest-5-ene-3β,25-diol 3-glucuronide ammonium salt 65 was prepared from cholest-5-ene-
3β,25-diol 52 (1.06 mg, 2.63 μmol) by method A with a 20% conversion as determined by 600 
MHz 1H NMR integration of the H6 protons. Synthesis by method B (10.0 mg of the parent 
steroid) afforded pure cholest-5-ene-3β,25-diol 3-glucuronide ammonium salt 65 as a 
colourless solid (1.2 mg, 8%).  
Rf 0.40 (7:2:1 EtOAc:MeOH:H2O); 1H NMR (600 MHz, CD3OD): δ 5.37 (1H, d, JH6–H7 5.1, H6), 4.40 
(1H, d, JH28–H29 7.8, H28), 3.65 (1H, m, H3), 3.55 (1H, d, JH32–H31 9.5, H32), 3.44 (1H, t, JH31–H32 ≈ 
JH31–H30 9.1, H31), 3.40 (1H, t, JH30–H31 ≈ JH30–H29 8.9, H30), 3.19 (1H, t, JH29–H30 ≈ JH29–H28 8.3, H29), 
2.43 (1H, m), 2.25 (1H, m), 2.05 (1H, m), 1.99–1.96 (2H, m), 1.88–1.85 (2H, m), 1.64–1.60 (2H, 
m), 1.58–1.22 (13H, m), 1.19 (6H, s, 2x CH3), 1.14–1.10 (2H, m), 1.08–1.02 (5H, m), 0.97–0.94 
(4H, m), 0.72 (3H, s, CH3); 13C NMR (150 MHz, CD3OD): δ 176.8 (C33), 141.9 (C5), 122.5 (C6), 
102.1 (C28), 79.3, 77.8, 76.2, 74.9, 73.7, 71.4, 58.1, 57.5, 51.6, 45.2, 43.4, 41.1, 39.5, 38.5, 37.8, 
37.7, 37.0, 33.2, 33.0, 30.5, 29.2, 29.1, 29.0, 25.2, 22.1, 21.8, 19.8, 19.1, 12.2; LRMS (–ESI) m/z 
577 ([M−NH4]–);  HRMS (–ESI) m/z calcd. for C33H53O8 ([M−NH4]–) 577.3740, found 577.3740.  
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5.4.3.21 Furazadrol 17-glucuronide 73, ammonium salt 
 
Furazadrol 17‐glucuronide ammonium salt 73 was prepared from furazadrol 72 (2.78 mg, 8.8 
μmol) by method A with a 22% conversion as determined by 600 MHz 1H NMR integration of 
the H17 protons. Re-purification by method B afforded pure furazadrol 17-glucuronide 
ammonium salt 73 as a colourless solid (1.4 mg, 32%).  
Rf 0.40 (7:2:1 EtOAc : MeOH : H2O); 1H NMR (CD3OD, 600 MHz) δ 8.14 (1H, s, H20), 4.37 (1H, d, 
JH21-H22 7.8, H21), 3.83 (1H, t, JH17-H16 8.6, H17), 3.55 (1H, d, JH25-H24 9.6, H25), 3.46 (1H, t, JH24-H25 ≈ 
JH24-H23 9.3, H24), 3.37 (1H, t, JH23-H24 ≈ JH23-H22 9.0, H23), 3.21 (1H, t, JH22-H23 ≈ JH22-H21 8.4, H22), 
2.68 (1H, dd, JH4a-H5 4.5, JH4a-H4b 17.3, H4a), 2.52 (1H, d, JH1a-H1b 15.5, H1a), 2.30 (1H, dd, JH4b-H5 
12.2, JH4b-H4a 17.4, H4b), 2.12 (1H, d, JH1b-H1a 15.5, H1b), 2.09 (1H, m), 2.03 (1H, m), 1.76 (1H, m), 
1.67-1.58 (4H, m), 1.54-1.41 (3H, m), 1.34-1.23 (3H, m), 1.06-0.89 (3H, m), 0.87 (3H, s, CH3), 
0.77 (3H, s, CH3); 13C NMR (CD3OD, 150 MHz) δ 167.7 (C3), 151.2 (C20), 112.9 (C2), 104.6 (C21), 
101.4, 89.5 (C17), 78.0 (C23), 77.8 (C25), 75.3 (C22), 73.7 (C24), 55.0, 52.1, 44.2, 43.6, 38.8, 
37.6, 36.9, 35.0 (C1), 32.3, 29.9, 27.4 (C4), 24.3, 22.0, 12.0 (CH3), 11.8 (CH3), C26 not observed; 
LRMS (-ESI) m/z 490 ([M−NH4]–); HRMS (-ESI) m/z calc. for ([M−NH4]–) C26H33NO8 490.2441, 
found 490.2442. 
5.4.3.22 Trenazone 17-glucuronide 71, ammonium salt273 
 
Trenazone 17‐glucuronide ammonium salt 71 was prepared from trenazone 70 (1.00 mg, 3.04 
μmol) by method A with a 21% conversion as determined by 600 MHz 1H NMR integration of 
the H17 protons. Synthesis by method B (9.4 mg of the parent steroid) afforded pure trenazone 
17-glucuronide ammonium salt 71 as a colourless solid (5.3 mg, 34%).  
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Rf 0.45 (7:2:1 EtOAc:MeOH:H2O); 1H NMR (600 MHz, CD3OD): δ 5.64 (1H, s, H4), 4.37 (1H, d, 
JH19–H20 7.8, H19), 3.85 (1H, t, JH17–H16 9.0, H17), 3.53 (1H, d, JH23–H22 9.3, H23), 3.42 (1H, t, JH22–H23 ≈ 
JH22–H21 9.1, H22), 3.38 (1H, t, JH21–H22 ≈ JH21–H20 8.9, H21), 3.21 (1H, t, JH20–H21 ≈ JH20–H19 8.5, H20), 
2.95 (1H, m), 2.85 (1H, m), 2.55 (1H, m), 2.47–2.37 (4H, m), 2.31 (1H, m), 2.20 (1H, m), 2.15–
2.09 (2H, m), 1.94 (1H, m), 1.73 (1H, m), 1.64 (1H, m), 1.42–1.34 (2H, m), 1.29–1.16 (2H, m), 
1.02 (3H, s, CH3); 13C NMR (150 MHz, CD3OD): δ 202.5 (C3), 176.8, 160.9, 149.3, 126.2, 122.0, 
104.4, 88.8, 77.8, 76.5, 75.2, 73.7, 52.4, 44.1, 40.4, 38.5, 37.8, 31.7, 29.6, 28.1, 26.7, 24.1, 11.2 
(CH3), one carbon overlapping or obscured; LRMS (–ESI) m/z 447 ([M−NH4]–);  HRMS (–ESI) 
m/z calcd. for C24H31O8 ([M−NH4]–) 447.2019, found 447.2020.  
5.4.4 Synthesis of non-steroidal glucuronides 
5.4.4.1  4-Methylumbelliferone 7-glucuronide 87, ammonium salt274 
 
4-Methylumbelliferone 7-glucuronide ammonium salt 87 was prepared from 4-
methylumbelliferone 86 (2.10 mg, 11.9 μmol) by method A with a 53% conversion as 
determined by 400 MHz 1H NMR integration of the H5 protons. Re-purification by method B 
afforded pure 4-methylumbelliferone 7-glucuronide ammonium salt 87. 
Rf 0.04 (7:2:1 EtOAc:MeOH:H2O); 1H NMR (400 MHz, CD3OD): δ 7.71 (1H, d, JH5–H6 8.8, H5), 7.15 
(1H, dd, JH6–H5 8.8, JH6–H8 2.1, H6), 7.09 (1H, s, H8), 6.20 (1H, s, H3), 5.07 (1H, d, JH12–H13 5.3, H12), 
3.83 (1H, d, JH16–H15 7.7, H16), 3.54 (3H, s, H13, H14, H15), 2.46 (3H, s, H11); LRMS (–ESI) m/z 
351 ([M−NH4]–); HRMS (–ESI) m/z calcd. for ([M−NH4]–) C16H15O9 351.0716, found 351.0717.  
5.4.4.2  Chloramphenicol 3-glucuronide 84, ammonium salt178 
 
Chloramphenicol 3‐glucuronide ammonium salt 84 was prepared from chloramphenicol 83 
(1.09 mg, 3.37 μmol) by method A with an 11% conversion as determined by 800 MHz 1H NMR 
integration of the H3 protons. Re-purification by method B afforded pure chloramphenicol 3‐
glucuronide ammonium salt 84.  
Chapter 5: Experimental 
159 
 
Rf 0.37 (7:2:1 EtOAc:MeOH:H2O); 1H NMR (800 MHz, CD3OD): δ 8.17 (2H, m, H6, H8), 7.70 (2H, 
m, H5, H9), 6.32 (1H, s, H11), 5.28 (1H, d, JH1–H2 3.3, H1), 4.34 (1H, d, JH12–H13 = 7.9 Hz, H12), 
4.28 (1H, m, H2), 4.01 (1H, dd, JH3a–H3b 10.4, JH3a–H2 7.9, H3a), 3.71 (1H, dd, JH3b–H3a 10.4 JH3b–H2 4.8, 
H3b), 3.61 (1H, d, JH16–H15 9.6, H16), 3.46 (1H, t, JH15–H16 ≈ JH15–H14 9.2, H15), 3.43 (1H, t, JH14–H15 ≈ 
JH14–H13 8.8, H14), H13 obscured by CD3OH; 13C NMR (200 MHz, CD3OD, derived from 800 MHz 
HSQC and HMBC spectra): δ 176.8 (C17), 151.2 (C7), 148.2 (C4), 128.4 (C6, C8), 123.8 (C5, C9), 
104.0 (C12), 77.5 (C14), 75.0 (C13), 74.9 (C16), 73.5 (C15), 70.3 (C1), 69.4 (C3), 66.5 (C11), 56.6 
(C2), C10 not observed; LRMS (–ESI) m/z 497 ([M−NH4]–); HRMS (–ESI) m/z calcd. for 
([M−NH4]–) C17H19N2O1135Cl2 497.0366, found 497.0366; C17H19N2O1135Cl37Cl 499.0336, found 
499.0336; C17H19N2O1137Cl2 501.0307, found 501.0317. 
5.5 Synthesis of an 18O-labelled glucuronide 
5.5.1 Model studies 
5.5.1.1  1-O-methyl α-D-glucopyranuronate 108, ammonium salt207 
 
Method 1 (Bobbitt’s salt + 2,6-lutidine): to methyl α-D-glucopyranoside 28 (10 mg, 0.055 mmol) 
and 4-acetamido-2,2,6,6-tetramethylpiperidine-1-oxoammonium tetrafluoroborate 100 (77 mg, 
0.257 mmol) in a mass spectrometry vial was added acetonitrile (103 µL), sodium carbonate 
buffer (ci = 1.0 M, 103 µL, cf = 0.5 M, pH 9) and 2,6-lutidine (18 µL, 0.154 mmol) and the reaction 
stirred on ice. Upon complete consumption of starting material (by TLC, 5 h), the reaction was 
diluted with milliQ water (500 µL) and washed with chloroform (3x 500 µL). The light yellow 
aqueous layer was collected and the solvent removed under reduced pressure at 30 °C to afford 
an orange solid. Proton NMR (400 MHz, D2O) analysis was performed on the crude material to 
reveal the presence of the title compound. No further purification was performed. 
Method 2 (TEMPO+BAIB): to methyl α-D-glucopyranoside 28 (10 mg, 0.055 mmol), TEMPO 95 
(1.6 mg, 0.010 mmol) and iodobenzene diacetate 106 (37 mg, 0.115 mmol) in a mass 
spectrometry vial was added acetonitrile (103 µL) and sodium carbonate buffer (ci = 1.0 M, 103 
µL, cf = 0.5 M, pH 9) and the suspension stirred on ice overnight and allowed to warm to room 
temperature. Upon complete consumption of starting material (by TLC, 24 h) the reaction was 
diluted with milliQ water (500 µL) and washed with chloroform (3x 500 µL). The colourless 
aqueous layer was collected and the solvent removed under reduced pressure at 30 °C to afford 
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a white solid. Proton NMR (400 MHz, D2O) analysis was performed on the crude material to 
reveal the presence of the title compound. No further purification was performed. 
Rf: 0.07 (7:2:1 EtOAc:MeOH:H2O); 1H NMR (400 MHz, D2O): 4.81 (1H, obscured by solvent, H1 
assigned by COSY cross peak analysis), 3.91 (1H, d, JH5-H4 10.1, H5), 3.70 (1H, t, JH3-H4 ≈ JH3-H2 9.3, 
H3), 3.62 (1H, dd, JH2-H3 9.7, JH2-H1 3.7, H2), 3.51 (1H, t, JH4-H5 ≈ JH4-H3 9.5, H4), 3.44 (3H, s, CH3); 13C 
NMR (100 MHz, D2O + CD3OD): 182.4 (C6), 100.4 (C1), 73.9, 73.00, 72.97, 72.1 (C2-C5), 56.2 
(CH3); LRMS (-ESI) m/z: 207 ([M–NH4]–), 189 ([M–H2O–NH4]–). 
5.5.1.2  α-D-Glucopyranuronyl fluoride 29, ammonium salt200 
 
Method 1 (TEMPO+BAIB): to α-D-glucosyl fluoride 28 (10 mg, 0.055 mmol), TEMPO 95 (1.7 mg, 
0.011 mmol) and iodobenzene diacetate 106 (39 mg, 0.121 mmol) in a mass spectrometry vial 
was added acetonitrile (110 µL) and sodium carbonate buffer (ci = 1.0 M, 110 µL, cf = 0.5 M, pH 
9) and the suspension stirred on ice overnight. After 24 h the reaction was diluted with milliQ 
water (500 µL) and washed with chloroform (3x 500 µL). The colourless aqueous layer was 
collected and the solvent removed under reduced pressure at 30 °C to afford a white solid in a 
conversion of 78% as determined by 400 MHz 1H NMR integration of the H1 protons. The crude 
material was dissolved in about 1 mL of milliQ water and loaded on to a small-scale anion 
exchange column (3 cc in total). The column was washed with methanol (10 cv or 5x 2 mL), 
milliQ water (10 cv or 5x 2 mL to remove starting material) and finally eluted with 0.1 M 
aqueous NH4HCO3 until complete elution of the title compound was observed. The solvent was 
removed under reduced pressure at 30 °C to afford a white solid (4.5 mg) with some minor 
aromatic contaminants, likely derived from iodobenzene diacetate. Additional purification was 
performed by azeotroping with toluene and water (3x 2mL, 1:1) to remove acetic acid traces. 
Spectroscopic data matched literature and previously synthesised material (section 5.3.4). 
Method 2 (Bobbitt’s salt + 2,6-lutidine): to α-D-glucosyl fluoride 28 (10 mg, 0.055 mmol) and 4-
acetamido-2,2,6,6-tetramethylpiperidine-1-oxoammonium tetrafluoroborate 100 (82 mg, 0.274 
mmol) in a mass spectrometry vial was added acetonitrile (110 µL), sodium carbonate buffer (ci 
= 1.0 M, 110 µL, cf = 0.5 M, pH 9) and 2,6-lutidine (19 µL, 0.163 mmol) and the reaction stirred 
on ice. After 24 h the reaction was diluted with milliQ water (500 µL) and washed with 
chloroform (3x 500 µL). The pale yellow aqueous layer was collected and the solvent removed 
under reduced pressure at 30 °C to afford an orange solid in a conversion of 56% as determined 
Chapter 5: Experimental 
161 
 
by 400 MHz 1H NMR integration of the H1 protons. The crude material was dissolved in about 1 
mL of milliQ water and loaded on to a small-scale anion exchange column (3 cc in total). The 
column was washed with methanol (10 cv or 5x 2 mL), milliQ water (10 cv or 5x 2 mL to 
remove starting material) and finally eluted with 0.1 M aqueous NH4HCO3 until complete elution 
of the title compound was observed. The solvent was removed under reduced pressure at 30 °C 
to afford a colourless solid (3.6 mg) with some minor aromatic contaminants, likely from 2,6-
lutidine. Spectroscopic data matched literature and previously synthesised material (section 
5.3.4). 
5.5.2 Synthesis of α-D-(18O)-glucuronyl fluoride 111 and 112 
5.5.2.1   (18Ox)α-D-Glucopyranuronyl fluoride 111 & 112, ammonium salt 
 
Method 1 (TEMPO+BAIB): To vacuum-dried α-D-glucosyl fluoride 28 (10 mg, 0.055 mmol), 
TEMPO 95 (1.7 mg, 0.011 mmol) and iodobenzene diacetate 106 (39 mg, 0.121 mmol) in a mass 
spectrometry vial was added dry acetonitrile (110 µL) and sodium carbonate buffer (ci = 1.0 M, 
110 µL, cf = 0.5 M, pH 9; prepared in H218O) and the suspension stirred on ice overnight and 
allowed to warm to room temperature. After 24 h the reaction was diluted with milliQ water 
(500 µL) and washed with chloroform (3x 500 µL). The colourless aqueous layer was collected 
and the solvent removed under reduced pressure at 30 °C to afford a white solid in a conversion 
of 51% as determined by 400 MHz 1H NMR integration of the H1 protons. Purification of the 
material was performed by anion exchange chromatography as per section 5.3.4 to afford the 
title compound as a colourless solid (4.2 mg) with some minor aromatic contaminants, likely 
derived from iodobenzene diacetate. 
Rf: 0.03 (7:2:1 EtOAc:MeOH:H2O); 1H NMR (400 MHz, D2O): 5.72 (1H, d, JH1-F 53.3, JH1-H2 2.4, H1), 
4.09 (1H, d, JH5-H4 10.1, H5), 3.77 (1H, t, JH3-H4 ≈ JH3-H2 9.4, H3), 3.67 (1H, ddd, JH2-F 26.0, JH2-H3 9.8, 
JH2-H1 2.4, H2), 3.59 (1H, t, JH4-H5 ≈ JH4-H3 9.6, H4); LRMS (-ESI) m/z 199 ([M(18O2)–NH4]– 27%), 
197 ([M(18O1)–NH4]– 6%), 179 ([M(18O2)–NH4–HF]– 44%), 177 ([M(18O1)–NH4–HF]– 7%); HRMS 
(-ESI) m/z calcd. for C6H8O4(18O2)F ([M–NH4]–) 199.0618, found 199.0618. 
Method 2 (Bobbitt’s salt + 2,6-lutidine): To vacuum-dried α-D-glucosyl fluoride 28 (10 mg, 0.055 
mmol) and 4-acetamido-2,2,6,6-tetramethylpiperidine-1-oxoammonium tetra-fluoroborate 100 
(82 mg, 0.274 mmol) in a mass spectrometry vial was added dry acetonitrile (110 µL) and 
sodium sodium carbonate buffer (ci = 1.0 M, 110 µL, cf = 0.5 M, pH 9; prepared in H218O) and dry 
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2,6-lutidine (19 µL, 0.163 mmol) and the reaction stirred on ice. After 24 h the reaction was 
diluted with milliQ water (500 µL) and washed with chloroform (3x 500 µL). The pale yellow 
aqueous layer was collected and the solvent removed under reduced pressure at 30 °C to afford 
an orange solid in a conversion of 38% as determined by 400 MHz 1H NMR integration of the H1 
protons. Purification of the material was performed by anion exchange chromatography as per 
section 5.3.4 to afford the title compound as a colourless solid (3.2 mg) with some minor 
aromatic contaminants, likely from 2,6-lutidine. 
Rf: 0.03 (7:2:1 EtOAc:MeOH:H2O); LRMS (-ESI) m/z 199 ([M(18O2)–NH4]–, 3%), 197 ([M(18O1) –
NH4]–, 31%), 195 ([M–NH4]–, 8%), 179 ([M(18O2)–NH4–HF]–, 4%), 177 ([M(18O1)–NH4–HF]–, 
50%), 175 ([M–NH4–HF]–, 11%). 
5.5.3 Synthesis of bis-glucuronides 
5.5.3.1  Epiandrosterone 3-hemisuccinate 115213 
 
To epiandrosterone 35 (200 mg, 0.689 mmol) and succinic anhydride (689 mg, 6.89 mmol, 10 
equiv.) was added dry pyridine (34 mL) and the reaction heated to 120 °C for 21 h. The reaction 
was then allowed to cool to room temperature, diluted with chloroform (120 mL) and washed 
with 2 M hydrochloric acid (6x 40 mL), water (3x 40 mL), and finally brine (10 mL). The organic 
layer was then dried over anhydrous magnesium sulfate, filtered, and the solvent removed 
under reduced pressure at 40 °C to afford the title compound as a pale brown solid (260 mg, 
97%). 
Rf 0.13 (7:3 EtOAc : pet. ether); mp: 216–248 °C (lit.71: 255–257 °C); IR (NaCl): 3300-2400 
(COO-H, br), 2943, 2914, 2852 (C-H), 1730 (C=O, vs), 1473, 1378, 1298, 1164 cm–1; 1H NMR 
(400 MHz, CDCl3): δ 4.76-4.68 (1H, m, H3), 2.69-2.58 (4H, m, H21, H22), 2.47-0.90 (21H, m), 
0.84 (3H, s, CH3), 0.83 (3H, s, CH3), 0.73 (1H, m), COOH not observed; 13C NMR (100 MHz, 
CDCl3): δ 221.6 (C17), 177.8 (C23), 171.8 (C20), 74.2 (C3), 54.4, 51.5, 47.9, 44.8, 36.8, 36.0, 35.8, 
35.2, 34.0, 31.6, 30.9, 29.4, 29.1, 28.4, 27.5, 21.9, 13.9, 12.3, one carbon overlapping or obscured; 
LRMS (-ESI) m/z 389 ([M–H]–); HRMS (-ESI) m/z calcd. for C23H33O5 ([M–H]–) 389.2328, found 
389.2328;  
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5.5.3.2  5α-Androstan-3β,17β-diol 3-hemisuccinate 116275 
 
Epiandrosterone 3-hemisuccinate 115 (20 mg, 0.051 mmol) dissolved in methanol (3 mL) was 
added drop-wise to sodium borohydride (9.8 mg, 0.259 mmol) on ice under an atmosphere of 
nitrogen and the reaction stirred at 4 °C for 1 h. MilliQ water (3 mL) was added and the reaction 
quenched by the addition of 2 M hydrochloric acid until the pH of the solution was ~1-2. The 
suspension was extracted with chloroform (3x 12 mL), then washed with milliQ water (2x 12 
mL) and brine (4 mL). The organic layer was dried over anhydrous magnesium sulphate, 
filtered, and the solvent removed under reduced pressure at 40 °C to afford the title compound 
116 as a colourless solid (20 mg, 99%). 
Rf 0.45 (5:2 EtOAc : pet. ether); mp: 197–230 °C; IR (NaCl): 3300-2400 (COO–H, br), 2933, 2849 
(C-H), 1730 (C=O, vs), 1470, 1355, 1170, 1046, 1004 cm–1; 1H NMR (400 MHz, CD3OD): δ 4.67 
(1H, m, H3), 3.56 (1H, t, JH17-H16 8.6, H17), 2.56 (4H, s, H21, H22), 1.97 (1H, m), 1.84-1.75 (3H, m), 
1.70 (1H, d, 12.4), 1.60-1.20 (11H, m), 1.08-0.85 (5H, m), 0.87 (3H, s, CH3), 0.73 (3H, s, CH3) 0.69 
(1H, m); 13C NMR (100 MHz, CD3OD): δ 176 (C23), 173.7 (C20), 82.5 (C17), 75.3 (C3), 55.9, 52.3, 
46.1, 44.1, 38.02, 37.97, 36.7, 35.1, 32.8, 30.6, 30.4, 29.8, 29.7, 28.5, 24.3, 21.9, 12.7, 11.7, one 
carbon overlapping or obscured; LRMS (-ESI) m/z 391 ([M–H]–); HRMS (-ESI) m/z calcd. for 
C23H35O5 ([M–H]–) 391.2484, found 391.2484. 
5.5.3.3  5α-Androstan-3β,17β-diol 3-hemisuccinate-17-glucuronide 117, bis-
ammonium salt  
 
5α-Androstan-3β,17β-diol 3-hemisuccinate 116 (1.03 mg, 2.61 μmol) and α-D-
glucopyranuronyl fluoride 29 (2.66 mg, 12.5 μmol) were dissolved in tert-butanol (379 μL) and 
sodium phosphate buffer (50 mM, 1.52 mL, pH 7.5). E504G glucuronylsynthase (0.44 mg/mL, 
1.89 mL, final concentration = 0.2 mg/mL) was added and the reaction incubated at 37 °C for 3 
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days. The reaction was subjected to solid-phase extraction (see general method B in section 
5.4.3.2) then the methanolic ammonium hydroxide fraction was collected and concentrated 
down to afford the title compound as a colourless solid.  
Rf 0.37 (7:2:1 EtOAc:MeOH:H2O); 1H NMR (400 MHz, CD3OD): 4.38 (1H, d, JH24-H25 9.2, H24), 3.82 
(1H, t, JH17-H16 7.8, H17), 3.54 (1H, d, JH28-H27 8.2, H28) 3.44-3.37 (2H, m, H27, H26), 3.21 (1H, t, 
JH25-H26 ≈ JH25-H24 8.5, H25), 2.55-2.50 (4H, m, H21, H22), 2.07 (1H, m), 2.00 (1H, d, 11.8), 1.84-
1.78 (2H, m), 1.71 (1H, d, 7.6), 1.66-1.52 (6H, m), 1.46-1.21 (8H, m), 1.08-1.01 (2H, m), 0.97-0.91 
(1H, m), 0.89 (3H, s, CH3), 0.86 (3H, s, CH3), 0.71 (1H, m); LRMS (-ESI) m/z 589 ( [M+Na–2NH4]–
), 567 ([M–2NH4]–); HRMS (-ESI) m/z calcd. for C29H43O11 ([M–2NH4]–) 567.2805, found 
567.2805;  
5.5.3.4  5α-Androstan-3β,17β-diol 119276 
 
To 5α-androstan-3β,17β-diol 3-hemisuccinate 116 (7 mg, 17.8 µmol) dissolved in methanol 
(178 µL) was added lithium hydroxide (21 mg, 0.892 mmol) and the suspension was stirred at 
room temperature for 2 days. The reaction was diluted with milliQ water (1 mL) and acidified to 
pH ~1-2 with 2 M hydrochloric acid. The reaction was extracted with chloroform (3x 2 mL) then 
the organic layer washed with saturated sodium bicarbonate (2x 4 mL) and brine (4 mL). The 
organic layer was collected and the solvent was removed under reduced pressure at 30 °C to 
afford the title compound as a colourless solid (4.8 mg, 92%). 
Rf: 0.80 (7:2:1 EtOAc:MeOH:H2O); mp: 197–230 °C; 1H NMR (400 MHz, CDCl3): 3.63 (1H, t, JH17-
H16 8.6, H17), 3.59 (1H, m, H3), 2.05 (1H, m), 1.81-1.64 (4H, m), 1.59-1.52 (3H, m), 1.46-1.33 (3H, 
m), 1.30-1.20 (5H, m), 1.14-0.84 (5H, m), 0.82 (3H, s, CH3), 0.73 (3H, s, CH3), 0.63 (1H, m), 2x OH 
not observed; LRMS (-ESI) m/z 291 ([M–H]–). 
5.5.3.5  5α-Androstan-3β,17β-diol 3-glucuronide 122, ammonium salt277 
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To epiandrosterone 3-glucuronide 36 (1 mg, 2.14 µmol) in MeOH:H2O (19:1, 200 µL) on ice was 
added sodium borohydride (4 mg, 0.106 mmol) and the reaction stirred on ice for 2 h. The 
reaction was quenched with acetone (1 mL) then the pH adjusted to ~6-7 before the solvent 
was removed under reduced pressure at 30 °C to afford a white solid in a complete conversion 
as determined by 400 MHz 1H NMR analysis to the title compound. Solid-phase extraction was 
then performed on the crude material (see general method B in section 5.4.3.2) to afford the 
title compound as a colourless solid.  
Rf 0.29 (7:2:1 EtOAc:MeOH:H2O); 1H NMR (800 MHz, CD3OD): 4.41 (1H, d, JH20-H21 7.8, H20), 3.77 
(1H, m, H3), 3.56 (1H, d, JH24-H23 8.13, H24), 3.56 (1H, t, JH17-H16 8.5, H17), 3.43 (1H, t, JH23-H24 ≈ JH23-
H22 8.8, H23), 3.38 (1H, t, JH22-H23 ≈ JH22-H21 8.9, H22), 3.17 (1H, t, JH21-H22 ≈ JH21-H20 8.4, H21), 2.20 
(1H, m), 1.98-1.91 (2H, m), 1.83 (1H, m), 1.74-1.68 (2H, m), 1.61-1.49 (2H, m), 1.46-1.21 (7H, 
m), 1.13-1.10 (2H, m), 1.05-1.00 (2H, m), 0.97-0.83 (2H, m), 0.85 (3H s, CH3), 0.72 (3H, s, CH3) 
0.66 (1H, m); 13C NMR (200 MHz, CD3OD derived from an 800 MHz HSQC spectrum): 101.6 
(C20), 82.3 (C17), 78.3 (C3), 77.9 (C23), 76.0 (C24), 74.8 (C21), 73.5 (C22), 55.8, 52.1, 45.8, 38.0, 
37.8, 35.1, 32.7, 30.3, 30.0, 23.9, 21.6, 12.6, 11.4, C10, C13 and C25 not observed, two carbons 
obscured or overlapping; LRMS (-ESI) m/z 467 ([M–NH4]–); HRMS (-ESI) m/z calcd. for 
C25H39O8 ([M–NH4]–) 467.2645, found 467.2659. 
5.5.3.6  5α-Androstan-3β,17β-diol 3,17-bis-glucuronide 123, ammonium salt  
 
5α-androstan-3β,17β-diol 3,17-bis-glucuronide bis-ammonium salt 123 was prepared from 5α-
androstan-3β,17β-diol 3-glucuronide 122 (0.5 mg, 1.07 μmol) by the conversion method (see 
section 5.4.3.1) with a 60% conversion as determined by 800 MHz 1H NMR integration of the 
H17 protons. The sample was then purified by reverse-phase chromatography (30% aqueous 
methanol + 0.5 % ammonium hydroxide) to afford the pure bis-glucuronide 123 as a colourless 
solid. 
Rf 0.08 (7:2:1 EtOAc:MeOH:H2O); 1H NMR (800 MHz, CD3OD): 4.41 (1H, d, JH20-H21 7.7, H20), 4.35 
(1H, d, JH26-H27 7.7, H26), 3.78 (1H, t, JH17-H16 8.6, H17), 3.77 (1H, m, H3), 3.58 (1H, d, JH24-H23 9.8, 
H24), 3.54 (1H, d, JH30-H29 9.8, H30), 3.45-3.42 (2H, m, H23, H29), 3.38-3.36 (2H, m, H22, H28),  
3.20-3.18 (2H, m, H21, H27), 2.06 (1H, m), 1.98-1.90 (2H, m), 1.74-1.48 (7H, m), 1.44-1.17 (6H, 
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m), 1.12 (1H, m), 1.04-0.97 (2H, m), 0.94-0.88 (2H, m), 0.85 (3H, s, CH3), 0.83 (3H, s, CH3), 0.67 
(1H, m); 13C NMR (200 MHz, CD3OD derived from an 800 MHz HSQC spectrum): 101.7 (C20), 
104.3 (C26), 89.5 (C17), 78.7 (C3), 76.2 (C30), 76.1 (C24), 77.7, 74.9, 73.5, 55.8, 52.0, 45.8, 38.7, 
38.3, 37.9, 37.7, 36.6, 35.0 32.5, 30.3, 24.0, 21.4, 12.4, 12.0, C10, C13, C25 and C31 not observed, 
three carbons obscured or overlapping; LRMS (-ESI) m/z 643 ([M–NH4–NH3]–), 467 ([M–NH4–
NH3–C6H8O6]–); HRMS (-ESI) m/z calcd. for C31H47O14 ([M–NH4–NH3]–) 643.2966, found 
643.2964. 
5.5.3.7  Epiandrosterone 3-(18O2)-glucuronide 121, ammonium salt  
 
Epiandrosterone 3-(18O2)-glucuronide ammonium salt 121 was prepared from epiandrosterone 
35 (1.00 mg, 3.44 μmol) and (18O2)-α-D-glucopyranuronyl fluoride 111 (3.7 mg, 1.72 μmol, 5 
eq.) (section 5.5.2.1) by the conversion method (see section 5.4.3.1) with a 90% conversion as 
determined by 800 MHz 1H NMR integration of the H3 protons. Re-purification by method B 
afforded pure epiandrosterone 3-(18O2)-glucuronide ammonium salt 121 as a colourless solid. 
Rf 0.40 (7:2:1 EtOAc:MeOH:H2O); 1H NMR (800 MHz, CD3OD): 4.42 (1H, d, JH20-H21 7.8, H20), 3.76 
(1H, m, H3), 3.56 (1H, d, JH24-H23 9.5, H24), 3.42 (1H, t, JH23-H24 ≈ JH23-H22 9.2, H23), 3.39 (1H, t, JH22-
H23 ≈ JH22-H21 8.9, H22), 3.18 (1H, t, JH21-H22 ≈ JH21-H20 8.4, H21), 2.43 (1H, dd, J 19.6, 8.8), 2.07 (1H, 
dt, J 19.4, 9.4), 1.97-1.90 (2H, m), 1.83 (1H, m), 1.75-1.72 (3H, m), 1.67 (1H, m), 1.61 (1H, m), 
1.56-1.50 (2H, m), 1.39-1.30 (5H, m), 1.22 (1H, m), 1.15 (1H, m), 1.05-1.01 (2H, m), 0.88 (3H, s, 
CH3), 0.87 (3H, s, CH3), 0.74 (1H, m); LRMS (-ESI) m/z 469 ([M(18O2)–NH4]–, 100%), 467 
([M(18O)–NH4]–, 19%); HRMS (+ESI) m/z calcd. for C25H38O1618O2Na ([M–NH3+Na]+) 493.2549, 
found 493.2549. 
5.5.3.8  5α-Androstan-3β,17β-diol 3-(18O2)-glucuronide 120, ammonium salt  
 
To epiandrosterone 3-(18O2)-glucuronide 121 (1 mg, 2.14 µmol) in MeOH:H2O (19:1, 205 µL) on 
ice was added sodium borohydride (4 mg, 0.106 mmol) and the reaction stirred on ice for 2 h. 
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The reaction was quenched with acetone (2 mL) then the pH adjusted to ~6-7 before the 
solvent was removed under reduced pressure at 30 °C to afford a white solid. The material was 
re-dissolved in MeOH:H2O (1:1, 2 mL) and subjected to solid-phase extraction by the conversion 
method (see section 5.4.3.1) to afford a colourless solid. 400 MHz 1H NMR analysis indicated 
that a small amount of starting material (~7%) remained. The sample was re-subjected to the 
same conditions for 1 h and then quenched and purified by solid-phase extraction as above to 
afford the title compound as a colourless solid with complete conversion as determined by 400 
MHz 1H NMR analysis. 
Rf 0.27 (7:2:1 EtOAc:MeOH:H2O); 1H NMR (800 MHz, CD3OD): 4.41 (1H, d, JH20-H21 7.8, H20), 3.77 
(1H, m, H3), 3.56 (1H, t, JH17-H16 8.7, H17), 3.55 (1H, d, JH24-H23 9.2, H24), 3.43 (1H, t, JH23-H24 ≈ JH23-
H22 8.4, H23), 3.40 (1H, t, JH22-H23 ≈ JH22-H21 8.2, H22), 3.17 (1H, t, JH21-H22 ≈ JH21-H20 8.4, H21), 1.99-
1.89 (2H, m), 1.82 (1H, m), 1.75-1.68 (2H, m), 1.60-1.20 (11H, m), 1.13 (1H, m), 1.07-0.87 (4H, 
m), 0.85 (3H, s, CH3), 0.72 (3H, s, CH3), 0.66 (1H, m); LRMS (-ESI) m/z 471 ([M(18O2)–NH4]–, 
91%), 469 ([M(18O1)–NH4]–, 19%); HRMS (-ESI) m/z calcd. for C25H39O1618O2 ([M–NH4]–) 
471.2730, found 471.2733. 
5.5.3.9  5α-Androstan-3β,17β-diol 3(18O2),17-bis-glucuronide 113, ammonium salt 
 
5α-androstan-3β,17β-diol 3(18O2),17-bis-glucuronide bis-ammonium salt 113 was prepared 
from 5α-androstan-3β,17β-diol 3(18O2)-glucuronide ammonium salt 120 (~0.75 mg, 1.16 μmol) 
by method A (see section 5.4.3.1) with a 31% conversion as determined by 800 MHz 1H NMR 
integration of the H17 protons. The sample was purified by C18 SPE by loading the mixture on 
to a pre-conditioned (3 mL MeOH then 9 mL milliQ water) Oasis C18 SPE cartridge (150 mg, 3 
mL) and eluted with 20% aqueous methanol to afford the pure bis-glucuronide as a colourless 
solid. 
Rf 0.00 (7:2:1 EtOAc:MeOH:H2O); 1H NMR (800 MHz, CD3OD): 4.41 (1H, d, JH20-H21 7.8, H20), 4.35 
(1H, d, JH26-H27 7.8, H26), 3.80 (1H, t, JH17-H16 8.6, H17), 3.78 (1H, m, H3), 3.54 (1H, d, JH24-H23 9.5, 
H24), 3.51 (1H, d, JH30-H29 9.7, H30), 3.40-3.36 (4H, m, H23, H29, H22, H28), 3.20-3.16 (2H, m, 
H21, H27), 2.07 (1H, m), 1.98-1.90 (2H, m), 1.74-1.49 (7H, m), 1.44-1.17 (6H, m), 1.12 (1H, m), 
1.03-0.97 (2H, m), 0.95-0.89 (2H, m), 0.85 (3H, s CH3), 0.83 (3H, s, CH3), 0.67 (1H, m); LRMS (-
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ESI) m/z 647 ([M(18O2)–NH4–NH3]–, 12%), 645 ([M(18O1)–NH4]–, 2%), 471 ([M(18O2)–C6H8O6–
NH4–NH3]–, 4%), 469 ([M(18O1)–NH4–NH3–C6H8O6]–, 1%), 323 [(M(18O2)–2NH4)2–, 40%]; HRMS 
(+ESI) m/z calcd. for C31H4716O12(18O2) ([M–NH4]–) 647.3051, found 647.3058. 
5.6 Hydrolysis of the α-D-glucuronyl fluoride 29 
5.6.1 Buffer solutions 
Stock solutions of sodium phosphate (NaPi), MOPS, Tris, and TES buffers at a concentration of 
0.2 M were prepared and adjusted to pH 7.5±0.1.  
5.6.2 Experimental – initial rate experiments without enzyme 
Calibration curves for each buffer were acquired using 10 μM, 50 μM, 100 μM, 500 μM, and 1 
mM fluoride standards (sodium fluoride, NaF; in the relevant buffer) in a temperature-
controlled water bath at 37 °C (figures 53 and 54).  
Hydrolysis experiments for α-D-glucosyl fluoride 28 (FGlc) and α-D-glucuronyl fluoride 29 
(FGlu), each at 1 mM concentration, were performed in 2 mM and 100 mM solutions of the 
above buffers, followed by incubation in a temperature-controlled water bath at 37 °C for 4 h. 
Measurements were carried out every 30 min with the least concentrated fluoride standard 
checked every 2 h for the possibility of drift using a fluoride-selective probe. All hydrolysis 
experiments were carried out in triplicate. Rates of fluoride liberation were obtained from 
linear fits to the first-order rate equation (i.e. equation 31) for the initial region of <10% 
hydrolysis. Results are presented as (mean ± standard error, n = 3; see figures 50 through 52 in 
section 4.5.2 and section 4.5.3). 
𝑑[F]
𝑑𝑡
=
−𝑑[FGlu]
𝑑𝑡
= −𝑘[FGlu] (31) 
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Figure 53: an example calibration curve for fluoride concentration from sodium fluoride (NaF). 
Conditions: NaPi (2 mM, pH 7.5), 37 °C 
 
Figure 54: example linear plots of fluoride concentration against time for the hydrolysis of α-D-
glucuronyl fluoride 29 (FGlu; 1 mM) by sodium phosphate. Conditions: NaPi (2 & 100 mM, pH 
7.5), 37 °C 
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5.7 Effect of tert-butanol on the E504G glucuronylsynthase 
5.7.1 Synthesis of CMO-DHEA 33 & CMO-DHEA 3-glucuronide 34, ammonium salt 
5.7.1.1  Dehydroepiandrosterone O-(carboxymethyloxime) 33153 
 
To dehydroepiandrosterone 19 (500 mg, 1.73 mmol) dissolved in ethanol (25 mL) was added O-
(carboxymethyl)hydroxylamine hemihydrochloride 126 (568 mg, 5.20 mmol) dissolved in 
aqueous sodium hydroxide (2 M, 2.6 mL, 5.20 mmol) and the reaction heated to 80-85 °C with 
vigorous stirring. Upon completion by TLC (4 h) the reaction was cooled to room temperature at 
which point a white precipitate separated from solution. This precipitate was collected by 
vacuum filtration with two additional washings of ethanol (~20 mL), dried, then placed under 
high vacuum overnight to afford the title compound as a colourless solid (364 mg, 58%). 
A further 140 mg (22%) of pure CMO-DHEA 33 was obtained by concentrating the ethanol 
filtrate under reduced pressure at 30 °C then suspending the resulting colourless solid in 
acidified milliQ water (50 mL, pH ~1) and extracting with ethyl acetate (3x 100 mL) with 
sonication. The organic layers were combined and washed with milliQ water (2x 50 mL) then 
the solvent removed under reduced pressure at 30 °C and the resulting colourless solid dried 
under high vacuum overnight to afford a second crop of the title compound (identical by 1H 
NMR) for a combined yield of 80%. 
Rf 0.48 (7:2:1 EtOAc:MeOH:H2O); [α]20D –34.3 (c 1.0, DMSO) [lit.153 [α]23D –36.0 (c 1.0, DMSO)]; 
mp: 203 – 210 °C (decomp.) (lit.153: 215 – 217 °C (decomp.)); 1H NMR (400 MHz, CD3OD): 5.37 
(1H, d, JH6-H7 5.13, H6), 4.49 (2H, s, H20), 3.40 (1H, m, H3), 2.56 (2H, m), 2.28-2.18 (2H, m), 2.10-
2.05 (1H, m), 1.94-1.79 (4H, m), 1.70-1.37 (7H, m), 1.25-1.18 (1H, m), 1.10-1.00 (2H, m), 1.05 
(3H, s, CH3), 0.94 (3H, s , CH3); 13C NMR (200 MHz, CD3OD): 174.5 (C21), 173.7 (C17), 142.4 
(C5), 122.0 (C6), 72.4 (C3), 71.0 (C20), 55.5, 51.9, 45.2, 43.0, 38.5, 37.8, 35.2, 32.6, 32.4, 32.3, 
26.9., 24.2, 21.7, 19.9 (CH3), 17.3 (CH3); LRMS (-ESI) m/z 360 ([M–H]–), 286 ([M–C2H2O3–H]–); 
HRMS (-ESI): calcd. for C21H30NO4 ([M–H]–) 360.2175, found 360.2169. 
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5.7.1.2  Dehydroepiandrosterone O-(carboxymethyloxime) 3-glucuronide 34, 
ammonium salt153 
 
To CMO-DHEA 33 (9.00 mg, 25.0 μmol) dissolved in tert-butanol (3.6 mL) and sodium 
phosphate buffer (28.9 mL, 50 mM, pH 7.5) was added E504G glucuronylsynthase (ci = 7.15 
mg/mL, 1.01 mL, cf = 0.2 mg/mL) and α-D-glucuronyl fluoride 29 (26.5 mg, 0.125 mmol, 5 
equiv.) dissolved in sodium phosphate buffer (2.5 mL, 50 mM) and the reaction incubated at 37 
°C for 2 d without agitation. The reaction was then subjected to solid-phase purification in two 
batches. An Oasis WAX SPE cartridge (500 mg, 6 mL) was pre-conditioned with methanol (6 
mL) and milliQ water (18 mL). The crude reaction was loaded onto the cartridge and washed 
with aqueous formic acid (6 mL, 2% v/v), milliQ water (18 mL), and finally with saturated 
aqueous ammonium hydroxide in methanol (12 mL, 5% v/v). The appropriate fractions were 
combined and the solvent removed under reduced pressure at 30 °C to afford a mixture of CMO-
DHEA 33 and CMO-DHEA 3-glucuronide ammonium salt 34 with an 87% conversion as 
determined by 600 MHz 1H NMR integration of the H6 protons. 
Re-purification via reverse-phase chromatography and eluting with 30% aqueous methanol + 
5% ammonium hydroxide afforded the pure glucuronide ammonium salt 34 as a colourless 
solid (10.2 mg, 76%).  
Rf 0.00 (7:2:1 EtOAc:MeOH:H2O); 1H NMR (800 MHz, CD3OD): 5.43 (1H, d, JH6-H7 4.8, H6), 4.48 
(1H, d, JH22-H23 7.9, H22), 4.37 (2H, s, H20), 3.63 (1H, m, H3), 3.62 (1H, d, JH26-H25 8.0, H26), 3.47-
3.44 (2H, m, H25, H24), 3.23 (1H, t, JH23-H24 ≈ JH23-H22 8.2, H23), 2.65-2.51 (2H, m), 2.46-2.42 (1H, 
m), 2.26 (1H, t, J 11.9), 2.07-2.05 (1H, m), 1.99-1.79 (4H, m), 1.66-1.48 (5H, m), 1.44-1.33 (2H, 
m), 1.24-1.17 (1H, m), 1.12-0.98 (2H, m), 1.04 (3H, s, CH3), 0.93 (3H, s, CH3); LRMS (-ESI) m/z 
536 ([M–NH4]–), 360 ([M–C6H8O6–NH4]–), 286 ([M–C6H8O6–C2H2O3–NH4]–); HRMS (-ESI) m/z 
calcd. for C27H38NO10 ([M–NH4]–) 536.2496, found 536.2496. 
5.7.2 Calibration curve for CMO-DHEA 3-glucuronide 34 
A solution of DHEA O-(carboxymethyl)oxime 3-glucuronide 34 (cf = 0, 50, 100, 200, 500, 1000 
μM) in sodium phosphate buffer (50 mM, pH 7.5) was prepared and subjected to the HPLC assay 
in triplicate. A mobile phase of 45% methanol in ammonium acetate buffer (10 mM, pH 7.5) 
provided a retention time of 2.56 min. The area under the curve was plotted against the 
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concentration to provide the absorption coefficient of 2227.8529 μV sec μM–1 for the 
glucuronide 34 to provide the calibration curve as shown in figure 55. 
 
Figure 55: the calibration curve of CMO-DHEA 3-glucuronide 34 as a function of concentration 
against area under the curve. Conditions: 211 nm, 37 °C, 45:55 MeOH:NH4OAC (10 mM, pH 7.5). 
5.7.3 Effect of tert-butanol v/v% on the initial rate of the E504G synthase 
To a solution of DHEA O-(carboxymethyl)oxime 33 (cf = 2 mM) in sodium phosphate buffer (50 
mM, pH 7.5) was added tert-butanol (cf = 0, 5, 10, 15 and 20% v/v), E504G glucuronylsynthase 
(cf = 0.2 mg/mL) followed by a solution of α-D-glucuronyl fluoride 29 in sodium phosphate 
buffer (cf = 10 mM), and the reaction subjected to the HPLC assay in triplicate at 37 °C. A mobile 
phase of 45% methanol in ammonium acetate buffer (10 mM, pH 7.5) was used. Five injections 
were made to monitor the initial rate of the reactions (<5% conversion) at 15 min intervals. 
Data points that encompassed the initial linear rate were used to generate a graph of initial 
rates against tert-butanol concentration (see figure 32, section 4.4.1).  
5.7.4 Michaelis-Menten kinetics of DHEA O-(carboxymethyl)oxime 33 
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5.7.4.1  At 37 °C, 10% v/v tBuOH 
To a solution of DHEA O-(carboxymethyl)oxime 3-glucuronide 33 (cf = 100, 150, 200, 500, 1000, 
2000, 5000 and 10000 μM) in sodium phosphate buffer (50 mM, pH 7.5) and tert-butanol (cf = 
10% v/v) was added E504G glucuronylsynthase (cf = 0.2 mg/mL) followed by a solution of α-D-
glucuronyl fluoride 29 in sodium phosphate buffer (ci = 5 mM, 200 μL, cf = 1 mM) in triplicate, 
and the reaction subjected to the HPLC assay at 37 °C. A mobile phase of 45% methanol in 
ammonium acetate buffer (10 mM, pH 7.5) was used. Five injections were made to monitor the 
initial rate of the reactions (<10% conversion) at 15 min intervals. Data points that 
encompassed the initial linear rate were used to generate a plot of initial rates against DHEA O-
(carboxymethyl)oxime 3-glucuronide 34 concentration to provide a plot of initial rates against 
CMO-DHEA 33 concentration (see figure 37, section 4.4.3.1). The data was fitted to the 
Michaelis-Menten model (i.e. equation 13) by least-squares fitting using the Kaleidagraph 
program (where [S] represents substrate concentration). Parameters are reported with 
standard error (n = 3). 
𝑣 =
Vmax𝑎
𝐾M+𝑎
=
Vmax[𝑆]
𝐾M+[𝑆]
  (13) 
The first 3 data points at low substrate concentrations were also fitted to the modified 
Michaelis-Menten model (i.e. equation 14 for the case where [S] ≪ KM) to estimate Vmax/KM. 
Parameters are reported with standard error (n = 3) calculated by Microsoft Excel using the 
LINEST function. 
𝑣 =
Vmax𝑎
𝐾M
=
Vmax[𝑆]
𝐾M
  (14) 
Shown in figure 56 is the plot of concentration of CMO-DHEA 3-glucuronide 34 against time in 
minutes for differing concentrations of CMO-DHEA 33. This was used to obtain data points for 
the corresponding plot of initial rates against substrate concentration to fit to the Michaelis-
Menten model as described above. 
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Figure 56: the plots of CMO-DHEA 3-glucuronide 34 concentration against time at 37 °C, 10% 
v/v tert-butanol for differing concentrations of CMO-DHEA 33. Conditions: tert-butanol (10% 
v/v), E504G (0.2 mg/mL), α-D-glucuronyl fluoride 29 (1 mM), NaPi (50 mM, pH 7.5), 37 °C 
5.7.4.2  At 37 °C, 0% v/v tBuOH 
To a solution of DHEA O-(carboxymethyl)oxime 33 (cf = 100, 150, 200, 500, 1000, 1500, 2000 
μM) in sodium phosphate buffer (50 mM, pH 7.5) was added E504G glucuronylsynthase (cf = 0.2 
mg/mL) followed by a solution of α-D-glucuronyl fluoride 29 in sodium phosphate buffer (ci = 5 
mM, 200 μL, cf = 1 mM), and the reaction subjected to the HPLC assay in triplicate at 37 °C. A 
mobile phase of 45% methanol in ammonium acetate buffer (10 mM, pH 7.5) was used. Five 
injections were made to monitor the initial rate of the reactions (<10% conversion) at 15 min 
intervals. Data analysis was performed as for 5.7.4.1 above.  
5.7.4.3  At 21 °C, 10% v/v tBuOH 
To a solution of DHEA O-(carboxymethyl)oxime 33 (cf = 200, 400, 500, 800, 1000, 2000, 5000, 
10000 μM) in sodium phosphate buffer (50 mM, pH 7.5) and tert-butanol (cf = 10% v/v) was 
added E504G glucuronylsynthase (cf = 0.2 mg/mL) followed by a solution of α-D-glucuronyl 
fluoride 29 in sodium phosphate buffer (ci = 5 mM, 200 μL, cf = 1 mM), and the reaction 
subjected to the HPLC assay in triplicate at 21 °C. A mobile phase of 45% methanol in 
ammonium acetate buffer (10 mM, pH 7.5) was used. Five injections were made to monitor the 
initial rate of the reactions (<10% conversion) at 15 min intervals. Data analysis was performed 
as for 5.7.4.1 above. 
0
5 10
5
1 10
6
1.5 10
6
2 10
6
0 20 40 60 80 100 120 140
Effect of the substrate concentration of CMO-DHEA
on the initial rate of the E504G glucuronylsynthase
FGlu (1 mM), E504G (0.2 mg/mL), 
t
BuOH (10% v/v), 37 
o
C
10 mM
5 mM
2 mM
1 mM
500 uM
100 uM
150 uM
200 uM
y = 24514.867 + 15186.674x   R
2
= 0.992 
y = 21247.867 + 11616.611x   R
2
= 0.997 
y = -9899.867 + 6441.679x   R
2
= 0.999 
y = -8688.2 + 3232.44x   R
2
= 0.994 
y = -3336.533 + 1755.312x   R
2
= 0.997 
y = 451.333 + 376.248x   R
2
= 0.997 
y = 1398 + 409.697x   R
2
= 0.995 
y = -1533.933 + 826.943x   R
2
= 0.995 C
o
n
c
e
n
tr
a
ti
o
n
 (

M
)
Time (min)Time ( in) 
C
o
n
ce
n
tr
at
io
n
 o
f 
gl
u
cu
ro
n
id
e 
(µ
M
) 
Initial rates of production of CMO-DHEA 3-glucuronide 
34 for the glucuronylsynthase reaction with various 
substrate concentrations of CMO-DHEA 33 
Chapter 5: Experimental 
175 
 
5.7.4.4  At 21 °C, 0% v/v tBuOH 
To a solution of DHEA O-(carboxymethyl)oxime 33 (cf = 200, 400, 500, 600, 800, 1000, 1200, 
1500 and 2000 μM) in sodium phosphate buffer (50 mM, pH 7.5) was added E504G 
glucuronylsynthase (cf = 0.2 mg/mL) followed by a solution of α-D-glucuronyl fluoride 29 in 
sodium phosphate buffer (ci = 5 mM, 200 μL, cf = 1 mM), and the reaction subjected to the HPLC 
assay in triplicate at 21 °C. A mobile phase of 45% methanol in ammonium acetate buffer (10 
mM, pH 7.5) was used. Five injections were made to monitor the initial rate of the reactions 
(<10% conversion) at 15 min intervals. Data analysis was performed as for 5.7.4.1 above, with 
the exception that the data was fitted to a substrate inhibition model rather than the standard 
Michaelis-Menten model (i.e. equation 20). 
𝑣 =  
𝑉′[𝑆]
𝐾′+[𝑆](1+
[𝑆]
𝐾𝑠𝑖
)
=
𝑉′[𝑆]
𝐾′+[𝑆]+
[𝑆]2
𝐾𝑠𝑖
  (20) 
5.7.5 Size-exclusion chromatography 
The E504G glucuronylsynthase (cf = 0.2 mg/mL, 1 mL injection) was passed through a SuperDex 
200 Prep Grade (120 mL bed volume) size-exclusion column at 4 °C in salted sodium phosphate 
buffer (50 mM, pH 7.5; NaCl, 150 mM) with and without tert-butanol (10% v/v) and monitored 
by UV at 280 nm. Protein standards were prepared as 1 mg/mL solutions in the respective 
buffers. 
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Chapter 6: Example spectra 
Furazadrol 17-glucuronide (600 MHz 1H NMR, CD3OD) 
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Furazadrol 17-glucuronide (150 MHz 13C NMR, CD3OD) 
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5α-Androstan-3β,17β-diol 3,17-bis-glucuronide (600 MHz 1H NMR, CD3OD) 
 
 
Chapter 7: References 
179 
 
Chapter 7: References 
 
(1)  McNaught, A. D. Pure Appl. Chem. 1996, 68 (10). 
(2)  Moss, G. P. Pure Appl. Chem. 1989, 61 (10). 
(3)  Zanger, U. M.; Schwab, M. Pharmacol. Ther. 2013, 138 (1), 103. 
(4)  Dayer, P.; Desmeules, J.; Leemann, T.; Striberni, R. Biochem. Biophys. Res. Commun. 1988, 
152 (1), 411. 
(5)  Vree, T. B.; Wissen, C. P. W. G. M. V.-V. Biopharm. Drug Dispos. 1992, 13 (6), 445. 
(6)  Kirchheiner, J.; Schmidt, H.; Tzvetkov, M.; Keulen, J.-T.; Lötsch, J.; Roots, I.; Brockmöller, J. 
Pharmacogenomics J. 2006, 7 (4), 257. 
(7)  Bowalgaha, K.; Miners, J. O. Br. J. Clin. Pharmacol. 2001, 52 (5), 605. 
(8)  Hum, D. W.; Bélanger, A.; Lévesque, É.; Barbier, O.; Beaulieu, M.; Albert, C.; Vallée, M.; 
Guillemette, C.; Tchernof, A.; Turgeon, D.; Dubois, S. J. Steroid Biochem. Mol. Biol. 1999, 69 
(1–6), 413. 
(9)  Lobo, R. A.; Paul, W. L.; Gentzschein, E.; Serafini, P. C.; Catalino, J. A.; Paulson, R. J.; Horton, 
R. J. Clin. Endocrinol. Metab. 1987, 65 (4), 711. 
(10)  Knights, K. M.; Miners, J. O. Drug Metab. Rev. 2010, 42 (1), 63. 
(11)  Viani, A.; Temellini, A.; Tusini, G.; Pacifici, G. M. Hum. Exp. Toxicol. 1990, 9 (2), 65. 
(12)  Chen, F.; Ritter, J. K.; Wang, M. G.; McBride, O. W.; Lubet, R. A.; Owens, I. S. Biochemistry 
(Mosc.) 1993, 32 (40), 10648. 
(13)  Zamek-Gliszczynski, M. J.; Hoffmaster, K. A.; Nezasa, K.; Tallman, M. N.; Brouwer, K. L. R. 
Eur. J. Pharm. Sci. 2006, 27 (5), 447. 
(14)  Xu, C.; Li, C. Y.-T.; Kong, A.-N. T. Arch. Pharm. Res. 2005, 28 (3), 249. 
(15)  Robertson, E. E.; Rankin, G. O. Pharmacol. Ther. 2006, 109 (3), 399. 
(16)  Yamashiro, W.; Maeda, K.; Hirouchi, M.; Adachi, Y.; Hu, Z.; Sugiyama, Y. Drug Metab. 
Dispos. 2006, 34 (7), 1247. 
(17)  Tukey, R. H.; Strassburg, C. P. Annu. Rev. Pharmacol. Toxicol. 2000, 40 (1), 581. 
(18)  Rowland, A.; Miners, J. O.; Mackenzie, P. I. Int. J. Biochem. Cell Biol. 2013, 45 (6), 1121. 
(19)  Coffman, B. L.; Rios, G. R.; King, C. D.; Tephly, T. R. Drug Metab. Dispos. 1997, 25 (1), 1. 
(20)  Smith, M. T.; Watt, J. A.; Cramond, T. Life Sci. 1990, 47 (6), 579. 
(21)  Bartlett, S. E.; Dodd, P. R.; Smith, M. T. Pharmacol. Toxicol. 1994, 75 (2), 73. 
(22)  Pasternak, G. W.; Bodnar, R. J.; Clark, J. A.; Inturrisi, C. E. Life Sci. 1987, 41 (26), 2845. 
(23)  Osborne, R.; Thompson, P.; Joel, S.; Trew, D.; Patel, N.; Slevin, M. Br. J. Clin. Pharmacol. 
1992, 34 (2), 130. 
(24)  Kilpatrick, G. J.; Smith, T. W. Med. Res. Rev. 2005, 25 (5), 521. 
(25)  Klimas, R.; Mikus, G. Br. J. Anaesth. 2014, 113 (6), 935. 
(26)  Irving, C. C.; Veazey, R. A.; Hill, J. T. Biochim. Biophys. Acta BBA - Nucleic Acids Protein 
Synth. 1969, 179 (1), 189. 
(27)  Wells, D. S.; Janssen, F. W.; Ruelius, H. W. Xenobiotica 1987, 17 (12), 1437. 
(28)  Olson, J. A.; Moon, R. C.; Anders, M. W.; Fenselau, C.; Shane, B. J. Nutr. 1992, 122 (3S), 615. 
(29)  Ritter, J. K. Chem. Biol. Interact. 2000, 129 (1–2), 171. 
(30)  Shipkova, M.; Wieland, E. Clin. Chim. Acta 2005, 358 (1–2), 2. 
(31)  Food and Drug Administration. Guidance for Industry - Safety Testing of Drug Metabolites; 
U.S. Department of Health and Human Services, 2008. 
(32)  Faed, E. M. Drug Metab. Rev. 1984, 15 (5–6), 1213. 
(33)  Bailey, M. J.; Dickinson, R. G. Chem. Biol. Interact. 2003, 145 (2), 117. 
(34)  Roberts, D. M. S.; Magnusson, B. M.; Burczynski, F. J.; Weiss, M. Clin. Pharmacokinet. 2002, 
41 (10), 751. 
(35)  Gugler, R.; Kürten, J. W.; Jensen, C. J.; Klehr, U.; Hartlapp, J. Eur. J. Clin. Pharmacol. 1979, 15 
(5), 341. 
Chapter 7: References 
180 
 
(36)  Alimonti, A.; Gelibter, A.; Pavese, I.; Satta, F.; Cognetti, F.; Ferretti, G.; Rasio, D.; Vecchione, 
A.; Di Palma, M. Cancer Treat. Rev. 2004, 30 (6), 555. 
(37)  Dickinson, R. G.; King, A. R. Life Sci. 2001, 70 (1), 25. 
(38)  Grubb, N.; Weil, A.; Caldwell, J. Biochem. Pharmacol. 1993, 46 (3), 357. 
(39)  Kretz-Rommel, A.; Boelsterli, U. A. Drug Metab. Dispos. 1994, 22 (6), 956. 
(40)  Wang, M.; Dickinson, R. G. Drug Metab. Dispos. 1998, 26 (2), 98. 
(41)  Ware, J. A.; Graf, M. L. M.; Martin, B. M.; Lustberg, L. R.; Pohl, L. R. Chem. Res. Toxicol. 1998, 
11 (3), 164. 
(42)  Kumar, S.; Samuel, K.; Subramanian, R.; Braun, M. P.; Stearns, R. A.; Chiu, S.-H. L.; Evans, D. 
C.; Baillie, T. A. J. Pharmacol. Exp. Ther. 2002, 303 (3), 969. 
(43)  Kenny, J. R.; Maggs, J. L.; Meng, X.; Sinnott, D.; Clarke, S. E.; Park, B. K.; Stachulski, A. V. J. 
Med. Chem. 2004, 47 (11), 2816. 
(44)  Walker, A. M. Arthritis Rheum. 1997, 40 (2), 201. 
(45)  Smith, P. C.; Langendijk, P. N. J.; Bosso, J. A.; Benet, L. Z. Clin. Pharmacol. Ther. 1985, 38 
(2), 121. 
(46)  J. Bailey, M.; Worrall, S.; de Jersey, J.; G. Dickinson, R. Chem. Biol. Interact. 1998, 115 (2), 
153. 
(47)  Srinivasan, K.; Nouri, P.; Kavetskaia, O. Biomed. Chromatogr. 2010, 24 (7), 759. 
(48)  Monrad, R. N.; Errey, J. C.; Barry, C. S.; Iqbal, M.; Meng, X.; Iddon, L.; Perrie, J. A.; Harding, J. 
R.; Wilson, I. D.; Stachulski, A. V.; Davis, B. G. Chem. Sci. 2014, 5 (10), 3789. 
(49)  Shipkova, M.; Beck, H.; Voland, A.; Armstrong, V. W.; Gröne, H.-J.; Oellerich, M.; Wieland, E. 
PROTEOMICS 2004, 4 (9), 2728. 
(50)  Sallustio, B. C.; DeGraaf, Y. C.; Weekley, J. S.; Burcham, P. C. Chem. Res. Toxicol. 2006, 19 
(5), 683. 
(51)  Southwood, H. T.; DeGraaf, Y. C.; Mackenzie, P. I.; Miners, J. O.; Burcham, P. C.; Sallustio, B. 
C. Chem. Res. Toxicol. 2007, 20 (10), 1520. 
(52)  Miyashita, T.; Kimura, K.; Fukami, T.; Nakajima, M.; Yokoi, T. Drug Metab. Dispos. 2014, 42 
(1), 1. 
(53)  Fishman, W. H.; Anlyan, A. J. Science 1947, 106 (2742), 66. 
(54)  Bosslet, K.; Straub, R.; Blumrich, M.; Czech, J.; Gerken, M.; Sperker, B.; Kroemer, H. K.; 
Gesson, J.-P.; Koch, M.; Monneret, C. Cancer Res. 1998, 58 (6), 1195. 
(55)  Kyle, R. A.; Costa, G.; Cooper, M. R.; Ogawa, M.; Silver, R. T.; Glidewell, O.; Holland, J. F. 
Cancer Res. 1973, 33 (5), 956. 
(56)  Young, C. W.; Yagoda, A.; Bittar, E. S.; Smith, S. W.; Grabstald, H.; Whitmore, W. Cancer 
1976, 38 (5), 1887. 
(57)  Wang, S.-M.; Chern, J.-W.; Yeh, M.-Y.; Ng, J. C.; Tung, E.; Roffler, S. R. Cancer Res. 1992, 52 
(16), 4484. 
(58)  Renoux, B.; Legigan, T.; Bensalma, S.; Chadéneau, C.; Muller, J.-M.; Papot, S. Org. Biomol. 
Chem. 2011, 9 (24), 8459. 
(59)  Grinda, M.; Clarhaut, J.; Renoux, B.; Tranoy-Opalinski, I.; Papot, S. MedChemComm 2012, 3 
(1), 68. 
(60)  Legigan, T.; Clarhaut, J.; Renoux, B.; Tranoy-Opalinski, I.; Monvoisin, A.; Berjeaud, J.-M.; 
Guilhot, F.; Papot, S. J. Med. Chem. 2012, 55 (9), 4516. 
(61)  Warnecke, A.; Fichtner, I.; Garmann, D.; Jaehde, U.; Kratz, F. Bioconjug. Chem. 2004, 15 (6), 
1349. 
(62)  Schmid, B.; Chung, D.-E.; Warnecke, A.; Fichtner, I.; Kratz, F. Bioconjug. Chem. 2007, 18 
(3), 702. 
(63)  Kratz, F. J. Controlled Release 2008, 132 (3), 171. 
(64)  Tranoy-Opalinski, I.; Legigan, T.; Barat, R.; Clarhaut, J.; Thomas, M.; Renoux, B.; Papot, S. 
Eur. J. Med. Chem. 2014, 74, 302. 
(65)  Tygart, T. Cycling Investigation | U.S. Anti-Doping Agency (USADA) 
http://cyclinginvestigation.usada.org/ (accessed Oct 21, 2015). 
(66)  Kadi, F. Br. J. Pharmacol. 2008, 154 (3), 522. 
(67)  Kicman, A. T. Br. J. Pharmacol. 2008, 154 (3), 502. 
Chapter 7: References 
181 
 
(68)  Schänzer, W. Clin. Chem. 1996, 42 (7), 1001. 
(69)  Choi, M. H.; Kim, K. R.; Chung, B. C. Steroids 2000, 65 (1), 54. 
(70)  Parr, M. K.; Zapp, J.; Becker, M.; Opfermann, G.; Bartz, U.; Schänzer, W. Steroids 2007, 72 
(6–7), 545. 
(71)  Schänzer, W.; Thevis, M. Mass Spectrom. Rev. 2015, n/a. 
(72)  Graef, V.; Furuya, E.; Nishikaze, O. Clin. Chem. 1977, 23 (3), 532. 
(73)  Mareck, U.; Geyer, H.; Opfermann, G.; Thevis, M.; Schänzer, W. J. Mass Spectrom. 2008, 43 
(7), 877. 
(74)  Kuuranne, T.; Kotiaho, T.; Pedersen-Bjergaard, S.; Einar Rasmussen, K.; Leinonen, A.; 
Westwood, S.; Kostiainen, R. J. Mass Spectrom. 2003, 38 (1), 16. 
(75)  Pu, F.; McKinney, A. R.; Stenhouse, A. M.; Suann, C. J.; McLeod, M. D. J. Chromatogr. B 2004, 
813 (1–2), 241. 
(76)  Strahm, E.; Kohler, I.; Rudaz, S.; Martel, S.; Carrupt, P.-A.; Veuthey, J.-L.; Saugy, M.; Saudan, 
C. J. Chromatogr. A 2008, 1196–1197, 153. 
(77)  Jeon, B. W.; Yoo, H. H.; Jeong, E. S.; Kim, H. J.; Jin, C.; Kim, D. H.; Lee, J. Anal. Bioanal. Chem. 
2011, 401 (4), 1353. 
(78)  Badoud, F.; Grata, E.; Boccard, J.; Guillarme, D.; Veuthey, J.-L.; Rudaz, S.; Saugy, M. Anal. 
Bioanal. Chem. 2011, 400 (2), 503. 
(79)  Jiménez Girón, A.; Deventer, K.; Roels, K.; Van Eenoo, P. Anal. Chim. Acta 2012, 721, 137. 
(80)  Balcells, G.; Pozo, O. J.; Esquivel, A.; Kotronoulas, A.; Joglar, J.; Segura, J.; Ventura, R. J. 
Chromatogr. A 2015, 1389, 65. 
(81)  Thevis, M.; Schänzer, W. Anal. Bioanal. Chem. 2007, 388 (7), 1351. 
(82)  Mackay, L. G.; Kazlauskas, R. Anal. Bioanal. Chem. 2011, 401 (2), 483. 
(83)  Parr, M. K.; Schänzer, W. J. Steroid Biochem. Mol. Biol. 2010, 121 (3–5), 528. 
(84)  Koenigs, W.; Knorr, E. Berichte Dtsch. Chem. Ges. 1901, 34 (1), 957. 
(85)  Fischer, E.; Armstrong, E. F. Berichte Dtsch. Chem. Ges. 1901, 34 (2), 2885. 
(86)  Schapiro, E. Biochem. J. 1939, 33 (3), 385. 
(87)  Goebel, W. F.; Babers, F. H. J. Biol. Chem. 1935, 111 (2), 347. 
(88)  Bollenback, G. N.; Long, J. W.; Benjamin, D. G.; Lindquist, J. A. J. Am. Chem. Soc. 1955, 77 
(12), 3310. 
(89)  Bernstein, S.; Conrow, R. B. J. Org. Chem. 1971, 36 (7), 863. 
(90)  Ramu, K.; Baker, J. K. J. Med. Chem. 1995, 38 (11), 1911. 
(91)  Wallace, J. E.; Schroeder, L. R. J. Chem. Soc. Perkin Trans. 2 1977, No. 6, 795. 
(92)  Brown, R. T.; Carter, N. K.; Lumbard, K. W.; Scheinmann, F. Tetrahedron Lett. 1995, 36 
(47), 8661. 
(93)  Harding, J. R.; King, C. D.; Perrie, J. A.; Sinnott, D.; Stachulski, A. V. Org. Biomol. Chem. 2005, 
3 (8), 1501. 
(94)  Stachulski, A. V.; Meng, X. Nat. Prod. Rep. 2013, 30 (6), 806. 
(95)  Dodge, J. A.; Lugar, C. W.; Cho, S.; Osborne, J. J.; Phillips, D. L.; Glasebrook, A. L.; Frolik, C. A. 
Bioorg. Med. Chem. Lett. 1997, 7 (8), 993. 
(96)  Senn-Bilfinger, J.; Ferguson, J. R.; Holmes, M. A.; Lumbard, K. W.; Huber, R.; Zech, K.; 
Hummel, R.-P.; Zimmermann, P. J. Tetrahedron Lett. 2006, 47 (19), 3321. 
(97)  Brown, R. T.; Carter, N. E.; Mayalarp, S. P.; Scheinmann, F. Tetrahedron 2000, 56 (38), 
7591. 
(98)  O’Neill, P. M.; Scheinmann, F.; Stachulski, A. V.; Maggs, J. L.; Park, B. K. J. Med. Chem. 2001, 
44 (9), 1467. 
(99)  Engstrom, K. M.; Henry, R. F.; Marsden, I. Tetrahedron Lett. 2007, 48 (8), 1359. 
(100)  Tietze, L. F.; Schuster, H. J.; Schmuck, K.; Schuberth, I.; Alves, F. Bioorg. Med. Chem. 2008, 
16 (12), 6312. 
(101)  Schmidt, R. R.; Toepfer, A. Tetrahedron Lett. 1991, 32 (28), 3353. 
(102)  Desai, R. N.; Blackwell, L. F. Synlett 2003, No. 13, 1981. 
(103)  Müller, T.; Schneider, R.; Schmidt, R. R. Tetrahedron Lett. 1994, 35 (27), 4763. 
(104)  Wulff, G.; Röhle, G. Angew. Chem. Int. Ed. Engl. 1974, 13 (3), 157. 
(105)  Schmidt, R. R. Angew. Chem. Int. Ed. Engl. 1986, 25 (3), 212. 
Chapter 7: References 
182 
 
(106)  Stachulski, A. V.; Jenkins, G. V. Nat. Prod. Rep. 1998, 15 (2), 173. 
(107)  Zhu, X.; Schmidt, R. R. Angew. Chem. Int. Ed. 2009, 48 (11), 1900. 
(108)  Kuuranne, T.; Kurkela, M.; Thevis, M.; Schänzer, W.; Finel, M.; Kostiainen, R. Drug Metab. 
Dispos. 2003, 31 (9), 1117. 
(109)  Khymenets, O.; Joglar, J.; Clapés, P.; Parella, T.; Covas, M.-I.; de la Torre, R. Adv. Synth. 
Catal. 2006, 348 (15), 2155. 
(110)  Jäntti, S. E.; Kiriazis, A.; Reinilä, R. R.; Kostiainen, R. K.; Ketola, R. A. Steroids 2007, 72 (3), 
287. 
(111)  Hintikka, L.; Kuuranne, T.; Aitio, O.; Thevis, M.; Schänzer, W.; Kostiainen, R. Steroids 2008, 
73 (3), 257. 
(112)  Pallmann, T.; Jonas, U.; Wagner, M.; Thevis, M.; Kaeferstein, H.; Rothschild, M. A.; Bender, 
K. Eur. J. Pharm. Sci. 2010, 39 (4), 233. 
(113)  Chimalakonda, K. C.; Bratton, S. M.; Le, V.-H.; Yiew, K. H.; Dineva, A.; Moran, C. L.; James, L. 
P.; Moran, J. H.; Radominska-Pandya, A. Drug Metab. Dispos. 2011, 39 (10), 1967. 
(114)  Fan, J.; Brown, S. M.; Tu, Z.; Kharasch, E. D. Bioconjug. Chem. 2011, 22 (4), 752. 
(115)  Shoda, T.; Fukuhara, K.; Goda, Y.; Okuda, H. Drug Test. Anal. 2011, 3 (9), 594. 
(116)  Uldam, H. K.; Juhl, M.; Pedersen, H.; Dalgaard, L. Drug Metab. Dispos. 2011, 39 (12), 2264. 
(117)  Grisshammer, R.; Tateu, C. G. Q. Rev. Biophys. 1995, 28 (3), 315. 
(118)  Tate, C. G. FEBS Lett. 2001, 504 (3), 94. 
(119)  Loll, P. J. J. Struct. Biol. 2003, 142 (1), 144. 
(120)  Grisshammer, R. Curr. Opin. Biotechnol. 2006, 17 (4), 337. 
(121)  Wagner, S.; Bader, M. L.; Drew, D.; de Gier, J.-W. Trends Biotechnol. 2006, 24 (8), 364. 
(122)  Kurkela, M.; Garcı́a-Horsman, J. A.; Luukkanen, L.; Mörsky, S.; Taskinen, J.; Baumann, M.; 
Kostiainen, R.; Hirvonen, J.; Finel, M. J. Biol. Chem. 2003, 278 (6), 3536. 
(123)  Uridine 5′-diphosphoglucuronic acid trisodium salt 98-100% | Sigma-Aldrich 
http://www.sigmaaldrich.com/catalog/product/sigma/u6751?lang=en&region=AU 
(accessed Nov 12, 2015). 
(124)  Miners, J. O.; Mackenzie, P. I.; Knights, K. M. Drug Metab. Rev. 2010, 42 (1), 196. 
(125)  Wilkinson, S. M.; Liew, C. W.; Mackay, J. P.; Salleh, H. M.; Withers, S. G.; McLeod, M. D. Org. 
Lett. 2008, 10 (8), 1585. 
(126)  Smith, E. E. B.; Mills, G. T. Biochem. J. 1950, 47 (4), xlix. 
(127)  Mills, G. T. Biochem. J. 1948, 43 (1), 125. 
(128)  Buehler, H. J.; Katzman, P. A.; Doisy, P. P.; Doisy, E. A. Exp. Biol. Med. 1949, 72 (2), 297. 
(129)  Dodgson, K. S.; Lewis, J. I. M.; Spencer, B. Biochem. J. 1953, 55 (2), 253. 
(130)  Billett, F. Biochem. J. 1954, 57 (1), 159. 
(131)  Zechel, D. L.; Withers, S. G. Acc. Chem. Res. 2000, 33 (1), 11. 
(132)  Sinnott, M. L. Chem. Rev. 1990, 90 (7), 1171. 
(133)  Ly, H. D.; Withers, S. G. Annu. Rev. Biochem. 1999, 68 (1), 487. 
(134)  Liang, W.-J.; Wilson, K. J.; Xie, H.; Knol, J.; Suzuki, S. ’ichi; Rutherford, N. G.; Henderson, P. J. 
F.; Jefferson, R. A. J. Bacteriol. 2005, 187 (7), 2377. 
(135)  Johansson, E.; Hedbys, L.; Larsson, P.-O.; Mosbach, K.; Gunnarsson, A.; Svensson, S. 
Biotechnol. Lett. 1986, 8 (6), 421. 
(136)  Ajisaka, K.; Nishida, H.; Fujimoto, H. Biotechnol. Lett. 1987, 9 (4), 243. 
(137)  Wong, C.-H.; Halcomb, R. L.; Ichikawa, Y.; Kajimoto, T. Angew. Chem. Int. Ed. Engl. 1995, 34 
(5), 521. 
(138)  Baisch, G.; Öhrlein, R. Angew. Chem. Int. Ed. Engl. 1996, 35 (16), 1812. 
(139)  Prade, H.; Mackenzie, L. F.; Withers, S. G. Carbohydr. Res. 1997, 305 (3–4), 371. 
(140)  Mackenzie, L. F.; Wang, Q.; Warren, R. A. J.; Withers, S. G. J. Am. Chem. Soc. 1998, 120 (22), 
5583. 
(141)  Nashiru, O.; Zechel, D. L.; Stoll, D.; Mohammadzadeh, T.; Warren, R. A. J.; Withers, S. G. 
Angew. Chem. 2001, 113 (2), 431. 
(142)  Tolborg, J. F.; Petersen, L.; Jensen, K. J.; Mayer, C.; Jakeman, D. L.; Warren, R. A. J.; Withers, 
S. G. J. Org. Chem. 2002, 67 (12), 4143. 
(143)  Jahn, M.; Marles, J.; Warren, R. A. J.; Withers, S. G. Angew. Chem. Int. Ed. 2003, 42 (3), 352. 
Chapter 7: References 
183 
 
(144)  Vaughan, M. D.; Johnson, K.; DeFrees, S.; Tang, X.; Warren, R. A. J.; Withers, S. G. J. Am. 
Chem. Soc. 2006, 128 (19), 6300. 
(145)  Yang, M.; Davies, G. J.; Davis, B. G. Angew. Chem. 2007, 119 (21), 3959. 
(146)  Wada, J.; Honda, Y.; Nagae, M.; Kato, R.; Wakatsuki, S.; Katayama, T.; Taniguchi, H.; 
Kumagai, H.; Kitaoka, M.; Yamamoto, K. FEBS Lett. 2008, 582 (27), 3739. 
(147)  Blanksby, S. J.; Ellison, G. B. Acc. Chem. Res. 2003, 36 (4), 255. 
(148)  Williams, S. J.; Withers, S. G. Carbohydr. Res. 2000, 327 (1–2), 27. 
(149)  Wong, A. W.; He, S.; Grubb, J. H.; Sly, W. S.; Withers, S. G. J. Biol. Chem. 1998, 273 (51), 
34057. 
(150)  Chang, D.-E.; Smalley, D. J.; Tucker, D. L.; Leatham, M. P.; Norris, W. E.; Stevenson, S. J.; 
Anderson, A. B.; Grissom, J. E.; Laux, D. C.; Cohen, P. S.; Conway, T. Proc. Natl. Acad. Sci. U. 
S. A. 2004, 101 (19), 7427. 
(151)  Hoskins, L. C.; Agustines, M.; McKee, W. B.; Boulding, E. T.; Kriaris, M.; Niedermeyer, G. J. 
Clin. Invest. 1985, 75 (3), 944. 
(152)  Hoskins, L. C.; Boulding, E. T. J. Clin. Invest. 1981, 67 (1), 163. 
(153)  Wilkinson, S. M.; Watson, M. A.; Willis, A. C.; McLeod, M. D. J. Org. Chem. 2011, 76 (7), 
1992. 
(154)  Kim, D.; Jin, Y.; Jung, E.; Han, M.; Kobashi, K. Biol. Pharm. Bull. 1995, 18 (9), 1184. 
(155)  Wilkinson, S. M. Experimental and Kinetic Studies of the Escherichia coli 
Glucuronylsynthase: An Engineered Enzyme for the Synthesis of Glucuronides. Doctor of 
Philosophy, The Australian National University: Canberra, ACT, 2010. 
(156)  Banait, N. S.; Jencks, W. P. J. Am. Chem. Soc. 1991, 113 (21), 7958. 
(157)  Murby, J. Certified Reference Materials for accuracy in longitudinal monitoring for 
testosterone abuse https://www.wada-ama.org/en/resources/science-
medicine/certified-reference-materials-for-accuracy-in-longitudinal-monitoring-for 
(accessed Oct 28, 2015). 
(158)  Kramer, E. B.; Farabaugh, P. J. RNA 2007, 13 (1), 87. 
(159)  Harris, R. P.; Kilby, P. M. Curr. Opin. Biotechnol. 2014, 30, 45. 
(160)  Nielen, M. W. F.; Bovee, T. F. H.; van Engelen, M. C.; Rutgers, P.; Hamers, A. R. M.; van Rhijn, 
J. (Hans) A.; Hoogenboom, L. (Ron) A. P. Anal. Chem. 2006, 78 (2), 424. 
(161)  Cavalcanti, G. de A.; Leal, F. D.; Garrido, B. C.; Padilha, M. C.; Neto, F. R. de A. Steroids 2013, 
78 (2), 228. 
(162)  Joseph, J.; Parr, M. Curr. Neuropharmacol. 2015, 13 (1), 89. 
(163)  Parr, M. K.; Gütschow, M.; Daniels, J.; Opfermann, G.; Thevis, M.; Schänzer, W. Steroids 
2009, 74 (3), 322. 
(164)  Ma, P.; Kanizaj, N.; Chan, S.-A.; Ollis, D. L.; McLeod, M. D. Org. Biomol. Chem. 2014, 12 (32), 
6208. 
(165)  Becker, J. F. Biochim. Biophys. Acta BBA - Gen. Subj. 1965, 100 (2), 574. 
(166)  Wotiz, H. H.; Smakula, E.; Lichtin, N. N.; Leftin, J. H. J. Am. Chem. Soc. 1959, 81 (7), 1704. 
(167)  Yoshimura, H.; Oguri, K.; Tsukamoto, H. Tetrahedron Lett. 1968, 9 (4), 483. 
(168)  Rukhman, I.; Yudovich, L.; Nisnevich, G.; Gutman, A. L. Tetrahedron 2001, 57 (6), 1083. 
(169)  Scheinmann, F.; Stachulski, A.; Ferguson, J.; Law, J. Process for Making Morphine-6-
Glucuronide and Its Analogues Using Haloglucuronate Ester Intermediates. WO0078764 
(A1), December 28, 2000. 
(170)  Mannens, G. S. J.; Snel, C. a. W.; Hendrickx, J.; Verhaeghe, T.; Jeune, L. L.; Bode, W.; 
Beijsterveldt, L. van; Lavrijsen, K.; Leempoels, J.; Osselaer, N. V.; Peer, A. V.; Meuldermans, 
W. Drug Metab. Dispos. 2002, 30 (5), 553. 
(171)  Brown, R. T.; Carter, N. E.; Scheinmann, F.; Turner, N. J. Tetrahedron Lett. 1995, 36 (7), 
1117. 
(172)  Spyridaki, M.-H.; Kiousi, P.; Vonaparti, A.; Valavani, P.; Zonaras, V.; Zahariou, M.; Sianos, E.; 
Tsoupras, G.; Georgakopoulos, C. Anal. Chim. Acta 2006, 573–574, 242. 
(173)  SUHRLAND LG; WEISBERGER AS. Arch. Intern. Med. 1963, 112 (5), 747. 
(174)  Bogusz, M. J.; Hassan, H.; Al-Enazi, E.; Ibrahim, Z.; Al-Tufail, M. J. Chromatogr. B 2004, 807 
(2), 343. 
Chapter 7: References 
184 
 
(175)  Ferguson, J.; Baxter, A.; Young, P.; Kennedy, G.; Elliott, C.; Weigel, S.; Gatermann, R.; 
Ashwin, H.; Stead, S.; Sharman, M. Anal. Chim. Acta 2005, 529 (1–2), 109. 
(176)  Fedeniuk, R. W.; Mizuno, M.; Neiser, C.; O’Byrne, C. J. Chromatogr. B 2015, 991, 68. 
(177)  Glazko, A. J.; Dill, W. A.; Rebstock, M. C. J. Biol. Chem. 1950, 183 (2), 679. 
(178)  Chen, M.; Howe, D.; Leduc, B.; Kerr, S.; Williams, D. A. Xenobiotica 2007, 37 (9), 954. 
(179)  Chen, M.; LeDuc, B.; Kerr, S.; Howe, D.; Williams, D. A. Drug Metab. Dispos. 2010, 38 (3), 
368. 
(180)  Pallante, S. L.; Stogniew, M.; Colvin, M.; Liberato, D. J. Anal. Chem. 1982, 54 (14), 2612. 
(181)  Nagy, N.; Kuipers, H. F.; Frymoyer, A. R.; Ishak, H. D.; Bollyky, J. B.; Wight, T. N.; Bollyky, P. 
L. Front. Immunol. 2015, 6. 
(182)  Vigetti, D.; Rizzi, M.; Viola, M.; Karousou, E.; Genasetti, A.; Clerici, M.; Bartolini, B.; Hascall, 
V. C.; Luca, G. D.; Passi, A. Glycobiology 2009, 19 (5), 537. 
(183)  Uchakina, O. N.; Ban, H.; McKallip, R. J. Leuk. Res. 2013, 37 (10), 1294. 
(184)  Kultti, A.; Pasonen-Seppänen, S.; Jauhiainen, M.; Rilla, K. J.; Kärnä, R.; Pyöriä, E.; Tammi, R. 
H.; Tammi, M. I. Exp. Cell Res. 2009, 315 (11), 1914. 
(185)  Edward, M.; Quinn, J. a.; Pasonen-Seppänen, S. m.; McCann, B. a.; Tammi, R. h. Br. J. 
Dermatol. 2010, 162 (6), 1224. 
(186)  Zenser, T. V.; Lakshmi, V. M.; Davis, B. B. Drug Metab. Dispos. 1999, 27 (9), 1064. 
(187)  Mano, Y.; Usui, T.; Kamimura, H. Biopharm. Drug Dispos. 2006, 27 (1), 1. 
(188)  López-López, M.; Balbuzano-Deus, A.; Rodríguez-Domínguez, J.; Hernández, M.; Villalobo, 
A.; Reyes, Y.; Kirsch, G. Synlett 2007, 2007 (4), 649. 
(189)  Park, S.; Shin, I. Org. Lett. 2007, 9 (4), 619. 
(190)  Schänzer, W.; Guddat, S.; Thomas, A.; Opfermann, G.; Geyer, H.; Thevis, M. Drug Test. Anal. 
2013, 5 (11–12), 810. 
(191)  Geisslinger, G.; Dietzel, K.; Loew, D.; Schuster, O.; Rau, G.; Lachmann, G.; Brune, K. J. 
Chromatogr. B. Biomed. Sci. App. 1989, 491, 139. 
(192)  Adams, S. S. J. Clin. Pharmacol. 1992, 32 (4), 317. 
(193)  Johnson, D. W.; Phillipou, G.; Seamark, R. F. J. Steroid Biochem. 1981, 14 (8), 793. 
(194)  Bong-Chul, C.; Mallamo, J. P.; Juniewicz, P. E.; Shackleton, C. H. L. Steroids 1992, 57 (11), 
530. 
(195)  Sanaullah; Bowers, L. D. J. Steroid Biochem. Mol. Biol. 1996, 58 (2), 225. 
(196)  Wudy, S. A. Steroids 1990, 55 (10), 463. 
(197)  Dehennin, L.; Reiffsteck, A.; Scholler, R. Biol. Mass Spectrom. 1980, 7 (11–12), 493. 
(198)  Björkhem, I.; Blomstrand, R.; Svensson, L.; Tietz, F.; Carlström, K. Clin. Chim. Acta 1975, 62 
(3), 385. 
(199)  Brun, E.; Brumer, H.; MacKenzie, L. F.; Withers, S. G.; McIntosh, L. P. J. Biomol. NMR 2001, 
21 (1), 67. 
(200)  Heeres, A.; van Doren, H. A.; Gotlieb, K. F.; Bleeker, I. P. Carbohydr. Res. 1997, 299 (4), 221. 
(201)  Lucio Anelli, P.; Biffi, C.; Montanari, F.; Quici, S. J. Org. Chem. 1987, 52 (12), 2559. 
(202)  Mercadante, M. A.; Kelly, C. B.; Bobbitt, J. M.; Tilley, L. J.; Leadbeater, N. E. Nat. Protoc. 
2013, 8 (4), 666. 
(203)  de Nooy, A. E. J.; Besemer, A. C.; van Bekkum, H. Synthesis 1996, No. 10, 1153. 
(204)  Golubev, V. A.; Rozantsev, É. G.; Neiman, M. B. Bull. Acad. Sci. USSR Div. Chem. Sci. 1965, 14 
(11), 1898. 
(205)  Golubev, V. A.; Borislavskii, V. N.; Aleksandrov, A. L. Bull. Acad. Sci. USSR Div. Chem. Sci. 
1977, 26 (9), 1874. 
(206)  Semmelhack, M. F.; Schmid, C. R.; Cortés, D. A. Tetrahedron Lett. 1986, 27 (10), 1119. 
(207)  de Nooy, A. E. J.; Besemer, A. C.; van Bekkum, H. Tetrahedron 1995, 51 (29), 8023. 
(208)  Ma, Z.; Bobbitt, J. M. J. Org. Chem. 1991, 56 (21), 6110. 
(209)  Bailey, W. F.; Bobbitt, J. M.; Wiberg, K. B. J. Org. Chem. 2007, 72 (12), 4504. 
(210)  Epp, J. B.; Widlanski, T. S. J. Org. Chem. 1999, 64 (1), 293. 
(211)  Breton, T.; Bashiardes, G.; Léger, J.-M.; Kokoh, K. B. Eur. J. Org. Chem. 2007, 2007 (10), 
1567. 
Chapter 7: References 
185 
 
(212)  De Mico, A.; Margarita, R.; Parlanti, L.; Vescovi, A.; Piancatelli, G. J. Org. Chem. 1997, 62 
(20), 6974. 
(213)  Jao, S.-C.; Chen, J.; Yang, K.; Li, W.-S. Bioorg. Med. Chem. 2006, 14 (2), 304. 
(214)  Pearson, R. G. J. Am. Chem. Soc. 1963, 85 (22), 3533. 
(215)  Fabregat, A.; Pozo, O. J.; Marcos, J.; Segura, J.; Ventura, R. Anal. Chem. 2013, 85 (10), 5005. 
(216)  Bogusz, M. J.; Maier, R.-D.; Krüger, K. D.; Webb, K. S.; Romeril, J.; Miller, M. L. J. Chromatogr. 
A 1999, 844 (1–2), 409. 
(217)  Gabelica, V.; Pauw, E. D. Mass Spectrom. Rev. 2005, 24 (4), 566. 
(218)  Philomin, V.; Vessieres, A.; Gruselle, M.; Jaouen, G. Bioconjug. Chem. 1993, 4 (6), 419. 
(219)  Rosenfeld, R. S.; Rosenberg, B.; Kream, J.; Hellman, L. Steroids 1973, 21 (5), 723. 
(220)  Antonini, E.; Carrea, G.; Cremonesi, P. Enzyme Microb. Technol. 1981, 3 (4), 291. 
(221)  Brink, L. E. S.; Tramper, J.; Luyben, K. C. A. M.; Van ’t Riet, K. Enzyme Microb. Technol. 
1988, 10 (12), 736. 
(222)  Michaelis, L.; Menten, M. Biochem. Z. 1913, 49, 333. 
(223)  Michaelis, L.; Menten, M. M. L. FEBS Lett. 2013, 587 (17), 2712. 
(224)  Johnson, K. A.; Goody, R. S. Biochemistry (Mosc.) 2011, 50 (39), 8264. 
(225)  O’Sullivan, C.; Tompson, F. W. J. Chem. Soc. Trans. 1890, 57 (0), 834. 
(226)  Brown, A. J. J. Chem. Soc. Trans. 1892, 61 (0), 369. 
(227)  Briggs, G. E.; Haldane, J. B. S. Biochem. J. 1925, 19 (2), 338. 
(228)  Lineweaver, H.; Burk, D. J. Am. Chem. Soc. 1934, 56 (3), 658. 
(229)  Hanes, C. S. Biochem. J. 1932, 26 (5), 1406. 
(230)  Haldane, J. B. S. Nature 1957, 179 (4564), 832. 
(231)  Cornish-Bowden, A. Fundamentals of Enzyme Kinetics, 4th ed.; Wiley-Blackwell: 
Singapore, 2012. 
(232)  Pesheck, P. S.; Lovrien, R. E. Biochem. Biophys. Res. Commun. 1977, 79 (2), 417. 
(233)  Bowers, L. D.; Johnson, P. R. Biochim. Biophys. Acta BBA - Enzymol. 1981, 661 (1), 100. 
(234)  Fishman, W. H.; Green, S. J. Biol. Chem. 1957, 225 (1), 435. 
(235)  Butler, L. G. Enzyme Microb. Technol. 1979, 1 (4), 253. 
(236)  Khmelnitsky, Y. L.; Levashov, A. V.; Klyachko, N. L.; Martinek, K. Enzyme Microb. Technol. 
1988, 10 (12), 710. 
(237)  Maurel, P. J. Biol. Chem. 1978, 253 (5), 1677. 
(238)  Frank, H. S.; Evans, M. W. J. Chem. Phys. 1945, 13 (11), 507. 
(239)  Ben-Naim, A. J. Chem. Phys. 2013, 139 (16), 165105. 
(240)  Galamba, N. J. Phys. Chem. B 2013, 117 (7), 2153. 
(241)  Rezus, Y. L. A.; Bakker, H. J. Phys. Rev. Lett. 2007, 99 (14), 148301. 
(242)  Galamba, N. J. Phys. Chem. B 2014, 118 (15), 4169. 
(243)  Sinibaldi, R.; Casieri, C.; Melchionna, S.; Onori, G.; Segre, A. L.; Viel, S.; Mannina, L.; De Luca, 
F. J. Phys. Chem. B 2006, 110 (17), 8885. 
(244)  Di Michele, A.; Freda, M.; Onori, G.; Paolantoni, M.; Santucci, A.; Sassi, P. J. Phys. Chem. B 
2006, 110 (42), 21077. 
(245)  Comez, L.; Paolantoni, M.; Lupi, L.; Sassi, P.; Corezzi, S.; Morresi, A.; Fioretto, D. J. Phys. 
Chem. B 2015, 119 (29), 9236. 
(246)  Wilcox, D. S.; Rankin, B. M.; Ben-Amotz, D. Faraday Discuss. 2014, 167 (0), 177. 
(247)  Wallace, B. D.; Wang, H.; Lane, K. T.; Scott, J. E.; Orans, J.; Koo, J. S.; Venkatesh, M.; Jobin, C.; 
Yeh, L.-A.; Mani, S.; Redinbo, M. R. Science 2010, 330 (6005), 831. 
(248)  Tayyab, S.; Qamar, S.; Islam, M. Biochem. Educ. 1991, 19 (3), 149. 
(249)  GE Healthcare BioSciences AB November 2014,. 
(250)  Aiba, H.; Baba, T.; Hayashi, K.; Inada, T.; Isono, K.; Itoh, T.; Kasai, H.; Kashimoto, K.; 
Kimura, S.; Kitakawa, M.; Kitagawa, M.; Makino, K.; Miki, T.; Mizobuchi, K.; Mori, H.; Mori, 
T.; Motomura, K.; Nakade, S.; Nakamura, Y.; Nashimoto, H.; Nishio, Y.; Oshima, T.; Saito, N.; 
Sampei, G.; Seki, Y.; Sivasundaram, S.; Tagami, H.; Takeda, J.; Takemoto, K.; Takeuchi, Y.; 
Wada, C.; Yamamoto, Y.; Horiuchi, T. DNA Res. 1996, 3 (6), 363. 
(251)  Wei, J.; Lv, X.; Lü, Y.; Yang, G.; Fu, L.; Yang, L.; Wang, J.; Gao, J.; Cheng, S.; Duan, Q.; Jin, C.; Li, 
X. Eur. J. Org. Chem. 2013, 2013 (12), 2414. 
Chapter 7: References 
186 
 
(252)  Jung, S. M.; Mayer, R. M. Arch. Biochem. Biophys. 1981, 208 (1), 288. 
(253)  Amyes, T. L.; Jencks, W. P. J. Am. Chem. Soc. 1989, 111 (20), 7888. 
(254)  Banait, N. S.; Jencks, W. P. J. Am. Chem. Soc. 1991, 113 (21), 7951. 
(255)  Chan, J.; Sannikova, N.; Tang, A.; Bennet, A. J. J. Am. Chem. Soc. 2014, 136 (35), 12225. 
(256)  Matsunaga, H.; Kanno, C.; Yamada, H.; Takahashi, Y.; Suzuki, T. M. Talanta 2006, 68 (3), 
1000. 
(257)  Sykes, P. A Guidebook to Mechanism in Organic Chemistry, 6th ed.; Longman Scientific & 
Technical: London, 1986. 
(258)  Khmelnitsky, Y. L.; Levashov, A. V.; Klyachko, N. L.; Martinek, K. Enzyme Microb. Technol. 
1988, 10 (12), 710. 
(259)  Klibanov, A. M. Nature 2001, 409 (6817), 241. 
(260)  Vic, G.; Thomas, D.; Crout, D. H. G. Enzyme Microb. Technol. 1997, 20 (8), 597. 
(261)  Vogel, A. I.; Furniss, B. I.; Hannaford, A. J.; Smith, P. W. G.; Tatchell, A. R. Vogel’s Textbook of 
Practical Organic Chemistry, 5th ed.; Longman Scientific & Technical: London, 1989. 
(262)  Brauns, D. H. J. Am. Chem. Soc. 1923, 45 (3), 833. 
(263)  Kitahata, S.; Brewer, C. F.; Genghof, D. S.; Sawai, T.; Hehre, E. J. J. Biol. Chem. 1981, 256 
(12), 6017. 
(264)  Thevis, M.; Opfermann, G.; Schmickler, H.; Schänzer, W. J. Mass Spectrom. 2001, 36 (2), 
159. 
(265)  Amarasinghe, K.; Chu, P.-S.; Evans, E.; Reimschuessel, R.; Hasbrouck, N.; Jayasuriya, H. J. 
Agric. Food Chem. 2012, 60 (20), 5084. 
(266)  Casati, S.; Ottria, R.; Ciuffreda, P. Steroids 2009, 74 (2), 250. 
(267)  Murai, T.; Samata, N.; Iwabuchi, H.; Ikeda, T. Drug Metab. Dispos. 2006, 34 (7), 1102. 
(268)  Werschkun, B.; Gorziza, K.; Thiem, J. J. Carbohydr. Chem. 1999, 18 (6), 629. 
(269)  Kashima, Y.; Kitade, T.; Kashima, Y.; Okabayashi, Y. Chem. Pharm. Bull. (Tokyo) 2010, 58 
(3), 354. 
(270)  Antignac, J.-P.; Brosseaud, A.; Gaudin-Hirret, I.; André, F.; Bizec, B. L. Steroids 2005, 70 (3), 
205. 
(271)  Mills, C. O.; Milkiewicz, P.; Molloy, D. P.; Baxter, D. J.; Elias, E. Biochim. Biophys. Acta BBA - 
Gen. Subj. 1997, 1336 (3), 485. 
(272)  Goto, J.; Suzaki, K.; Nambara, T. Chem. Pharm. Bull. (Tokyo) 1979, 27 (8), 1926. 
(273)  Scarth, J. P.; Clarke, A. D.; Teale, P.; Pearce, C. M. Steroids 2010, 75 (10), 643. 
(274)  Park, S.; Shin, I. Org. Lett. 2007, 9 (4), 619. 
(275)  Ottolina, G.; Carrea, G.; Riva, S. Biocatalysis 1991, 5 (2), 131. 
(276)  Kennedy, N.; Cohen, T. J. Org. Chem. 2015, 80 (16), 8134. 
(277)  Badoud, F.; Boccard, J.; Schweizer, C.; Pralong, F.; Saugy, M.; Baume, N. J. Steroid Biochem. 
Mol. Biol. 2013, 138, 222. 
 
 
 
